Standard Operating Procedures
Human Ethics Committee

Tata Memorial Centre
Tata Memorial Hospital
Dr Ernest Borgest Road,
Parel, Mumbai
Contents

S. No. | Title | Pg. Nos.
--- | --- | ---
1. | List of Acronyms | xiv-xv

Chapter 1  Preparing Standard Operating Procedures (SOPs): Writing, Reviewing, Distributing & Amending SOPs for the Human Ethics Committee (HEC), TMC

1.1 Purpose 7
1.2 Scope 7
1.3 Responsibility 7
1.4 Detailed instructions
1.4.1 Identify the need for new or amendment to SOP 8
1.4.2 Appointing the SOP team 8
1.4.3 List of relevant SOPs 8
1.4.4 Design a format and layout 8
1.4.5 Write, Review and Approve SOP 9
1.4.6 Review by Consultation 9
1.4.7 Preparation and submission of final draft 9
1.4.8 Final Approval of new and revised SOP 10
1.4.9 Implement, distribute and file all SOPs 10
1.4.10 Review and request for a revision of an existing SOP 10
1.4.11 Manage and archive superseded SOPs 10
References 11
Glossary 12

List of Annexure
AX 1 V1/SOP01/V1 List of SOPs of Ethics Committee for Research on Human Subjects 13
AX 2 V1/SOP01/V1 Template for SOP 14
Chapter 2  Constitution of Human Ethics Committee, TMC

2.1 Purpose  23
2.2 Mandate  23
2.3 Scope  23
2.4 Responsibility  24
2.5 Ethical Basis  24
2.6 Composition
  2.6.1 Membership  26
  2.6.2 Terms of Appointment  26
    2.6.2.a Duration  26
    2.6.2.b Renewal  27
    2.6.2.c Resignation / Replacement procedure  27
    2.6.2.d Termination / Removal procedure  27
    2.6.3 Conditions of Appointment  28
    2.6.4 Independent Consultants  28
2.7 Office Bearers  28
  2.7.1 Chairperson  28
  2.7.2 Member Secretary  29
  2.7.3 Secretariat 10-12  29
2.8 Roles and Responsibilities of the HEC members  30
2.9 Quorum Requirements  30
2.10 Decision making  31
2.11 Education for HEC Members  31
2.12 Prepare an annual activity report of the HEC for submission to the Director, TMC  32

References  32
Glossary  33
List of Annexure

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Title</th>
<th>Pg. Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td>AX1</td>
<td>V1/SOP02/V2 Confidentiality &amp; Conflict of Interest Agreement Form for HEC Members</td>
<td>34</td>
</tr>
<tr>
<td>AX2</td>
<td>V1/SOP02/V2 Confidentiality Agreement Form for Independent Consultants</td>
<td>37</td>
</tr>
<tr>
<td>AX3</td>
<td>V1/SOP02/V2 Confidentiality Agreement Form for Observer Attendees to HEC, TMC Meetings</td>
<td>38</td>
</tr>
<tr>
<td></td>
<td>Flow chart</td>
<td>39</td>
</tr>
</tbody>
</table>

Chapter 3  Management of Protocol Submissions  41

3.1 Purpose  43
3.2 Scope  43
3.3 Responsibility  43
3.4 Detailed process  43
  3.4.1 Receive submitted packages  43
  3.4.2 Verify Contents of Submitted Package  43
3.5 Detailed description of Study Project Submission  44
3.6 Resubmission of Protocols with corrections  45
3.7 Research Protocol Amendments and other study related documents  45
3.8 Annual Continuing Reviews of Approved Protocols  46
3.9 Protocol Completion  46
Reference  46
Glossary  46

List of Annexure

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Title</th>
<th>Pg. Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td>AX1</td>
<td>V1/SOP03/V2 Project Submission Application Form for Initial Review</td>
<td>47</td>
</tr>
<tr>
<td>AX2</td>
<td>V1/SOP03/V2 Checklist of Documents</td>
<td>64</td>
</tr>
<tr>
<td>AX3</td>
<td>V1/SOP03/V2 Document Receipt Form</td>
<td>65</td>
</tr>
<tr>
<td>AX4</td>
<td>V1/SOP03/V2 Guidelines for devising ICF and Sample format of an Informed Consent Document.</td>
<td>67</td>
</tr>
<tr>
<td>AX5</td>
<td>V1/SOP03/V2 Child Information Sheet and Assent Form</td>
<td>72</td>
</tr>
<tr>
<td></td>
<td>Flow Chart</td>
<td>76</td>
</tr>
</tbody>
</table>

Chapter 4  Initial Review of Submitted Protocol  77

4a.1 Purpose  79
4a.2 Scope  79
<table>
<thead>
<tr>
<th>S. No.</th>
<th>Title</th>
<th>Pg. Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td>4a.3</td>
<td>Categorization of protocols</td>
<td>79</td>
</tr>
<tr>
<td>4a.4</td>
<td>Initial Review</td>
<td>79</td>
</tr>
<tr>
<td>4a.5</td>
<td><strong>Elements of Review</strong></td>
<td>81</td>
</tr>
<tr>
<td></td>
<td>4a.5.1 Scientific Design and Conduct of the Study</td>
<td>81</td>
</tr>
<tr>
<td></td>
<td>4a.5.2 Care and Protection of Research Participants</td>
<td>81</td>
</tr>
<tr>
<td></td>
<td>4a.5.3 Protection of Research Participant Confidentiality</td>
<td>82</td>
</tr>
<tr>
<td></td>
<td>4a.5.4 Informed Consent Process</td>
<td>82</td>
</tr>
<tr>
<td></td>
<td>4a.5.5 Community Considerations</td>
<td>82</td>
</tr>
<tr>
<td></td>
<td>4a.5.6 Recruitment of Research Participants</td>
<td>83</td>
</tr>
<tr>
<td>4a.6</td>
<td>Responsibility</td>
<td>83</td>
</tr>
<tr>
<td>4a.7</td>
<td>Detailed instructions</td>
<td>83</td>
</tr>
<tr>
<td>4a.8</td>
<td>Review the protocol</td>
<td>84</td>
</tr>
<tr>
<td>4a.9</td>
<td>Use of study assessment forms</td>
<td>84</td>
</tr>
<tr>
<td></td>
<td>4a.9.1 Gather the assessment reports</td>
<td>84</td>
</tr>
<tr>
<td>4a.10</td>
<td>AT HEC meeting</td>
<td>84</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>85</td>
</tr>
<tr>
<td></td>
<td>Glossary</td>
<td>85</td>
</tr>
<tr>
<td></td>
<td><strong>List of Annexure</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AX1 V1SOP04a/V2 Study Assessment Form</td>
<td>87</td>
</tr>
<tr>
<td></td>
<td>Flow chart</td>
<td>92</td>
</tr>
</tbody>
</table>

**Chapter 4b Expedited Review of Submitted Protocol** 93

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Title</th>
<th>Pg. Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td>4b.1</td>
<td>Purpose</td>
<td>94</td>
</tr>
<tr>
<td>4b.2</td>
<td>Categorization of protocols</td>
<td>94</td>
</tr>
<tr>
<td>4b.3</td>
<td>Expedited Review</td>
<td>94</td>
</tr>
<tr>
<td>4b.4</td>
<td>Scope</td>
<td>96</td>
</tr>
<tr>
<td>4b.5</td>
<td>Responsibility</td>
<td>96</td>
</tr>
<tr>
<td>4b.6</td>
<td><strong>Detailed Instructions</strong></td>
<td>96</td>
</tr>
<tr>
<td></td>
<td>4b.6.1 Receipt of protocols/documents</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td>4b.6.2 Expedited process</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td>4b.6.3 Communication between the HEC and the investigator</td>
<td>97</td>
</tr>
<tr>
<td></td>
<td>Reference</td>
<td>97</td>
</tr>
<tr>
<td></td>
<td>Glossary</td>
<td>97</td>
</tr>
<tr>
<td></td>
<td>Flow chart</td>
<td>98</td>
</tr>
</tbody>
</table>
Chapter 4c  Exemption from the Ethical Review for Research Projects 99

4c.1  Purpose 101
4c.2  Categorization of protocols 101
4c.3  Exemption from review 101
4c.4  Scope 102
4c.5  Responsibility 102
4c.6  Detailed Instructions 102
  4c.6.1  Receipt of protocols/documents 102
  4c.6.2  Determine protocols eligible for exemption from review 102
  4c.6.3  Exemption Process 102
  4c.6.4  Communication between the HEC and the investigator 103
Reference 103
Glossary 103
List of Annexure 103
 AX1  V1/SOP04c/V2  Review Exemption Application Form 104
Flow chart 108

Chapter 5  Agenda Preparation, Meeting Procedures and Recording of Minutes 109

5.1  Purpose 111
5.2  Scope 111
5.3  Responsibility 111
5.4  Detailed instruction 111
  5.4.1  Receive submitted packages 111
  5.4.2  Distribution of Protocol/ Documents Packages to the HEC Members 111
  5.4.3  Preparation for the meeting 112
  5.4.4  During the Meeting 112
  5.4.5  Decision Making Process 112
  5.4.6  After the HEC meeting 113
    5.4.6 a  Preparing the minutes and the decision letters 113
    5.4.6 b  Approval of the minutes and the decision 113
    5.4.6 c  Filing of the minutes of the meeting 114
  5.4.7  Communicating Decision 114
Reference 115
Chapter 6  Review of Amended protocol / Protocol related documents 123

6.1 Purpose 125
6.2 Scope 125
6.3 Responsibility 125
6.4 Review amended protocols/documents/letters:
   6.4.1 Decision 125
   6.4.2 Storage of Documents 126
   6.4.3 Minor amendments and notifications 126
Reference 126
Glossary 126

List of Annexure
AX1 V1/SOP06/V2 Project Amendment/Document Amendment Approval letter 127
AX2 V1/SOP06/V2 Amendment Reporting Form 128
Flow chart 129

Chapter 7  Continuing review of study Protocols 131

7.1 Purpose 133
7.2 Scope 133
7.3 Responsibility 133
7.4 Detailed Instructions
   7.4.1 Determine the date of continuing review 133
   7.4.2 Notify the Principal Investigator or the study team 134
   7.4.3 Manage continuing review package upon receipt. 134
   7.4.4 Verify the contents of the package. 134
   7.4.5 Filing the continuing review package 134
   7.4.6 Notify the Members of the HEC 135
<table>
<thead>
<tr>
<th>S. No.</th>
<th>Title</th>
<th>Pg. Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7.4.7 Prepare meeting agenda</td>
<td>135</td>
</tr>
<tr>
<td></td>
<td>7.4.8 Protocol Review Process</td>
<td>135</td>
</tr>
<tr>
<td></td>
<td>7.4.9 Store original documents</td>
<td>135</td>
</tr>
<tr>
<td></td>
<td>7.4.10 Communicate the HEC Decision to the Principal Investigator</td>
<td>135</td>
</tr>
<tr>
<td></td>
<td>Reference</td>
<td>136</td>
</tr>
<tr>
<td></td>
<td><strong>List of Annexure</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AX1 V1/SOP 07/V2 Continuing Review Application Form</td>
<td>137</td>
</tr>
<tr>
<td></td>
<td>AX2 V1/SOP 07/V2 Reminder letter by the HEC to investigator</td>
<td>140</td>
</tr>
<tr>
<td></td>
<td>AX3 V1/SOP 07/V2 HEC Decision on Continuing Review Report</td>
<td>141</td>
</tr>
<tr>
<td></td>
<td>AX4 V1/SOP 07/V2 Project Report Approval Letter</td>
<td>142</td>
</tr>
<tr>
<td></td>
<td>Flow chart</td>
<td>143</td>
</tr>
<tr>
<td></td>
<td><strong>Chapter 8 Reporting of Protocol Deviation / Non-Compliance / Violation / Waiver</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8.1 Purpose</td>
<td>147</td>
</tr>
<tr>
<td></td>
<td>8.2 Scope</td>
<td>147</td>
</tr>
<tr>
<td></td>
<td>8.3 Responsibility</td>
<td>147</td>
</tr>
<tr>
<td></td>
<td><strong>8.4 Detailed instructions</strong></td>
<td>147</td>
</tr>
<tr>
<td></td>
<td>8.4.1 Detection of Protocol deviation / non-compliance / violation</td>
<td>147</td>
</tr>
<tr>
<td></td>
<td>8.4.2 Noting protocol deviation / non-compliance / violation by the Secretariat</td>
<td>148</td>
</tr>
<tr>
<td></td>
<td>8.4.3 Board discussion, Decision, and Action</td>
<td>148</td>
</tr>
<tr>
<td></td>
<td>8.4.4 Notify the investigator</td>
<td>149</td>
</tr>
<tr>
<td></td>
<td>8.4.5 Records and follow up to be kept by IRB secretariat</td>
<td>149</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>149</td>
</tr>
<tr>
<td></td>
<td>Glossary</td>
<td>150</td>
</tr>
<tr>
<td></td>
<td><strong>List of Annexure</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AX 1 V1/SOP08/V2 Deviation / Non-Compliance / Violation / waiver Reporting form</td>
<td>151</td>
</tr>
<tr>
<td></td>
<td>Flow chart</td>
<td>152</td>
</tr>
<tr>
<td></td>
<td><strong>Chapter 9 Review of Serious Adverse Events (SAE) Reports</strong></td>
<td>153</td>
</tr>
<tr>
<td></td>
<td>9.1 Purpose</td>
<td>155</td>
</tr>
<tr>
<td></td>
<td>9.2 Scope</td>
<td>155</td>
</tr>
<tr>
<td></td>
<td>9.3 Responsibility</td>
<td>155</td>
</tr>
</tbody>
</table>
### Chapter 9

#### Detailed Instructions

- **On site SAEs**
- **Off Site SAEs**

#### During the HEC meeting

#### After the review of SAE

### Chapter 10

#### Purpose

#### Scope

#### Responsibility

#### Maintain the active study files

#### Disposal of closed files

#### Accessibility / Retrieval

#### Final Disposal of Master files

### List of Annexure

**AX1** V1/SOP10/V2 - Document Request Form

**AX2** V1/SOP10/V2 - Format of written off register

Flow chart
<table>
<thead>
<tr>
<th>S. No.</th>
<th>Title</th>
<th>Pg. Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Chapter 11  Documentation of the HEC activities</strong></td>
<td>175</td>
</tr>
<tr>
<td>11.1</td>
<td>Purpose</td>
<td>177</td>
</tr>
<tr>
<td>11.2</td>
<td>Scope</td>
<td>177</td>
</tr>
<tr>
<td>11.3</td>
<td>Responsibility</td>
<td>177</td>
</tr>
<tr>
<td>11.4</td>
<td><strong>Detailed Instructions</strong></td>
<td>177</td>
</tr>
<tr>
<td></td>
<td>11.4.1 HEC records</td>
<td>177</td>
</tr>
<tr>
<td></td>
<td>11.4.2 Access to HEC records</td>
<td>177</td>
</tr>
<tr>
<td></td>
<td>Flow Chart</td>
<td>178</td>
</tr>
<tr>
<td></td>
<td><strong>Chapter 12  Review of study completion reports</strong></td>
<td>179</td>
</tr>
<tr>
<td>12.1</td>
<td>Purpose</td>
<td>181</td>
</tr>
<tr>
<td>12.2</td>
<td>Scope</td>
<td>181</td>
</tr>
<tr>
<td>12.3</td>
<td>Responsibility</td>
<td>181</td>
</tr>
<tr>
<td>12.4</td>
<td><strong>Detailed Instructions</strong></td>
<td>181</td>
</tr>
<tr>
<td></td>
<td>12.4.1 Before each board meeting</td>
<td>181</td>
</tr>
<tr>
<td></td>
<td>12.4.2 Before and during board meeting</td>
<td>181</td>
</tr>
<tr>
<td></td>
<td>12.4.3 After the board meeting</td>
<td>181</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>182</td>
</tr>
<tr>
<td></td>
<td><strong>List of Annexure</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AX1 V1/SOP 12/V2 Study Completion Report Form</td>
<td>183</td>
</tr>
<tr>
<td></td>
<td>Flow Chart</td>
<td>184</td>
</tr>
<tr>
<td></td>
<td><strong>Chapter 13  Management of Premature Termination / Suspension / Discontinuation of the study</strong></td>
<td>185</td>
</tr>
<tr>
<td>13.1</td>
<td>Purpose</td>
<td>187</td>
</tr>
<tr>
<td>13.2</td>
<td>Scope</td>
<td>187</td>
</tr>
<tr>
<td>13.3</td>
<td>Responsibility</td>
<td>187</td>
</tr>
<tr>
<td>13.4</td>
<td><strong>Detailed instructions</strong></td>
<td>187</td>
</tr>
<tr>
<td></td>
<td>13.4.1 Receive recommendation for study termination/ suspension/discontinuation</td>
<td>187</td>
</tr>
<tr>
<td></td>
<td>13.4.2 Review and discuss the Termination / suspension/ discontinuation Package</td>
<td>187</td>
</tr>
<tr>
<td></td>
<td>13.4.3 Notify the PI</td>
<td>188</td>
</tr>
<tr>
<td></td>
<td>13.4.4 Store the protocol documents</td>
<td>188</td>
</tr>
<tr>
<td>S. No.</td>
<td>Title</td>
<td>Pg. Nos.</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>188</td>
</tr>
<tr>
<td></td>
<td><strong>List of Annexure</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AX 1 V1/SOP13/V2 Premature Termination / Suspension / Discontinuation Report</td>
<td>189</td>
</tr>
<tr>
<td></td>
<td>Flow chart</td>
<td>190</td>
</tr>
<tr>
<td></td>
<td><strong>Chapter 14  Request for Waiver of Written Informed Consent</strong></td>
<td>191</td>
</tr>
<tr>
<td>14.1</td>
<td>Purpose</td>
<td>193</td>
</tr>
<tr>
<td>14.2</td>
<td>Scope</td>
<td>193</td>
</tr>
<tr>
<td>14.3</td>
<td>Responsibility</td>
<td>193</td>
</tr>
<tr>
<td>14.4</td>
<td>Detailed Instructions</td>
<td>193</td>
</tr>
<tr>
<td>14.5</td>
<td>Type of research projects which may qualify for consent waiver</td>
<td>193</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>195</td>
</tr>
<tr>
<td></td>
<td><strong>List of Annexure</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AX 1 SOP14/V2 - Application form for requesting waiver of consent</td>
<td>196</td>
</tr>
<tr>
<td></td>
<td>Flow Chart</td>
<td>197</td>
</tr>
<tr>
<td></td>
<td><strong>Chapter 15  Site Monitoring</strong></td>
<td>199</td>
</tr>
<tr>
<td>15.1</td>
<td>Purpose</td>
<td>201</td>
</tr>
<tr>
<td>15.2</td>
<td>Scope</td>
<td>201</td>
</tr>
<tr>
<td>15.3</td>
<td>Responsibility</td>
<td>201</td>
</tr>
<tr>
<td>15.4</td>
<td><strong>Detailed instructions</strong></td>
<td>201</td>
</tr>
<tr>
<td></td>
<td>15.4.1 Selection of study sites</td>
<td>201</td>
</tr>
<tr>
<td></td>
<td>15.4.2 Before the visit</td>
<td>201</td>
</tr>
<tr>
<td></td>
<td>15.4.3 During the visit</td>
<td>202</td>
</tr>
<tr>
<td></td>
<td>15.4.4 After the visit</td>
<td>202</td>
</tr>
<tr>
<td></td>
<td>Glossary</td>
<td>203</td>
</tr>
<tr>
<td></td>
<td><strong>List of Annexure</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AX 1 V1/SOP15/V1 Site Monitoring Visit Report</td>
<td>204</td>
</tr>
<tr>
<td></td>
<td>Flow chart</td>
<td>206</td>
</tr>
</tbody>
</table>
Chapter 16  Dealing with participants / patients requests and complaints

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Title</th>
<th>Pg. Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.1</td>
<td>Purpose</td>
<td>209</td>
</tr>
<tr>
<td>16.2</td>
<td>Scope</td>
<td>209</td>
</tr>
<tr>
<td>16.3</td>
<td>Responsibility</td>
<td>209</td>
</tr>
<tr>
<td>16.4</td>
<td>Detailed instructions</td>
<td>209</td>
</tr>
<tr>
<td>16.5</td>
<td>Filling the request document</td>
<td>210</td>
</tr>
</tbody>
</table>

**List of Annexure**

<table>
<thead>
<tr>
<th>AX1</th>
<th>V1/SOP 16/V1 - Request Record Form</th>
<th>211</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Flow chart</td>
<td>212</td>
</tr>
</tbody>
</table>

**Appendices**

1. Policy on Recruitment of TMC Students and Staff                   215
2. Policy on the Recruitment of Research Subjects                    216
3. Policy on Research Costs to Subjects                              217
4. Guidelines on Compensation for Research Subjects                  218
5. Policy on the Use of Third Party/Surrogate Consent in Research at TMC 219
8. Policy for Documentation of Informed Consent                     224
9. Health Record Research                                             227
10. Guidelines for Research Protocols That Require Collection and/or Storage of Genetic Materials 229
12. Recommended Terms for Use in Consent Forms                       234
## List of Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Full Title/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAHRPP</td>
<td>Association for the Accreditation of Human Research Protection Programs</td>
</tr>
<tr>
<td>ACTREC</td>
<td>Advanced Centre for Treatment, Research and Education in Cancer</td>
</tr>
<tr>
<td>ADR</td>
<td>Adverse Drug Reaction</td>
</tr>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>AIIMS</td>
<td>All India Institute of Medical Sciences</td>
</tr>
<tr>
<td>ASU</td>
<td>Ayurveda, Siddha, Unani.</td>
</tr>
<tr>
<td>BA</td>
<td>Bio-availability</td>
</tr>
<tr>
<td>BARC</td>
<td>Bhabha Atomic Research Centre</td>
</tr>
<tr>
<td>BE</td>
<td>Bio-equivalence</td>
</tr>
<tr>
<td>BIS</td>
<td>Bureau of Indian Standards</td>
</tr>
<tr>
<td>CDC</td>
<td>Center for Disease Control and Prevention</td>
</tr>
<tr>
<td>CDSCO</td>
<td>Central Drugs Standard Control Organization</td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
</tr>
<tr>
<td>CIOMS</td>
<td>Council for International Organizations of Medical Sciences</td>
</tr>
<tr>
<td>CoI</td>
<td>Conflict of Interest</td>
</tr>
<tr>
<td>CONSORT</td>
<td>Consolidated standards of reporting trials</td>
</tr>
<tr>
<td>CRF</td>
<td>Case Record Form</td>
</tr>
<tr>
<td>CRO</td>
<td>Contract Research Organization</td>
</tr>
<tr>
<td>CRS</td>
<td>Clinical Research Secretariat</td>
</tr>
<tr>
<td>CTA</td>
<td>Clinical Trial Agreement</td>
</tr>
<tr>
<td>DAE</td>
<td>Department of Atomic Energy</td>
</tr>
<tr>
<td>DBT</td>
<td>Department of Biotechnology</td>
</tr>
<tr>
<td>DCGI</td>
<td>Drug Controller General of India</td>
</tr>
<tr>
<td>DCR</td>
<td>Drugs and Cosmetic Rules, 1945</td>
</tr>
<tr>
<td>DGFT</td>
<td>Directorate General of Foreign Trade</td>
</tr>
<tr>
<td>DHHS</td>
<td>Department of Health and Human Services</td>
</tr>
<tr>
<td>DSMB</td>
<td>Data Safety Monitoring Board</td>
</tr>
<tr>
<td>DSMSC</td>
<td>Data Safety Monitoring Sub Committee</td>
</tr>
<tr>
<td>DTAB</td>
<td>Drugs Technical Advisory Board</td>
</tr>
</tbody>
</table>
ELSI  Ethical, Legal and Social Issues
FDA    Food and Drug Administration
FDC    Fixed Dose Combination
FERCAP Forum for Ethical Review Committees in Asia and the Western Pacific Region
GCP    Good Clinical Practice
GMP    Good Manufacturing Practices
HEC    Human Ethics Committee
HIPAA  Health Insurance Portability and Accountability Act
HMSC   Health Ministrys Screening Committee
IAEA   International Atomic Energy Agency
IB     Investigator’s Brochure
ICF    Informed Consent Form
ICH    International Committee on Harmonization
ICJME  International Committee of Medical Journal Editors
ICMR   Indian Council of Medical Research
IDE    Investigational Device Exemption
IMDRA  Indian Medical Devices Regulatory Authority
IND    Investigational New Drug
IRB    Institutional Review Board
ISI    Indian Standards Institute
MOU    Memorandum of Understanding
MTA    Material Transfer Agreement
NAC-SCRT National Apex Committee for Stem Cell Research and Therapy
NCE    New Chemical Entity
NDA    New Drug Application
NIH    National Institutes of Health
NOC    No-objection Certificate
OHRP   Office for Human Research Protections
PI     Principal Investigator
RCT    Randomized Controlled Trial
SAE    Serious Adverse Event
SOPs   Standard Operating Procedures
SRC    Scientific Review Committee
TMC    Tata Memorial Centre
TMH    Tata Memorial Hospital
TRAC   TMC-Research Administration Council
WHO    World Health Organization
WMA    World Medical Assembly
Human Ethics Committee, Tata Memorial Centre (HEC, TMC)

**SOP Codes**
SOP 01/V1, SOP 02/V2, SOP 03/V2, SOP 04a/V2, SOP 04b/V2, SOP 04c/V2, SOP 05/V2, SOP 06/V2, SOP 07/V2, SOP 08/V2, SOP 09/V2, SOP 10/V2, SOP 11/V2, SOP 12/V2, SOP 13/V2, SOP 14/V2, SOP 15/V1, SOP 16/V1

**Authors:**

<table>
<thead>
<tr>
<th>Name and Position on the HEC</th>
<th>Signature with date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Medha Joshi (Member Secretary HEC-II)</td>
<td></td>
</tr>
<tr>
<td>Dr. Sangeeta Desai (Member Secretary HEC-I)</td>
<td></td>
</tr>
<tr>
<td>Ms. Abhidnya Kandalkar (IRB Jr. Administrator)</td>
<td></td>
</tr>
</tbody>
</table>

**Approved by:**

<table>
<thead>
<tr>
<th>Name and Position on the HEC</th>
<th>Signature with date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ms. Shirin Bharucha (Chairperson HEC I)</td>
<td></td>
</tr>
<tr>
<td>Dr. Urmila Thatte (Chairperson HEC-II)</td>
<td></td>
</tr>
</tbody>
</table>

**Accepted by:**

<table>
<thead>
<tr>
<th>Name and Position on the HEC</th>
<th>Signature with date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. R. A. Badwe, Director, TMC</td>
<td></td>
</tr>
</tbody>
</table>
### Reviewed by:

<table>
<thead>
<tr>
<th>Name and Position on the HEC - I</th>
<th>Signature with date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Geeta Koppikar, Co Chairperson</td>
<td></td>
</tr>
<tr>
<td>Dr. R.C. Mistry, Member</td>
<td></td>
</tr>
<tr>
<td>Dr. Nithya Gogtay, Member</td>
<td></td>
</tr>
<tr>
<td>Mr. Gul Kripalani, Member</td>
<td></td>
</tr>
<tr>
<td>Ms. Viji Venkatesh, Member</td>
<td></td>
</tr>
<tr>
<td>Ms. Mrunal Marathe, Member</td>
<td></td>
</tr>
<tr>
<td>Dr. Pradnya Talawadekar, Member</td>
<td></td>
</tr>
<tr>
<td>Dr. S. K. Shrivastava, Member</td>
<td></td>
</tr>
<tr>
<td>Dr. S. D. Banavali, Member</td>
<td></td>
</tr>
<tr>
<td>Dr H.K.V. Narayan, Member</td>
<td></td>
</tr>
<tr>
<td>Dr. Parul J. Shukla, Member &amp; Jt. Secretary, DSMSC</td>
<td></td>
</tr>
<tr>
<td>Dr. A. Gajiwala, Member</td>
<td></td>
</tr>
<tr>
<td>Dr. Vikram Gota, Alternate Member</td>
<td></td>
</tr>
<tr>
<td>Name and Position on the HEC-II</td>
<td>Signature with date</td>
</tr>
<tr>
<td>---------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Dr. R. F. Chinoy, Co-Chairperson</td>
<td>![Signature]</td>
</tr>
<tr>
<td>Dr. V.R. Joshi, Member</td>
<td>![Signature]</td>
</tr>
<tr>
<td>Dr. R. Munagekar, Member</td>
<td>![Signature]</td>
</tr>
<tr>
<td>Mr. P.K. Rao, Member</td>
<td>![Signature]</td>
</tr>
<tr>
<td>Ms. Tessie George, Member</td>
<td>![Signature]</td>
</tr>
<tr>
<td>Dr. Reena Nair, Member</td>
<td>![Signature]</td>
</tr>
<tr>
<td>Dr. A. Puri, Member, &amp; Jt. Secretary, DSMSC</td>
<td>![Signature]</td>
</tr>
<tr>
<td>Dr. M.A. Muckaden, Member</td>
<td>![Signature]</td>
</tr>
<tr>
<td>Dr. P.S. Pai, Member</td>
<td>![Signature]</td>
</tr>
</tbody>
</table>
1.1 Purpose

This SOP defines the process for writing, reviewing, distributing, and amending SOPs within the HEC, TMC.

The SOPs will provide clear, unambiguous instructions to conduct activities of the HEC in accordance with the ICMR guidelines 2006, Schedule ‘Y’ (Drugs and Cosmetic Act 1940: Amendment 20th Jan 2005), WHO Operating Guidelines for Ethical Review Committee that Review Biomedical Research, and ICH (International Conference on Harmonization) Good Clinical Practice (GCP).

1.2 Scope

This SOP covers the procedures of writing, reviewing, distributing, and amending SOPs within the HEC, TMC.

1.3 Responsibility

It is the responsibility of Chairperson of the HEC to appoint the SOP Team to formulate the SOPs. SOP team comprising of Member Secretaries of the HECs draft an SOP, get it reviewed and approved by the HEC members and amend it as and when required. All members of HEC I and II will review the SOPs and approval will be given by Chairs of both HEC I and II. The SOPs will be also signed off by Director, TMC as these are Institutional Ethics Committees.

Secretariat of HEC / IRB:
- Co-ordinates activities of writing, reviewing, distributing, and amending SOPs
- Maintains on file all current SOPs and the list of SOPs
- Maintains an up-to-date distribution list of each SOP circulated to HEC members
- Maintain a record of the investigators to whom SOPs are distributed against a requisition
- Ensures all HEC members and involved administrative staff have access to the SOPs
- Ensures the HEC members and involved staff are working according to current version of SOPs
- Maintain a file of all past SOPs of the HEC
- Assist in the formulation of SOP procedure

SOP team (will consist of Member Secretaries of both HEC – I and HEC - II and one or two other members)
- Assess the request(s) for SOP revision in consultation with the Secretariat and Chairperson
- Propose new / modified SOPs as needed
- Select the format and coding system for SOPs
- Draft the SOP in consultation with the HEC members and involved administrative staff
- Review the draft SOP
- Submit the draft for approval to Chairperson
Chairperson of the ethics committee
- Appoint one or more SOP Teams
- Reviews and approves the SOPs
- Signs and dates the approved SOPs

HEC members and involved administrative staff
- Review, sign and date SOPs
- Maintain a file of all SOPs received
- Return all out-of date SOPs to IRB office

1.4 Detailed instructions

1.4.1 Identify the need for new or amendment to SOP

Any member of the HEC, secretariat or administrative staff or investigators, can make a request for revision or notices an inconsistency / discrepancy / has any suggestions on how to improve the existing SOPs or requests to design an entirely new SOP can put forth his request by using the Request Form for Formulation of new SOP / Revision of an SOP Form (AX5-V1/SOP01/V1) to make a request. This AX form is submitted to the Chairperson, HEC. The Chairperson will inform all HEC members about this request in a regular full board meeting.

If HEC members agree to the request, the Chairperson will appoint an appropriate SOP team comprising of Member Secretaries of both committees. The Chairperson may also appoint one or two committee members as members of SOP team, if necessary. This designated team will proceed with the task of revision / formulation process of the SOP. If HEC members do not agree to the request, no further action will be taken.

The Chairperson will inform the person / HEC member who made the request for modification of the SOP in writing about the decision.

1.4.2 Appoint the SOP team

The Chairperson will constitute an SOP team consisting of the Member-Secretary and two or more members of the HEC who have a thorough understanding of the ethical review process. The SOP writing team will carry out the subsequent steps (1.4.3-1.4.7).

1.4.3 List of relevant SOPs

- Write down step by step all the procedures of the HEC
- Organize, devise and, name each process
- Make a list of SOPs with coding reference (AX1-V1/SOP01/V1)

1.4.4 Design a format and layout

Each SOP should be given a number and a title that is self-explanatory and is easily understood.
A unique code number with the format **SOP xx / Vy** will be assigned to each SOP by the secretariat. xx will be a two-digit number assigned specifically to a particular SOP. “V” refers to version of the SOP and “y” will be a number identifying the version e.g. SOP01/V1 is SOP number 01 with V=version no.1.

Each AX will be given unique code number with the format **AXn–Vp/SOP xx/Vy**. e.g. AX1–V1/SOP01/V1 indicates AX is Annexure, n is Annexure no.1, version 1, belonging to the SOP 01/V1.

Each Appendix will be given unique code number with the format **APPn/Vy** e.g. APP1/V1 indicates APP is Appendix, n is Appendix no 1, V1 is version no.1.

Each SOP will be prepared according to the template for Standard Operating Procedures in AX2 – V1/SOP01/V1. Each page of the SOP will bear a header with the effective date which is the date of approval of the SOPs signed and dated by the Chairperson, HEC, and approved by the Director.

The SOP number will be on the left hand corner of the header while the left hand corner of the footer will bear the title of the SOP and page number as Page—of—total pages.

The first two pages of each SOP document will be signed and dated by the authors, the HEC members who have reviewed the SOPs, HEC Chairpersons who have approved and Director, TMC who has accepted the SOPs and subsequently the SOP will be implemented from that date.

### 1.4.5 Write, Review, and Approve SOP

With reference to section 1.4.1 and 1.4.2, the draft SOP will be prepared by the SOP team.

### 1.4.6 Review by Consultation

- The draft SOP will be discussed with members of both HECs and all administrative staff.
- The SOP should be approved by all involved in that particular task.
- The final version will be forwarded to the chairperson for review and approval.

### 1.4.7 Preparation and submission of final draft

- All the members of HEC-I and HEC- II will review the draft / revised SOP.
- During respective HEC meetings, members can put forth their suggestions / comments on the draft / revised SOP.
- The suggestions agreed upon unanimously by all HEC members will be incorporated and the final draft SOP will be formulated.
- The SOP team would stand automatically dissolved once the HEC takes final decision regarding the SOP.
1.4.8 Final Approval of new/revised SOP

- The final version will be presented to the Chairpersons of both committees for review and approval. The Chairpersons will sign and date the SOP on the first page of the SOP document. This date of approval is declared as the effective date for implementing the SOP.
- This approved document will then be submitted to the Director, TMC for acceptance.

1.4.9 Implementation, distribution, and filing all SOPs

- Approved SOPs will be implemented from the effective date.
- The secretariat will discuss the approved SOPs with the administrative staff and instruct them to implement the SOP accordingly.
- Approved SOPs will be distributed to HEC members and IRB staff according to the distribution list (AX4–V1/SOP 01/V1)
- When revised version is distributed, the old version will be retrieved from all members and destroyed. A copy of the old version will be archived in a master file.
- One complete original set of current SOPs will be archived in the SOP master file, by the IRB Secretariat and maintained in the IRB Office.
- A copy of the SOP master file will be maintained in the individual offices of HEC, and DSMSC.
- Photocopies made from these official paper versions of the SOP can be considered current or official, if stamped and signed by Member Secretary or authorized individual for distribution, a log of which should be maintained (AX6–V1/SOP 01/V2)

1.4.10 Review and request for revision of an existing SOP

- Any member of the HEC, secretariat or administrative staff who notices that current SOPs have some lacunae or have any suggestions to improve a procedure should make a written request, using a form (AX5–V1/SOP 01/V1)
- If HEC agrees with the request, the Chairperson will appoint an appropriate team to proceed with the revision process. If the committee does not agree, the chairperson will inform the concerned individual who made the request for revision.
- Revised SOPs will be reviewed and approved in the same manner as new SOPs (Section 1.4)
- The secretariat is expected to review the SOP at least once every 2 years and record the dates of review in the SOP master file.

1.4.11 Manage and archive old SOPs

Old SOPs should be retained and clearly marked “superseded” and archived in a file by the secretariat. The process of evolution of previous SOPs of the HEC will be documented in a defined format (AX3–V1/SOP01/V1).
References


Glossary

**Effective date**: The date of approval of the SOPs signed and dated by the Chairperson, HEC, TMC, and subsequently the SOP is implemented from that date

**HEC members**: Individuals serving as regular members of the Human Ethics Committee, TMC. The Committee has been constituted in accordance with the EC membership requirements set forth in Schedule Y (20th January 2005)

**Master SOP files**: An official collection of the Standard Operating Procedures (SOP) of HEC, TMC accessible to all staff, HEC members, auditors and government inspectors as a paper copy with an official stamp on each page and the approval signatures

**Past SOPs of the HEC**: A collection of previous official versions of a SOPs and relevant information regarding changes and all preplanned deviations

**Requestors**: Investigators, Sponsors, CROs, Regulatory authorities, Hospital administrators, and such others

**Revision date**: Date/year by which the SOP may be revised or reviewed.

**Recipients**: Stakeholders who would receive a copy of SOP, viz., two categories 1) HEC members 2) Non-HEC members i.e. investigators/sponsors

**SOP (Standard Operating Procedure)**: Detailed, written instructions, in a certain format, describing activities and actions undertaken by the HEC to achieve uniformity of the performance of a specific function. The aim of the SOPs and their accompanying checklists and forms is to simplify the functioning, whilst maintaining high standards of Good Clinical Practice

**SOP Team**: A team of members selected from the HEC, TMC including the Member Secretary, administrative staff, and any other member of HEC as identified by the chairperson who oversee the creation, preparation, review, and periodic revision of the HEC, TMC SOPs
## List of SOPs of Human Ethics Committee

<table>
<thead>
<tr>
<th>Sr. No</th>
<th>SOP TITLE</th>
<th>SOP CODE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Preparing Standard Operating Procedures (SOPs): Writing, Reviewing,</td>
<td>O1/V1</td>
</tr>
<tr>
<td></td>
<td>Distributing, &amp; Amending SOPs for the Human Ethics Committee (HEC), TMC</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>Constitution of Human Ethics Committee, TMC</td>
<td>02/V2</td>
</tr>
<tr>
<td>3.</td>
<td>Management of Protocol Submissions</td>
<td>03/V2</td>
</tr>
<tr>
<td>4.</td>
<td>4a  Initial Review of Submitted Protocol</td>
<td>04a/V2</td>
</tr>
<tr>
<td></td>
<td>4b Expedited Review of Submitted Protocol</td>
<td>04b/V2</td>
</tr>
<tr>
<td></td>
<td>4c Exemption from the Ethical Review for Research Projects</td>
<td>04c/V2</td>
</tr>
<tr>
<td>5.</td>
<td>Agenda Preparation, Meeting Procedures and Recording of Minutes</td>
<td>05/V2</td>
</tr>
<tr>
<td>6.</td>
<td>Review of Amended protocol / Protocol related documents</td>
<td>06/V2</td>
</tr>
<tr>
<td>7.</td>
<td>Continuing review of study Protocols</td>
<td>07/V2</td>
</tr>
<tr>
<td>8.</td>
<td>Reporting of Protocol Deviation / Non-Compliance / Violation / Waiver</td>
<td>08/V2</td>
</tr>
<tr>
<td>9.</td>
<td>Review of Serious Adverse Events (SAE) Reports</td>
<td>09/V2</td>
</tr>
<tr>
<td>10.</td>
<td>Maintenance of Active Project Files, Archival of closed files and</td>
<td>10/V2</td>
</tr>
<tr>
<td></td>
<td>Retrieval of documents</td>
<td></td>
</tr>
<tr>
<td>11.</td>
<td>Documentation of the HEC activities</td>
<td>11/V2</td>
</tr>
<tr>
<td>12.</td>
<td>Review of study completion reports</td>
<td>12/V2</td>
</tr>
<tr>
<td>13.</td>
<td>Management of Premature Termination / Suspension / Discontinuation of the</td>
<td>13/V2</td>
</tr>
<tr>
<td></td>
<td>study</td>
<td></td>
</tr>
<tr>
<td>14.</td>
<td>Request for Waiver of Written Informed Consent</td>
<td>14/V2</td>
</tr>
<tr>
<td>15.</td>
<td>Site Monitoring</td>
<td>15/V1</td>
</tr>
<tr>
<td>16.</td>
<td>Dealing with participants / patients requests and complaints</td>
<td>16/V1</td>
</tr>
</tbody>
</table>
### AX2-V1/SOP01/V1

Template for Standard Operating Procedures

<table>
<thead>
<tr>
<th>Human Ethics Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Title:</strong> <em>Title which is self-explanatory and is easily understood</em></td>
</tr>
<tr>
<td><strong>SOP No:</strong> SOPxx/Vy</td>
</tr>
<tr>
<td><strong>SOP Code:</strong> SOP xx/Vy</td>
</tr>
<tr>
<td><strong>Effective date:</strong> DD/MM/YYYY</td>
</tr>
<tr>
<td><strong>Authors:</strong> xxxxxxxxx</td>
</tr>
<tr>
<td><strong>Reviewed by:</strong> xxxxxxxx</td>
</tr>
<tr>
<td><strong>Approved by:</strong> xxxxxxxxx</td>
</tr>
</tbody>
</table>
## AX3-V1/SOP01/V1

### Document History of the SOP

<table>
<thead>
<tr>
<th>Name of the author</th>
<th>Version</th>
<th>Effective date (dd-mm-yy)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Details of superseded SOP

<table>
<thead>
<tr>
<th>Name of the Team</th>
<th>Version</th>
<th>Type (draft/final)</th>
<th>Date (dd-mm-yyyy)</th>
<th>Describe the main change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Log of the HEC members receiving SOPs

<table>
<thead>
<tr>
<th>No.</th>
<th>Name of Recipients</th>
<th>Designation</th>
<th>SOP code number</th>
<th>No. of Copies</th>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>XXXX</td>
<td>Chairperson</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>XXXX</td>
<td>Member Secretary</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>XXXX</td>
<td>Member</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>XXXX</td>
<td>Member</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>XXXX</td>
<td>Member</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>XXXX</td>
<td>Member</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Request for Formulation of new SOP / Revision of SOP

This form is to be completed by any member whenever a problem or a deficiency in an SOP is identified and maintained with the SOP until an authorized replacement is in place.

<table>
<thead>
<tr>
<th><strong>SOP No.</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Title:</td>
<td></td>
</tr>
</tbody>
</table>

Details of problems or deficiency in the existing SOP

Need to formulate an entirely new SOP (i.e. SOP not existing previously)

Identified by: Date (DD/MM/YYYY):

Discussed in HEC Meeting held on :-

| SOP revision required: | ☐ Yes | ☐ No |
| New SOP to be formulated: | ☐ Yes | ☐ No |

If yes, to be carried out by whom?

If no, why not?

Date SOP revised:

Date SOP approved:

Date SOP becomes effective:
AX6-V1/SOP01/V1

Log of SOP recipients

<table>
<thead>
<tr>
<th>No.</th>
<th>Name of Recipients</th>
<th>Designation</th>
<th>SOP code number</th>
<th>No. of Copies</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>XXXX</td>
<td>XXXX</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>XXXX</td>
<td>XXXX</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>XXXX</td>
<td>XXXX</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>XXXX</td>
<td>XXXX</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td>XXXX</td>
<td>XXXX</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td>XXXX</td>
<td>XXXX</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Flow Chart

Request for new or amendment to SOPs

Chairperson discusses, if necessary team is formed

SOP Team
- Member Secretary
- 2 or 3 HEC members

Writing / Drafting of SOPs

Review of SOPs by HEC members

Approved by Chairperson

Approval of SOPs

Acceptance for implementation by Director, TMC

Distribution & Training of SOPs
Human Ethics Committee, Tata Memorial Centre (HEC, TMC)

Title: Constitution of Human Ethics Committee, TMC

SOP Code: SOP 02/V2 Date: 01/09/2009 Pages: 20
The Hospital Ethics Committee is constituted by Director, Tata Memorial Centre (TMC) under authority vested by Governing Council of the TMC

The Hospital Ethics Committee (HEC) of TMC was established in 1996.

2.1 Purpose

The HEC was established to formalize and specify the Institution's commitment to promotion of high ethical standards in patient care, professional education, clinical research, and community interests.

2.2 Mandate

The HEC through its delegated sub-committees functions independently for maintaining consistent ethical framework in patient care and research, and in the integration of ethical values into practice, policy relationships, and organizational activities.

- The purpose of HEC is to cultivate a pluralistic and democratic exchange of ethical values, concerns and to critically analyze them looking for opportunities to enhance the ethical integrity of the Institution
- The mandate of HEC, TMC essentially targets patient care and ethical aspects of research and education.
- The terms of reference for the HEC are as follows:
  - To improve the standards of ethics practiced in TMC and to issue guidelines on dilemmas relating to patient care services at TMC
  - To ensure that all proposed research projects conform to standard ethical guidelines.
  - To initiate and commission research studies on ethical aspects of practice in TMC
  - Continuing education in research bioethics and ethical aspects of clinical practice by seminars, workshops and interactive discussions for all categories of staff members including nursing and paramedical staff
  - To function as a forum for redressal of complaints on ethical issues, from patients and their families
- The Ethics committee endeavours to produce guidance on a broad range of topics. Disclosures of diagnosis, diagnosis of brain death, indications for stopping resuscitation, true informed consent, etc. are some examples
- The committee does not address or interfere in matters of an administrative nature, nor does the committee function as a grievance cell for staff members.

2.3 Scope

The SOP applies to the formation of the HEC
2.4 Responsibility

HEC has responsibility within the institution with the following objectives:

- To ensure the competent review and evaluation of all ethical aspects of research projects received, to ensure compliance with the appropriate laws and safeguard welfare of subjects.
- Clinical ethics consultation
- Education of professional, administrative, and support staff about ethical issues
- Creation, developing revising and implementing ethical guidelines (SOPs)
- Initiate studies in ethics

Continuing education and training programs to ensure that HEC members are qualified to perform their specific duties.

2.5 Ethical Basis

- The committee consists of members who collectively have the qualifications and experience to review and evaluate the scientific, medical, and ethical aspects of a proposed research project.
- The HEC recognizes that the protocols it approves may also be approved by national and / or local ethics committees prior to their implementation in specific localities.
- In evaluating protocols and ethical issues, the HEC is aware of the diversity of laws, cultures and practices governing research and medical practices in various countries around the world
- The HEC also seeks to be informed, as appropriate, by national / other local ethics committees and researchers of the impact of the research it has approved.
- The HEC is guided in its reflection, advice and decision by
  - It makes further reference to the International Ethical Guidelines for e.g. The Nuremburg Code (1945), the Council of International organizations of Medical Sciences (CIOMS), the Belmont Report 1979, the International Ethical Guidelines for Biomedical Research Involving Human Subjects (Geneva 2002), and the European Convention on Human Rights and Biomedicine 1977
- The HEC establishes its own Standard Operating Procedures based on the ICMR guidelines (2006), Schedule Y (Drugs and Cosmetics Act 1940., amendment
The HEC seeks to fulfill the requirements for international assurances and is established and functions in accordance with the national law and regulations.

Due to amendment in Schedule Y, TMC, being a premier cancer institute in the country, has become a hub for oncology based trials. Moreover, scientific rigor and research atmosphere inculcated in this institution has led to significant increase in clinical trials. For various reasons, clinical trials are also coming under close public scrutiny. Hence there is a strong need for impeccable and efficient management of clinical trials to ensure human rights protection. Speed, time, and maintenance of high ethical standards for HEC review process are very important factors for multinational clinical research.

In view of the tremendous growth of clinical research in the institution, the Director, TMC in 2008, constituted two Human Ethics Committees to function as panels with the same purpose & SOPs to ease the work load. These two committees were renamed as Human Ethics Committee I and II to expedite and maintain high standard of ethical review.

### 2.6 Composition

Each HEC will be multidisciplinary and multi-sectorial in composition. Each committee is composed of a minimum of 7, and maximum of 15 members. The members are selected to have an equitable representation of all specialties in the institution. It includes scientific and non-scientific, clinicians and non-clinicians, Clinical pharmacologist, members of the community, a lawyer/expert in ethics, a social worker / layperson / patient representative to represent different point of view.

Each committee will comprise of a Chairperson, Co-Chairperson, a Member Secretary, and 7-15 active members who represent an appropriate balance of professional, ethical, legal, cultural, educational, and community interests.

The committee should have adequate representation of age, gender, community, etc. to safeguard the interests and welfare of all sections of the community / society. Members are expected to be aware of local, social and cultural norms, as this is the most important social control mechanism.

The member should have various backgrounds to promote complete and adequate review of research activities commonly conducted by that given institute / centre.

**Composition of HEC**

The composition should be as follows:-

1. Chairperson (not – affiliated to TMC)
2. Co-Chairperson (not – affiliated to TMC)
3. Member secretary (TMC Staff members)
4. 1-2 clinicians (not affiliated to TMC)
5. Basic medical scientists
7. One legal expert or retired judge or medico-legal expert
8. One social scientist / representative of non-governmental voluntary agency
9. One philosopher / ethicist / theologian / lay person from the community

2.6.1 Membership

All members will be appointed by the Director, TMC in consultation with the Chairperson, HEC and Member Secretaries.

Criteria for selection of members:
- Members are selected on their personal capacities, based on their interest, ethical and/or scientific knowledge and expertise, experience in domain field and profile.
- Conflict of interest will be avoided when making appointments, but where unavoidable, there will be transparency with regard to such interests.
- New members will be identified according to the requirement i.e. as per the composition specified in Section 2.6. of this SOP and provided the potential member fulfils the conditions of appointment as defined in 2.6.2 of this SOP.

The following qualities are sought in HEC members:
- interest and motivation
- time and effort
- commitment and availability
- experience and education
- respect for divergent opinions
- integrity and diplomacy

2.6.2 Terms of Appointment

2.6.2.a Duration

- The members of the HEC, TMC will be appointed for duration of 2 years.
- The appointment procedure for membership will be followed so that it allows for continuity, the development and maintenance of expertise within the HEC, and the regular input of fresh ideas and approaches.
- The members can be continued and there will be no limit on the number of times the membership is extended. Extension of membership will be based on the recommendation of the Chairperson & Member Secretary of HEC.
- All HEC-I members will be alternate members for HEC-II and vice versa. Alternate member may also be appointed in case of absence of a regular member with the concurrence of other HEC members.
- A Member Secretary, Chairperson or member may be newly appointed before the completion of the tenure of the existing appointed committee. This appointment will be effective for the remaining tenure of the existing committee.
2.6.2.b Renewal

- The membership will be renewed after the stated term of 2 years
- The process of renewal will be as follows:
  Selection of Member Secretary and other members should be done 6 months and 1 month in advance respectively. Member secretary designate should be inducted in the committee as a member before he/she takes on the mantle in the new HEC. Other members designate may attend the board meeting as observers before starting their tenure as HEC member
  Designated members of the HEC who wish to attend HEC meetings as observers should read, understand, accept and sign the agreement contained in the Confidentiality / Conflict of Interest form (AX3 – V1/SOP02/V2) at the beginning of the HEC meeting and/or before ethical review tasks of the HEC commence
- If a regular member resigns, or ceases to be a member due to disqualification, or death, a new member will be appointed for the remaining term as per the Conditions of appointment stated below – section 2.6.3

2.6.2.c Resignation / Replacement procedure

The members who have resigned may be replaced at the discretion of the appointing authority for the same. HEC members who decide to resign must provide the Director, TMC and Chairperson, HEC the written notification of their proposed resignation date at least 30 calendar days prior to the next scheduled meeting. In case of resignation, Director, TMC would appoint a new member, falling in the same category of membership ex. NGO representative with NGO representative. The recommendations may be sought from the resigning member. Appointment may be made in the consultation with Member Secretary and /or Chairperson

2.6.2.d Termination / Disqualification procedure

A member may be relieved or terminated of his/her membership in case of
- Conduct unbecoming for a member of the Ethics Committee
- Inability to participate in the meetings on any grounds
- If a regular member fails to attend more than 3 meetings of HEC. The membership shall be reviewed by the HEC if the member is a regular defaulter. If deemed necessary, the HEC may decide to terminate the membership and recommend to the Director, TMC, by the Chairperson HEC for necessary action
- Relocate to another city or any such matter

In all such situations/circumstances, Director, TMC will serve a letter of termination to the member. Documentation of the termination will be recorded in the meeting minutes of the next duly constituted HEC meeting and HEC membership circular/roster will be revised.
2.6.3 Conditions of Appointment

- Name, age, gender, profession, and affiliation of HEC members will be publicised.
- Members must accept the appointment in writing.
- Submit one page CV and training certificates in Ethics and /or GCP.
- Conflict of interest, if any, must be disclosed.
- Members must apprise themselves of the relevant documents, codes, GCP, ICH guidelines and the ICMR code & HEC, TMC SOPs Members are required to sign the confidentiality agreement (AX1-V1/SOP 02/V2) at the start of their term. The confidentiality agreement protects the privacy and confidentiality of all parties whose information may be disclosed to the HEC/IRB in the course of its work.
- An investigator can be a member of the HEC; however, the investigator-as-member cannot participate in the review and approval process for any project in which he or she has presence as a PI, Co-PI or CI or potential conflict of interest.

2.6.4 Independent Consultants

- The HEC may call upon, or establish a standing list of, independent consultants who may provide special expertise to the HEC on proposed research protocols, when the Chairperson / Member secretary or the HEC members determine that a study will involve procedures or information that is not within the area of expertise of the HEC members. These consultants may be specialists in ethical or legal aspects, specific diseases or methodologies, (e.g. genetic disorders, stem cell research etc.) or they may be representatives of communities, patients, or special interest groups. These consultants must sign the confidentiality agreement (AX2-V1/SOP02/V2) regarding meeting, deliberations, and related matters. These consultants or subject experts cannot vote for decision.

2.7 Office Bearers

The HEC will have the following office bearers who have the expertise and professional qualifications to review what comes in.

2.7.1 Chairperson

The HEC Chairperson should be a highly respected individual preferably from outside the institution, fully capable of managing the HEC and the matters brought before it with fairness and impartiality. The task of making the HEC a respected part of the institutional community will fall primarily on the shoulders of this individual. The HEC must be perceived to be fair and impartial, immune from pressure either by the institution’s administration, the investigators whose protocols are brought before it, or other professional and nonprofessional sources.

Co-Chairperson- The HEC Co-Chairperson should be a highly respected individual preferably from outside the institution, fully capable of managing the HEC and the matters brought before it with fairness and impartiality, in absence of the Chairperson.
2.7.2 **Member Secretary**

The Member Secretary will be a staff member of institute, committed to the task of coordinating and managing the activities of the committee. He/she will be responsible for scheduling the meetings, describing the agenda and ensuring that the function of the committee is conducted as per the norms and policies described in this SOPs.

In absence of Member Secretary of HEC-I, the Member Secretary of HEC-II will function as acting Secretary of HEC-I and vice-versa.

2.7.3 **Secretariat**

Secretariat is composed of Member Secretary, HEC and the administrative supporting staff. The supporting staff consists of staff members of the TMC appointed by the Director, TMC.

The secretariat shall have the following functions:

- Organizing an effective and efficient tracking procedure for each proposal received
- Preparation, maintenance and distribution of study files
- Organizing HEC meetings regularly
- Preparation of agenda and minutes of the meetings
- Maintaining HEC documentation and archive
- Communicating with HEC members and PIs
- Arrangement of training for personnel and HEC members
- Providing necessary administrative support for HEC related activities to the Member Secretary, HEC
- To receive IRB processing fees and issue official receipts for the same

The HEC Administrative Staff: Working Rules

1. There will be administrative officer/s and attendant/s /helper/s who will help the HEC Chairperson and Member Secretary in executing functions of the HEC. Additional staff may be appointed and duties assigned; as and when deemed necessary by the HEC. The eligibility criteria for new staff to be appointed will be laid down depending on the required job profile. The need for appointment of administrative staff, job profile and qualifications may be recommended by HEC members during regular HEC meeting and will be recorded in minutes; these are forwarded to the Director, TMC.

2. The administrative staff will be appointed by conducting formal interviews (to be conducted by panel of experts appointed by Director, TMC.
   a. Duties of the administrative officer/s/staff
   b. Correspondence with the HEC members and external experts
   c. Correspondence with the investigators
   d. Pre and post arrangements of HEC meetings
e. Preparing agenda and minutes of the HEC meetings
f. Answering queries of the investigators
g. Filing study related documents
h. Archiving and maintaining the study files

3. Duties of the attendant/s /helper/s
   a. Assisting the secretariat in arranging the HEC meetings
   b. Dispatching sets of study documents to HEC members and external experts
   c. Receiving the study related documents from and dispatching the HEC letters to the investigators
   d. Filing study related documents
   e. Archiving and maintaining the study files
   f. Correspondence with the HEC members and external experts

4. The administrative staff will report to the Chairperson and/or Member Secretary.

5. The office timing for the administrative staff will be as per TMC rules & regulations.

6. The administrative staff will avail leave as per TMC norms.

2.8 Roles and Responsibilities of the HEC members

- The Committee’s primary responsibilities will be protection of safety, rights and confidentiality of the research subjects.
- Participate in the HEC meeting.
- Review & discuss research proposals submitted for evaluation.
- Review progress reports and monitor ongoing studies.
- Monitor SAEs and recommend appropriate action(s).
- Maintain confidentiality of the documents and deliberations of the HEC meetings.
- Declare conflict of interest, if any.
- To carry out work delegated by Chairperson, Co-Chairperson & Member Secretary.
- To participate in continuing education activities in biomedical ethics and biomedical research.
- To provide information and documents related to training obtained in biomedical ethics and biomedical research to the HEC secretariat

2.9 Quorum Requirements

- A minimum of five (5) members is required to form the quorum without which a decision regarding the project should not be taken. The quorum requirements of HEC should have the following representation:
  (a) basic medical scientists (preferably one pharmacologist)
  (b) clinicians
  (c) legal expert
  (d) social scientist or representation of non-governmental voluntary agency or
philosopher or ethicist or theologian or similar person
(e) lay person from the community

In any case, the ethics committee must include at least one member whose primary area of interest/ specialization is non-scientific and at least one member who is independent of the institution / trial site. Besides, there should be appropriate gender representation on the HEC.

- A quorum should include at least one member whose primary area of expertise is in a non-scientific area, a clinician and at least one member who is independent of the institution/research site.
- No quorum should consist entirely of members of one profession or one gender.
- In absence of the Chairperson, Co-Chairperson will chair the meeting. In absence of both, member who is independent of the institution will chair the meeting as Acting Chairperson.

2.10 Decision making

- Decision is arrived at by consensus, if consensus not possible, voting is carried out.
- Opinions of absent members that are transmitted by mail or telephone or fax may be considered by the attending members during discussion but may not be counted as votes or quorum for formally convened full board meetings.
- Any committee member with a conflicting interest in a proposal will abstain from deliberations and in decision making process on that proposal, except to provide information as requested by the committee. Such abstentions will be recorded in the minutes. Decision is arrived at by consensus, if consensus not possible voting is carried out.

2.11 Education for HEC Members

HEC members have a need for initial and continued education regarding the ethics and science of biomedical research.

All HEC members must be conversant with ICMR Guidelines for Research involving Human Subjects 2006, Schedule Y of Drugs and Cosmetics Act and ICH-GCP guidelines.

HEC members will receive introductory training material in research bioethics and functioning of HEC and will be exposed to ongoing opportunities for enhancing their capacity for ethical review.

Training of the HEC members in Research Bioethics
- A new member will be inducted 1 month prior and will be requested to be an ‘observer’ for the first board meeting. An introductory training will be imparted by the Member Secretary.
The HEC members will be encouraged to receive ongoing training by attending workshops at least once every year. The HEC will conduct workshops from time to time to impart training to the HEC members and Institutional faculty members. The training programmes should be scheduled and spread over the year.

2.12 Prepare an annual activity report of the HEC for submission to the Director, TMC.

- A quantitative evaluation of the activities of the committee in a year
- List of the research proposals reviewed in a year
- Status of each research proposal

References

Glossary

Confidentiality: Prevention of disclosure, to other than authorized individuals, of information and documents related to HEC

Human Ethics Committee (HEC): It is an independent body whose responsibility is to ensure the protection of the rights, safety and well-being of human subjects involved in a clinical trial and to provide public assurance of that protection

Independent Consultants: Professionals with advanced training and expertise in the medical or non-medical areas related to the protocol being reviewed
Confidentiality and Conflict of Interest Agreement form for HEC Members

In recognition of the fact, that I, Dr.……… herein referred to as the “Undersigned”, has been appointed as a member of the Human Ethics Committee (HEC), would be asked to assess research studies involving human subjects in order to ensure that they are conducted in a humane and ethical manner, with the highest standards of care according to the applied national, local regulations, institutional policies and guidelines;

Whereas, the appointment of the undersigned as a member of the HEC is based on individual merits and not as an advocate or representative of a home province/territory/community nor as the delegate of any organization or private interest;

Whereas, the fundamental duty of an HEC member is to independently review research protocols involving human subjects and make a determination and the best possible objective recommendations, based on the merits of the submissions under review;

Whereas, the HEC must meet the highest ethical standards in order to merit the trust and confidence of the communities in the protection of the rights and well-being of human subjects;

The undersigned, as a member of the HEC is expected to meet the same high standards of ethical behavior to carry out its mandate.

This Agreement thus encompasses any information deemed Confidential or Proprietary provided to the Undersigned in conjunction with the duties as a member of the HEC. Any written information provided to the Undersigned that is of a Confidential, Proprietary, or Privileged nature shall be identified accordingly.

As such, the Undersigned agrees to hold all Confidential or Proprietary trade secrets (“information”) in trust or confidence and agrees that it shall be used only for contemplated purposes, shall not be used for any other purpose or disclosed to any third party. Written Confidential information provided for review shall not be copied or retained. All Confidential information (and any copies and notes thereof) shall remain the sole property of the HEC.

The Undersigned agrees not to disclose or utilize, directly or indirectly, any Confidential or Proprietary information belonging to a third party in fulfilling this agreement. Furthermore, the Undersigned confirms that my performance of this agreement is consistent with the Institute’s policies and any contractual obligations they may have to third parties.
Conflict of Interest

It has been recognized that the potential for conflict of interest will always exist but has faith in the HEC and its Chairperson to manage the conflict issues so that the ultimate outcome is the protection of human subjects.

In accordance of the policy of the HEC, I shall not participate in the review, comment or approval of any activity in which I have a conflict of interest, except to provide information as requested by the HEC.

Undersigned Signature  ________________  Date

The Undersigned will immediately disclose to the Chairperson of the HEC any actual or potential conflict of interest that I may have in relation to any particular proposal submitted for review by the committee, and to abstain from any participation in discussions or recommendations in respect of such proposals.

If an applicant submitting a protocol believes that a HEC member has a potential conflict, the investigator may request that the member be excluded from the review of the protocol.

The request must be in writing and addressed to the Chairperson. The request must contain evidence that substantiates the claim that a conflict exists with the HEC member(s) in question. The committee may elect to investigate the applicant’s claim of the potential conflict.

When a member has a conflict of interest, the member should notify the Chairperson and may not participate in the HEC review or approval except to provide information requested by the Committee.

Examples of conflict of interest cases may be any of the following:

- A member is involved in a potentially competing research program.
- Access to funding or intellectual information may provide an unfair competitive advantage.
- A member's personal biases may interfere with his or her impartial judgment.

Agreement on Confidentiality and Conflict of Interest.

In the course of my activities as a member of the HEC, I may be provided with confidential information and documentation (which we will refer to as the “Confidential Information”). I agree to take reasonable measures to protect the Confidential Information; subject to applicable legislation, including the access to it, as per the right to Information Act, not to disclose the Confidential Information to any person; not to use the Confidential Information for any purpose outside the Committee’s mandate, and in particular, in a manner which would result in a benefit
to myself or any third party; and to return all Confidential Information (including any minutes or notes I have made as part of my Committee duties) to the Chairperson upon termination of my functions as a Committee member.

Whenever I have a conflict of interest, I shall immediately inform the committee not to count me toward a quorum for consensus or voting.

I, Dr. ........ have read and I accept the aforementioned terms and conditions as explained in this Agreement.

________________________________________  ______________________________________
Undersigned Signature        Date

________________________________________  ______________________________________
Director of the TMC             Date
Confidentiality Agreement Form for Independent Consultants

I, ___________________ (Name and Designation) as a non-member of HEC understand that the copy (ies) given to me by the HEC is (are) confidential. I shall use the information only for the indicated purpose as described to the HEC and shall not duplicate, give or distribute these documents to any person(s) without permission from the HEC.

Upon signing this form, I agree to take reasonable measures and full responsibility to keep the information as confidential.

__________________________  ________________________
Undersigned Signature       Date

______________________________  ________________________
Chairperson of HEC            Date

I, ___________________________ (Enter name) acknowledge that I have received a copy of this Agreement signed by Chairperson, HEC and me.

______________________________  ________________________
Signature of the recipient     Date
Confidentiality Agreement Form for Observer Attendees to HEC, TMC Meetings

I, ______________________________, understand that I am allowed to attend the HEC meeting scheduled on ___________ at ______am/ pm as an Observer.

The meeting will be conducted in the IRB Meeting room, 3rd Floor Main Building, TMH.

In the course of the meeting of the HEC some confidential information may be disclosed or discussed.

Upon signing this form, I ensure to take reasonable measures to keep the information and discussion as confidential.

____________________
Signature of the Guest

____________________
Date

____________________
Chairperson of HEC

____________________
Date

I, ______________________________ (Enter name) acknowledge that I have received a copy of this Agreement signed by Chairperson, HEC and me.

____________________
Undersigned Signature

____________________
Date
Flow Chart

Director, TMC

Human Ethics Committee-I &II

Office Bearers
- Chairperson
- Member Secretaries
- Secretariat

Composition
- Chairperson
- Co-Chairperson
- Member-Secretary
- 7-15 members

Selection Criteria
- Time
- Interest
- Education
- Experience

Terms of appointment
- Duration
- Renewal
- Resignation
- Termination

Conditions of appointment
- Acceptance
- CV
- Confidentiality agreement
- Training
Human Ethics Committee, Tata Memorial Centre (HEC, TMC)

Title: Management of Protocol Submissions

SOP Code: SOP 03/V2 Date: 01/09/2009 Pages: 36
3.1 Purpose

This SOP is designed to describe and act as a guideline for the IRB Secretariat of the IRB to manage research protocol submissions.

3.2 Scope

The scope includes the following -

- Submission for initial review
- Resubmission of protocols with modifications
- Protocol amendments and any other amendments
- Continuing review of approved protocols
- Protocol completion/termination

3.3 Responsibility

It is the responsibility of the IRB secretariat to receive record and distribute the protocols for review by the SRC/HEC and communicate the decisions to PI in a prescribed format.

All project proposals submitted (both hard and soft copies) for initial reviews are first forwarded by IRB Secretariat to SRC for reviewing its scientific merit. The project is tabled for HEC review after SRC approval.

3.4 Detailed process

3.4.1 Receive submitted packages

The PI can submit research proposal to the HEC for review and approval under any of the 5 sections mentioned below:

- Initial Review Application
- Resubmission of Protocols with Corrections
- Protocol Amendment or any other Amendments
- Continuing Review of Approved Protocols
- Protocol Completion / Termination

3.4.2 Verify Contents of Submitted Package

- Check the applicable documents to ensure that all required forms and materials are contained within the submitted package. Checking is done as per checklist (AX2-V1/SOP 03/V2) for submissions for initial review.
- Verify contents of the submitted package which should include
  - Original Application Form for Initial Review or Project submission Form (AX1-V1/SOP 03/V2)
  - Study protocol
Other related documents necessary for initial review \((AX\ 2-V1/SOP\ 03/V2)\)
- Check completeness of necessary information and signature at all appropriate places in the application form submitted for initial review.
- Notify the applicants, if a package is incomplete.

State clearly the items missing in the package on the Protocol submission / document receipt form \((AX\ 3-V1/SOP03/V2)\) along with SRC approval document.

The Secretariat will
- Stamp, sign & date of receipt on the cover letter confirming receipt of the documents.
- Make a photocopy of the completed document receipt form \((AX\ 3-V1/SOP03/V2)\) and return the original copy of the \((AX\ 3-V1/SOP03/V2)\) to the applicants for their records.
- Count for correct numbers of hard copies (Initially 15 copies for investigator-initiated studies and 15 copies for pharma-sponsored studies).
- Store the hard copies and soft copy of the research project. The hard copies will be stored in locked cupboards in HEC office and soft copy of IRB submission form / study protocol accepted by email will be saved on HEC computer.
- The project file is numbered as serial number / P or E or I / Year / Number e.g. 628/P/09/01 will indicate – 628 as serial no of project, P – Pharma, 09 – year, number 01 project of the year 2009. (where P = Pharma sponsored trials, E = Extramural funding, I = Intramural funding). This coding system will be maintained on the excel sheet (inventory of projects) and also labeled on each project file.
- All correspondence for the projects, should quote only the serial number i.e 628 this unique identity number.
- Record the date of receipt, no. of copies and the name of the receiver in register.
- Store the received packages, which include original protocol file and copies of the protocol to be distributed for review.

### 3.5 Detailed description of Study Project Submission

The **study protocol** should be accompanied with the following relevant supporting documents for scientific and ethical review. These are –

1. Checklist (Refer \(AX\ 2-V1/SOP\ 03/V2\))
2. Project Submission Form
   - A. Grouping of Project
   - B. Project Fact Sheet
   - C. Project Submission Overview
   - D. Budget Sheet for the Proposed Study
3. Essential Documents
   - a. Informed Consent Documents (Refer \(AX4-V1/SOP\ 03/V2\))
   - b. Participant Information Sheet
4. Decision of other Ethics Committees (If required / asked for)
Details of Essential Documents along with protocol

1. Participant Information Sheet, Informed Consent Forms (ICFs), Assent Forms and Parent consent forms (if children / adolescents between 7 – 18 years of age are participants in the trial) - in English, Hindi and Marathi (Refer AX5-V1/SOP 03/V2)
2. Investigator's Brochure
3. CRF
4. One page, recent, signed and dated curriculum vitae of the investigators indicating qualifications and relevant experience.
5. Agreement to comply with national and international GCP protocols for clinical trials
6. Details of Funding agency / Sponsors and fund allocation
7. Regulatory clearance for all types of studies from appropriate regulatory authorities i.e. DCGI approval, DGFT approval (for export of study samples), ICMR, DBT, other local government agencies (as applicable)
8. For exchange of biological material in international collaborative study a MOU / MTA between the collaborating partners and of Health Ministry Screening Committee (HMSC)
9. CTA or MOU between the collaborators
10. Insurance/Indemnity policies, indicating who are covered
11. Any other information relevant to the study

3.6 Resubmission of Protocols with corrections as per HEC suggestions

- For resubmitted protocol, the PI will submit one copy of the amended Protocol and related documents along with justification for amendment, and clearly highlighted / demarcated sections which have undergone amendment
- The IRB Secretariat will verify the completeness and reconfirm that the copy contains the modification highlighted with respect to the earlier protocol
- The IRB Secretariat will perform the steps 3.4.2 as mentioned in initial review application. The protocol related documents which do not require to be changed and are already submitted to the HEC during initial review are need not be submitted again

3.7 Research Protocol Amendments and other study related documents

- The PI will submit 15 copies of the protocol amendments or any other study related documents to the IRB Secretariat.
- The IRB Secretariat will verify the completeness as per checklist for the contents of submitted package
- The PI will highlight the modification/s in the amendment, along with a summary of changes and whether these changes would entail changes in the ICF.
- The Member Secretary in consultation with Chairperson will decide whether to:
  - Carry out an expedited review in case of minor administrative amendment.
  - Table for discussion at the full board meeting / or revert back for SRC review

This is process is further elaborated in SOP 06/V2.
3.8 Annual Continuing Reviews of Approved Protocols

- The HEC will send reminders for annual report to Individual PI, 15 days prior to the expiry date of approval, which usually is one year from the date of approval letter.
- The HEC will receive a copy of Annual Study / Continuing Review Report in the prescribed format and related documents (as per SOP 07/V2) for the approved protocol.
- The IRB Secretariat will verify the completeness of the Continuing Review Application Form (AX1-V1/SOP 07/V2) Progress report/Request letter for extension of approval of the project. The IRB Secretariat will sign and date the documents.
- The progress or continuing review report will be tabled in the full board meeting of HEC.

3.9 Protocol Completion

- The HEC will send reminders for annual report to Individual PI, 15 days prior to the date of completion.
- The HEC will receive a copy of Study Completion Report in the prescribed format (as per SOP 12/V2).
- The IRB Secretariat will verify the completeness of the Study Completion Report Form (SOP12/V2) filled by the PI.
- The study completion report will be tabled in the full board meeting of HEC.

Reference


Glossary

Investigator’s Brochure: The Investigator’s Brochure (IB) is a compilation of the clinical and non-clinical data on the investigational product(s) that are relevant to the study of the product(s) in human subjects.

study Protocol: A document that describes the objective(s), design, methodology, statistical considerations and organization of a trial.
Tata Memorial Centre

(AXI-V1/SOP 03/V2)

Project Submission Form for review by SRC & HEC

A. Grouping of Project

<table>
<thead>
<tr>
<th>Project No.</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Title:</td>
<td></td>
</tr>
<tr>
<td>PI:</td>
<td></td>
</tr>
</tbody>
</table>

Please complete the questionnaire for submitting the research proposal for TMC-SRC/HEC

**Study Group**

(Please circle the applicable Y/N neatly)

<table>
<thead>
<tr>
<th>Group</th>
<th>Detail</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Controlled trials</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>01</td>
<td>A1 a                      Is this a randomized controlled trial?</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>02</td>
<td>A1 b                      Is this a non-randomized controlled trial?</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>03</td>
<td>A1 c                      Is this a controlled trial that seeks new indication for establishing drug, process or a procedure?</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td><strong>Uncontrolled trials</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>04</td>
<td>A2 a                      Is this a prospective trial testing new intervention, drug, or device on patients?</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>05</td>
<td>A2 b                      Is this a prospective trial designed to test new (unproven) indication for established drug, process, procedure or device on patients?</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>06</td>
<td>A2</td>
<td>c</td>
<td>Is this a pilot trial on new intervention, drug, and device on patients?</td>
</tr>
<tr>
<td>07</td>
<td>A3</td>
<td>a</td>
<td>Is this a multi-centre trial?</td>
</tr>
<tr>
<td>08</td>
<td>A3</td>
<td>b</td>
<td>Does this trial involves transfer of patients' data to another site (including industry)?</td>
</tr>
<tr>
<td>09</td>
<td>A3</td>
<td>c</td>
<td>Does this trial involves transfer of patients’ blood, serum, DNA, tissue to another site?</td>
</tr>
</tbody>
</table>

**Trial involves transfer of data / material from TMC**

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>A4</td>
<td>a</td>
<td>Are you seeking intramural funding?</td>
</tr>
<tr>
<td>11</td>
<td>A4</td>
<td>b</td>
<td>Does this trial use additional resources of TMC beyond the usual patients' work-up (e.g. IHC, molecular profiling, MRI etc. which is not a routine part of work-up)?</td>
</tr>
</tbody>
</table>

**Intramural Funding**

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>A5</td>
<td>a</td>
<td>Are you submitting application for extra-mural grant for this trial?</td>
</tr>
<tr>
<td>13</td>
<td>A5</td>
<td>b</td>
<td>Is this trial partly or wholly supported by grants from sponsored industry?</td>
</tr>
<tr>
<td>14</td>
<td>A5</td>
<td>c</td>
<td>Is this a phase IV / marketing trial undertaken on behalf of the industry?</td>
</tr>
</tbody>
</table>

**Extramural Grants**

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>A6</td>
<td>Are you seeking modification/s in the TMC-SRC/HEC approved trial?</td>
<td>Y N</td>
</tr>
</tbody>
</table>

**Modification in approved trials**

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>A7</td>
<td>a</td>
<td>Will the study participants bear the cost of experimental intervention or drug therapy?</td>
</tr>
<tr>
<td>17</td>
<td>A7</td>
<td>b</td>
<td>Will the study participants undergo additional blood sample collection, biopsy, endoscopy, procedure etc.?</td>
</tr>
<tr>
<td>18</td>
<td>A7</td>
<td>c</td>
<td>Will the study participants bear the cost of complications arising from experimental treatment?</td>
</tr>
</tbody>
</table>

**Study participants to bear the cost of trial**
<p>| | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>A7</td>
<td>d</td>
<td>For the trial purpose, does the study participants have to spend Rs. 5000/- or more above the usual expenses (for any reason such as drug therapy, additional investigation, prolonged stay or repeated travel)?</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>20</td>
<td>A8</td>
<td>a</td>
<td>Will this trial be undertaken in the community?</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>21</td>
<td>A8</td>
<td>b</td>
<td>Will this trial involve the screening?</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Community or screening trials</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>A9</td>
<td>Does this trial involve conducting genomics or proteomics studies on study participants specimens?</td>
<td>Y</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Trials involving genomics &amp; proteomics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>A10</td>
<td>Will this trial involve development of a device, drug or test leading to profits or patent?</td>
<td>Y</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Trials with conflict of interest</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>B1</td>
<td>Is this a prospective follow-up study (documentation of parameters only) of patients who are being offered standard treatment at TMH?</td>
<td>Y</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>B2</td>
<td>Is this a phase II-IV trial restricted to standard intervention / treatments published in EBM book?</td>
<td>Y</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>B3</td>
<td>Is this a feasibility study for introduction of new treatment, recently shown in major international studies, to be beneficial / superior and need to be started at TMC?</td>
<td>Y</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>B4</td>
<td>Is this a retrospective or prospective analysis of charts and audit of procedures / tests / treatments?</td>
<td>Y</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>B5</td>
<td>Is this a retrospective or prospective review of pathology specimen (may involve some additional staining techniques)?</td>
<td>Y</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>B6</td>
<td>Is this a retrospective or prospective review of radiology reports and their clinical correlation?</td>
<td>Y</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GROUP- B</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Trials that should be notified to SRC secretariat for entry in to the “TMH TRIAL REGISTER”.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>B7</td>
<td>Is this a retrospective or prospective review of laboratory reports and their clinical correlation?</td>
<td>Y</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>B8</td>
<td>Are you demonstrating an experimental procedure which is ‘not established standards of care’ at a workshop, or a public meeting?</td>
<td>Y</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>32</td>
<td>B9</td>
<td>Are you performing a procedure in workshop at TMH by non-TMH staff member? (Please check other requirements also)</td>
<td>Y</td>
<td>N</td>
<td></td>
</tr>
</tbody>
</table>

Name of PI: ___________________________ Signature: ___________________________
**B. Project Fact Sheet**

<table>
<thead>
<tr>
<th>Project No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>(To be filled by the Secretariat)</td>
</tr>
<tr>
<td>Date of receipt by IRB</td>
</tr>
<tr>
<td>Project Title</td>
</tr>
<tr>
<td>Key Words title (2-4 options)</td>
</tr>
<tr>
<td>Principal Investigator</td>
</tr>
<tr>
<td>Co-Principal Investigators (if any)</td>
</tr>
<tr>
<td>Co-investigators</td>
</tr>
<tr>
<td>Site/sites where study is to be conducted i.e. TMH / ACTREC / Both. (Please specify).</td>
</tr>
<tr>
<td>Number of ongoing studies, PI is involved?</td>
</tr>
<tr>
<td>Agency or Sponsor</td>
</tr>
<tr>
<td>Total estimated budget</td>
</tr>
<tr>
<td>Conflict of interest, if any</td>
</tr>
<tr>
<td>Duration of the Project (months)</td>
</tr>
<tr>
<td>Suggested date of starting the study</td>
</tr>
<tr>
<td>Total number of patients to be accrued in study (including TMC, if multi-institutional study)</td>
</tr>
<tr>
<td>Number of patients from TMC to be accrued</td>
</tr>
<tr>
<td>Will biological products be sent out of the country? If yes, has ICMR/HMSC/DGFT permission/NOC been obtained?</td>
</tr>
<tr>
<td>Signature of PI</td>
</tr>
<tr>
<td>Date of submission</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Project No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial Register No.</td>
</tr>
<tr>
<td><strong>Project Title</strong> (To be filled by PI)</td>
</tr>
<tr>
<td><strong>Revised Title</strong> if any (To be filled by IRB)</td>
</tr>
<tr>
<td><strong>Principal Investigator</strong></td>
</tr>
</tbody>
</table>

**TMC - SCIENTIFIC REVIEW COMMITTEE APPROVAL**

The above titled project with all the accompanying documents listed above was reviewed by the members of the TMC - Scientific Review Committee present on ……………………… at Tata Memorial Centre. The committee has granted approval on the scientific content of the project. The proposal may now be reviewed by the Human Ethics Committee for granting final approval.

Secretary ………………………………… Chairperson ………………………………
Name: ………………………………… Name: …………………………………
Date: ………………………………… Date: …………………………………

**HUMAN ETHICS COMMITTEE APPROVAL**

The members of the Human Ethics Committee met on ……………………… at Tata Memorial Centre and reviewed the above named project with all the documents listed above. The ethics committee after careful deliberations has granted final approval to the project. The above mentioned project / study may now be undertaken at Tata Memorial Centre in accordance with the study protocol submitted by the investigators, subject to fulfilling other institutional regulations.

Secretary ………………………………… Chairperson ………………………………
Name: ………………………………… Name: …………………………………
Date: ………………………………… Date: …………………………………
### Investigators Declaration

<table>
<thead>
<tr>
<th>No.</th>
<th>Statement</th>
</tr>
</thead>
<tbody>
<tr>
<td>01.</td>
<td>This research project (including collection of blood or tissues samples for research) will not be started until the final approval of the HEC has been obtained.</td>
</tr>
<tr>
<td>02.</td>
<td>We agree to undertake research proposal involving human subjects in accordance with the ICH-GCP and ICMR ethical guidelines, 2006. We will not modify the research protocol, consent, etc without prior approval by the HEC.</td>
</tr>
<tr>
<td>03.</td>
<td>The investigators agree to obtain a properly informed and understood consent for all trial subjects before their inclusion in the trial in the informed consent form that is approved by the HEC. Participants will receive an ‘information sheet’ which will detail the project design in simple understandable layperson’s language.</td>
</tr>
<tr>
<td>04.</td>
<td>The investigators agree to report within a week all serious adverse events (SAE) associated with the trial in the SAE form to the HEC. In the event of a death of the trial subject, the Secretary, HEC and DSMSC, will be informed within 24 hours.</td>
</tr>
<tr>
<td>05.</td>
<td>The investigators agree to submit periodic 6 monthly progress report of the trial in the appropriate form. A final report will be submitted at the end of the trial.</td>
</tr>
<tr>
<td>06.</td>
<td>Full details on funding and a proposed budget are included with the trial proposal. The proposed budget is presented on the specific budget sheet of this form.</td>
</tr>
<tr>
<td>07.</td>
<td>We understand that the HEC is concerned about transparent financial transactions during the trial. A report on how the trial funds were utilized will be presented to the EC along with the final project report at the end of the trial.</td>
</tr>
<tr>
<td>08.</td>
<td>The investigators agree to transfer 15% of the total budget to TMC as service charges. This will not apply to intramural projects, those projects co-sponsored by TMH / CRI / ACTREC / DAE and ICMR / DBT /DST/WHO/IAEA funded projects.</td>
</tr>
<tr>
<td>09.</td>
<td>The investigators agree that the grant money will be spent in accordance with the budget proposal only. The funds will not used for any other purposes without prior approval from the HEC. Thirty percent of the surplus grant if left over at the end of the study will be credited to TMC. The remaining 70% of the surplus grant money may be used by the investigators for conducting intramural research, improving teaching facilities in the department, providing financial assistance to investigators for conferences, etc after obtaining permission from the HEC.</td>
</tr>
<tr>
<td>10.</td>
<td>For all research proposals that are sponsored by a pharmaceutical or biomedical company, we the investigators will ensure that the Sponsor Company will underwrite all expenses such that neither the hospital nor the study participants are made to spend while participating in the trial. The investigators will also ensure that in the event of complications arising directly due to the trial or litigation, the cost of management or legal fees will be borne by the Sponsor Company totally.</td>
</tr>
<tr>
<td>11.</td>
<td>The investigators state that they do not stand to gain financially from the commercial sponsor and don’t have conflict of interest in the drug or product by way of consultations, shareholding, etc.</td>
</tr>
</tbody>
</table>
12. The investigators will ensure that personnel performing this study are qualified, appropriately trained and will adhere to the provisions of the Human Ethics Committee. TMC, approved protocol.

13. All data collected during the research project, including those supported by commercial sponsors (e.g. pharmaceutical company), will remain the property of Tata Memorial Centre.

14. The salaries to staff employed for the research project will be as shown in the budget sheet and at par with the prevailing TMC salary scales.

15. The case records (source documents) will be made available to members of the SRC or HEC any time for random verification and monitoring. The case records (source documents) will be preserved in the premises of TMC for at least 5 years after the last approval of application or publication.

16. The investigators promise to ensure that there is no falsification of data when compared to the source documents. We agree to clarify any doubts or discrepancies that may arise during the data monitoring evaluation.

17. All the findings and conclusions of the proposed project such as review of case records, analysis of forms of treatment, investigations, etc will be first presented to the staff members of TMC before they are released or presented elsewhere. The investigators will submit a copy of the abstract to the SRC and HEC well in advance of any proposed presentation at national or international conferences or seminars.

18. The investigators will not issue any press release before the data and conclusions have been peer-reviewed by the TMC staff or published in a peer-reviewed journal.

19. All serious injuries arising from the trial will be the responsibility of the investigators. The investigators agree to ensure that the sponsors undertake a product liability insurance to cover any expenses for injury or compensation arising from the study treatment.

20. The investigators will constantly inform the HEC about amendments in the study protocol, data collection forms, informed consent forms, budget expenses, salaries, other trial documents, etc. as and when they occur. No major changes in the treatment arms or the study protocol or randomization technique will be carried out without prior permission of the HEC.

21. The investigators realize that the HEC is particular that all aspects of the study are in accordance with the ICH-GCP and ICMR ethical guidelines, 2006. The investigators will comply with all policies and guidelines of the TMC and affiliating/collaborating institutions where this study will be conducted, as well as with all applicable laws regarding the research.

We the investigators of the proposed trial have read all the statements listed above and agree to observe / undertake these HEC requirements while conducting our proposed project / trial.
We understand that serious protocol violations and/or non-compliance during the trial by the investigators may result in withdrawal of project approval by Human Ethics Committee.

<table>
<thead>
<tr>
<th>CC No.</th>
<th>Investigator Name</th>
<th>Email</th>
<th>Status (PI, Co-PI, CI)</th>
<th>Sign &amp; date</th>
<th>Role &amp; responsibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Role & responsibility of investigator is categorized from A to Z as follows:**

A. Concept  
B. Design  
C. Screening of patients  
D. Selection & Recruitment of patients  
E. Laboratory investigations  
F. Laboratory report interpretation  
G. Treatment decision  
H. Patient evaluation  
I. SAE evaluation and reporting  
J. Examination of patients on follow-up  
K. Data collection and monitoring of data  
L. Interpretation of data  
M. Statistical analysis & Interpretation  
N. Maintaining patients file and master file of project  
O. Drafting final report  
P. Publication  
Z. Any other, please specify

*Please mention the category in column of role & responsibility.*

*Note: Investigators may clarify any of the points in this undertaking with the IRB secretariat*
To,
The Secretary
Scientific Review & Human Ethics Committee
Tata Memorial Centre

Project entitled: ………………………………………………………………………

Name of PI:

Conflict of Interest

☐ I hereby declare that I have no conflict of interest in my project.
☐ I have following conflict of interest:

Signature of PI Date

Consent of Head of the PI's Department

Date:………

I have reviewed the above project submitted by ……………………………………. Principal Investigator from my Department. I endorse the project and have ‘no objection’ for submission for consideration by Scientific & Ethics committee.

I concur with the participants / investigators included in the study.

Signature & date Name Department

Consent from Working Group

Date:………

The above project submitted by ……………………………………. , Principal Investigator, has been discussed in the ………………..working group and has been accepted to be submitted for submission for Scientific & Ethics committee consideration.

The investigators / participants included in the study are acceptable to the members.

Signature & date Name (senior member of working group)
C. Project Submission Overview

<table>
<thead>
<tr>
<th>Title</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Names of all Investigators</th>
</tr>
</thead>
<tbody>
<tr>
<td>(underline principle investigator)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Introduction / background</th>
</tr>
</thead>
<tbody>
<tr>
<td>Give the background, including human or animal research relevant to the design of the proposed study. When new techniques or procedure are to be used, provide a description of preliminary work. When an investigation drug is to be used, animal data and phase I or II data on the drug should be included. A summary of how the study may help in the future should be included in the protocol.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aims / Objectives</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clearly state the aims or objectives of the study. Whenever possible this should be in the form of a hypothesis.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Design of the Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase-I, Phase-II, Phase-III, Phase-IV, NA</td>
</tr>
<tr>
<td>Randomized [Double or single blind], Open [ ]</td>
</tr>
<tr>
<td>If multicentric, is TMH the co-coordinating centre?</td>
</tr>
<tr>
<td>Epidemiological [ ] Survey [ ] Observational [ ]</td>
</tr>
<tr>
<td>Case control [ ], Any other (Specify)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study methodology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Explain, in sequence, the conduct of study and all data collection procedures. Describe the involvement of human subjects including initial evaluation procedures and screening tests, phases, medical/surgical procedures and sequence of the study. Separate standard and experimental aspects of the study as much as possible. Give brief account of procedures for treatment, dose adjustments, etc. Describe the randomization procedure, if applicable. Specify if procedure involves banking of biological samples. Define stop points and criteria for withdrawing subjects from the study.</td>
</tr>
</tbody>
</table>
Eligibility
(Explain inclusion and exclusion criteria; To be stated clearly in the summary)
(specific explanation if participants will include Minor, Pregnant woman, Neonate, Person incompetent to give informed consent, Normal/Healthy volunteer, Student, Staff of the institute).

<table>
<thead>
<tr>
<th>How many subjects will be screened? How many subjects are likely to be enrolled?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Describe benefits to the subject/participant in this study. Also describe the benefits, if any, to the society.</td>
</tr>
</tbody>
</table>

Power estimates
Describe power calculations, if the study involves statistical comparisons between two or more groups. Mention evidence to support that adequate number of subjects can be enrolled during the study period by the investigators.

<table>
<thead>
<tr>
<th>Variables to be estimated</th>
</tr>
</thead>
<tbody>
<tr>
<td>(e.g. response, survival, toxicity, age, etc) Enumerate the variables, outcomes and end points that will be measured. Try to separate variables as response and explanatory variables. Describe the type and frequency of tests, admissions, outpatient visits, etc used to obtain these variables or variables.</td>
</tr>
</tbody>
</table>

Analysis of the variables
Describe how the variables obtained during the study will be statistically analyzed. e.g. Univariate comparison or Cox-proportional hazards model, etc

<table>
<thead>
<tr>
<th>Describe all possible risks and discomfort for subjects due to use of intervention and/or data collection methods proposed. Describe expected degree and frequency of such risks, discomfort, side effects of drug etc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>If the procedures in the trial are invasive or potentially harmful, describe what arrangements have been made for treatment of the complications arising from the trial?</td>
</tr>
<tr>
<td>Who will bear the cost of treating the complications arising from this trial?</td>
</tr>
<tr>
<td>Does your study involve testing of drug/s, device/s and/or biologics? Yes [ ] No [ ]</td>
</tr>
<tr>
<td>Question</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Are they already approved by the regulatory authorities and available in the market or are they new ones?</td>
</tr>
<tr>
<td>Who has prepared and /or is manufacturing the drug/s, device/s and biologics under investigation?</td>
</tr>
<tr>
<td>Who holds the patent or IND/IDE of the drug/s, device/s and biologics under investigation?</td>
</tr>
<tr>
<td>What are the reasonable possibilities of the availability after the study of the investigational drug(s), device(s) and biologics for the study participants/subjects if it is found to be effective?</td>
</tr>
<tr>
<td>Does your study require permission from regulatory authorities?</td>
</tr>
<tr>
<td>If yes,</td>
</tr>
<tr>
<td>(i) from DCGI</td>
</tr>
<tr>
<td>(ii) from the ICMR</td>
</tr>
<tr>
<td>(iii) From other govt. departments</td>
</tr>
<tr>
<td>If yes, specify the department Whether permission is obtained</td>
</tr>
<tr>
<td>Does your study require you to send human biological material outside India?</td>
</tr>
<tr>
<td>If yes, have you obtained permission of the director, TMH &amp; DGFT?</td>
</tr>
<tr>
<td>Has TMH and the foreign party signed agreement/MOU for that?</td>
</tr>
<tr>
<td>If yes, attach a copy of agreement/MOU</td>
</tr>
<tr>
<td>If study will be conducted fully or partially outside the TMH, please describe the need for permission from institution(s), health centre(s), local government/administrative bodies, etc.</td>
</tr>
<tr>
<td>Describe how you define adverse events in your study, how and to whom you propose to report them, and what rules you will use for stopping the study due to adverse events.</td>
</tr>
<tr>
<td>In what way will you ensure the confidentiality and privacy of the subjects?</td>
</tr>
<tr>
<td>If some procedures in this trial are emotionally upsetting describe what arrangements have been made for psychological counseling?</td>
</tr>
</tbody>
</table>
Describe (i) How, where, when and by whom the Informed Consent will be obtained. (ii) how much time the subject/participant will be given to consider participation and decide, (iii) describe additional plans/needs for informed consent in case the study involves special population such as minors, pregnant mothers, neonates, etc. (iv) Describe how you will assess that information is correctly understood by the participant.

Who will be maintaining the trial records and where?

For how long will the data be stored? Give details of where they will be stored, who will access

Describe briefly, if any, the financial and other interests of any of the investigators and/or close relative/s, with the sponsor/s and outcome of the study.

Have you made provision for insuring yourself, and TMC against any legal action that may arise out of this project?

Have you made provision for insuring trial subjects for any accidental unforeseen trial related injury?

How is it intended the results of the study will be reported and disseminated?

- Peer reviewed scientific journals
- Other publication
- Conference presentation
- Internal report
- Submission to regulatory authorities
- Access to raw data and right to publish freely by all the investigators in study or by independent steering committee on behalf of all investigators
- Other ………………..

Name of PI: 

Signature: 

Date:
### D. Budget Sheet for the Proposed Study

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Title of the Project:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>2. Principal Investigator</strong></td>
<td></td>
</tr>
<tr>
<td><strong>3. Designation and address of the PI</strong></td>
<td></td>
</tr>
<tr>
<td><strong>4. Co-investigators</strong></td>
<td></td>
</tr>
<tr>
<td><strong>5. Source of funding</strong></td>
<td></td>
</tr>
<tr>
<td>- Government</td>
<td>Central [ ], State [ ], Local [ ]</td>
</tr>
<tr>
<td>- Intramural</td>
<td></td>
</tr>
<tr>
<td>- Private Foundation</td>
<td>Indian [ ], Foreign [ ]</td>
</tr>
<tr>
<td>- Industry</td>
<td>Private [ ], Public [ ], Other [ ]</td>
</tr>
<tr>
<td>- Other</td>
<td></td>
</tr>
<tr>
<td>- No funding required</td>
<td></td>
</tr>
<tr>
<td>- Address, phone, fax. E-mail of sponsor with the name of the contact person</td>
<td></td>
</tr>
<tr>
<td><strong>6. Total Budget for the entire project</strong></td>
<td></td>
</tr>
<tr>
<td><strong>7. Duration of the Project</strong></td>
<td></td>
</tr>
<tr>
<td><strong>8. Proposed date of starting the project</strong></td>
<td></td>
</tr>
<tr>
<td><strong>9. Direct payments to investigators, if any</strong></td>
<td></td>
</tr>
<tr>
<td><strong>10. Any other benefits to the investigators</strong></td>
<td></td>
</tr>
<tr>
<td><strong>11. Conflict of Interests, if any</strong></td>
<td></td>
</tr>
<tr>
<td><strong>12. Type of project funding</strong></td>
<td></td>
</tr>
<tr>
<td>- Intramural from TMC</td>
<td></td>
</tr>
<tr>
<td>- Non profit agency / trust funded</td>
<td></td>
</tr>
<tr>
<td>- Pharma / industry sponsored</td>
<td></td>
</tr>
<tr>
<td>- Others – specify</td>
<td></td>
</tr>
</tbody>
</table>

Name of PI: ______________________ Signature: ______________________ Date: ______________________
### Detailed Budget for the Proposed Study

<table>
<thead>
<tr>
<th>1. Source of funding</th>
<th>1st Year</th>
<th>2nd Year</th>
<th>3rd Year</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Items</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. Salaries-personnel (Numbers)</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Research Nurse</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doctor (Research Fellow)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data operator</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any other specify</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. Equipment and Hardware</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. Drugs and Consumables</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. Clinical Investigations</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. Hospitalization</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. Travel expenditure for investigators</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Description</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td><strong>Travel expenditure for trial subject and one attendant</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td><strong>Honorarium to doctors/technicians</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td><strong>Insurance</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>i. for investigators</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ii. any unforeseen, accidental trial related injury</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td><strong>Any other expenditures</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td><strong>Miscellaneous (&lt;5% of budget)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td><strong>TMC Service Charge (10% of total)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(TMC, DAE, ICMR, DBT, DST, IAEA, WHO, IARC etc. funded project are exempted)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td><strong>Estimated Investigator fees</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(15% at the end of the study on actuals)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Grand Total</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Name of PI:  
Signature:  
Date:

**Note:**
- PI should devise incremental budget whenever necessary.
- Please provide the complete break-up of item nos. 3, 4 & 5 on separate sheet.

**Instructions:**
- This form must be printed and not handwritten.
- Fill the form completely (If there are any questions/queries, please contact the IRB office 022-24177262).
- Make sure to include the e-mail address and contact numbers of the PI, Co-investigators.
- Please submit the documents as per the checklist (AX2-V1/SOP03/V2) to ensure all requirements for submission are fulfilled so that the IRB review is not delayed.
- Submit this application (submission form) and appendices along with the supporting documentation to the IRB office.
## Checklist of Documents

<table>
<thead>
<tr>
<th>Item No.</th>
<th>Mandatory Documents</th>
<th>Yes</th>
<th>No</th>
<th>NA</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>IRB processing fee <em>(applicable for sponsored trials)</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Project Submission Form (both hard and soft copies)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>duly signed by the Principal Investigator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A.</td>
<td>Grouping of Project</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.</td>
<td>Project Fact Sheet</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Investigators Declaration</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Conflict of Interest Statement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consent of Head of the PI's Department</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consent from Working Group</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C.</td>
<td>Project Submission Overview</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D.</td>
<td>Budget Sheet for the Proposed Study</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Detailed Budget for the Proposed Study</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Study Protocol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Participant Information Sheet &amp; Informed consent forms (ICFs) in English, Marathi &amp; Hindi (and if required any other language)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Back translations of ICFs (not mandatory for Hindi and Marathi)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Case Record Form</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Investigator Brochure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Insurance policy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>DCGI approval letter / DCGI submission letter</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>NOC from DCGI / DGFT/ICMR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Appendix VII (Schedule Y) Undertaking by the Investigator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Clinical Trial Agreement (CTA) / Memorandum of Understanding (MOU) / Material Transfer Agreement (MTA) if applicable</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Brief resume of PI and Co-investigators (1 Page each)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Document Receipt Form

<table>
<thead>
<tr>
<th>TMH Study Number</th>
<th>Submitted date:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Type of Submission</th>
<th>Initial Review</th>
<th>Continuing Review of Approved Protocols</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Protocol Title:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mode of submission:</th>
<th>Post</th>
<th>E-submission</th>
<th>in Person</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Type of document:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

### Checklist to assess the projects before they are submitted to SRC & HEC review

<table>
<thead>
<tr>
<th>Item No.</th>
<th>Mandatory Documents</th>
<th>Yes</th>
<th>No</th>
<th>NA</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>IRB processing fee <em>(applicable for sponsored trials)</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Project Submission Form (both hard and soft copies) duly signed by the Principal Investigator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A. Grouping of Project</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>B. Project Fact Sheet</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Investigators Declaration</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Conflict of Interest</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consent of Head of the PI’s Department</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consent from Working Group</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Project Submission Overview</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Details</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Study Protocol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Participant Information Sheet &amp; Informed consent forms (ICFs) in English, Marathi &amp; Hindi (and if required any other languages)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Back translations of ICFs (not mandatory for Hindi and Marathi)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Case Record Form</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Investigators Brochure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Insurance policy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>DCGI approval letter / DCGI submission letter</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>DGFT approval letter / DGFT submission letter</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Appendix VII (Schedule Y) Undertaking by the Investigator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Clinical Trial Agreement (CTA) / Memorandum of Understanding (MOU) / Material Transfer Agreement (MTA) if applicable</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Brief resume of Principal Investigators and Co-investigators (1 Page each)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Documents submitted:**
- □ Complete
- □ Incomplete; will submit on…………...

**Comments:**

**Receiver Name, Sign & Date**  
(IRB Secretariat)  
**Secretary, SRC**  
Sign & Date

**Project submitted by Name & Sign**  
(Project or study team member)
Guidelines for devising ICF and Sample format of an Informed Consent Document.

**Guideline for preparation of the informed consent form**

While submitting your project report to the Human Ethics Committee, ensure that you have included an informed consent form that is prepared as per the guidelines for ICH – GCP, ICMR ethical guidelines 2006, and the Declaration of Helsinki. The consent form must necessarily include the following points listed below. Any further information you wish to add, is your choice.

The following are instructions for devising Informed Consent Form:

- Informed consent forms in English, Marathi, and Hindi
- Font: Arial
- Size: 12
- All the consent forms must have Version No, Date, Page no **in the footer**
- Separate forms should be prepared when minors (children) are study participants; assent form for the mature minors (teenagers) and consent form for the parents

The consent form must necessarily include the following points listed below and any further information you wish to add.

**Template for devising an “Informed Consent Form”**  
(Include or exclude information, as applicable)

**Informed Consent Form**

*The title of the project here exactly as it is in the project design with names of Principal Investigator and all other investigators.*

**Introduction:**

You are invited to participate in a study/research/experiment. This document gives you a description of the study/trial in which you are being asked to participate. Your participation in this study is voluntary, and you can enquire about all details before giving your written consent to participate in the study.

**Purpose:**

The purpose of this study is to …………………………………………………………………………………
**Information:**

List all procedures, which will be employed in the study. Point out any that are considered experimental/or otherwise, and explain technical and medical terminology in simple, non-technical & direct language.

Graphics could be used if helpful in making the text meaningful to the research subject.

If this is a randomized trial, details of both arms of the trial must be explained in writing to the subject being enrolled.

State the amount of time required of the subject per session, for the total duration of study and the expected duration of the study.

*If applicable to your study, list:*

1. The number of participants who will be participating in the research.
2. Information concerning taping or filming.
3. If tissues or biological samples are being retained for research, describe what will be done to the tissues in simple lay person’s terms.

**Alternative treatments:**

Disclose appropriate alternative treatments available, if any.

**Risks:**

List the foreseeable risks, if any, of each of the procedures to be used in the study, and any measures which will be used to minimize the risks, or treat them should they occur. Explanation of anticipated side effects, and even rare side effects, or known idiosyncratic reactions.

**Costs:**

Describe the cost for participating in the study to the subject/participant. The information must be written in clear terms regarding the cost which will be borne by sponsors/Principal Investigator/s of the project, and study participant.

**Reimbursement for Participation:**

Describe plan to reimburse or compensate participant for the inconvenience, time spent and for expenses incurred. If yes, the amount of payment proposed. Discuss travel details for trial subjects &/or attendant who need to come for follow-up, and spell out methodology for the reimbursement for travel.

**Emergency Medical Treatment:**

*(If applicable, add here)*

If physical injury is suffered in the course of research, or for more information, please notify the investigator in charge (list PI name and phone number).

Describe available medical treatment in case of complications.
Benefits:
List the benefits you anticipate will be achieved from this research, either to the participants, others, or the body of knowledge.
Also mention that the many of the most effective treatments used today are the result of clinical trials done in the past.

Confidentiality:
The information in the study records will be kept confidential and the clinical charts will be housed in the TMH/CRS. Data will be stored securely and will be made available only to persons conducting the study and to the regulatory authorities. The data will not be made available to another individual unless you specifically give permission in writing. No reference will be made in oral or written reports which could link you to the study. Result of the project will not be communicated to the subject unless deemed necessary.

Compensation for protocol Related Injury:
Describe the details of compensation or insurance for protocol related injury to the trial subject. Explain who will bear the cost in case of trial related injury?

Contact:
If you have questions at any time about the study or the procedures, (or you experience adverse effects as a result of participating in this study,) you may contact the researcher, [Name], at [Office Address], and [Office Phone Number]. If you have questions about your rights as a participant, contact the member secretary, HEC [Name], at [Office Address], and [Office Phone Number].

Participation:
Your participation in this study is voluntary; you may decline to participate at anytime without penalty and without loss of benefits to which you are otherwise entitled.
If you withdraw from the study prior to its completion, you will receive the usual standard of care for your disease, and your non participation will not have any adverse effects on your subsequent medical treatment or relationship with the treating physician
If you withdraw from the study before data collection is completed, your data will not be entered in the project report. Your legal rights will not be affected by signing this documents.
### Consent

I have read the above information and agree to participate in this study. I have received a copy of this form.

<table>
<thead>
<tr>
<th>Participant’s name (print):</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Participant’s signature:</td>
<td></td>
</tr>
<tr>
<td>Address (capital letters):</td>
<td></td>
</tr>
<tr>
<td>Phone Nos.:</td>
<td></td>
</tr>
<tr>
<td>Legal Representative name:</td>
<td></td>
</tr>
<tr>
<td>Legal Representative signature &amp; date:</td>
<td></td>
</tr>
<tr>
<td>Witness's name (Print):</td>
<td></td>
</tr>
<tr>
<td>Witness's signature &amp; date:</td>
<td></td>
</tr>
<tr>
<td>Name of PI or the person administering the consent (Print):</td>
<td></td>
</tr>
<tr>
<td>PI or person’s Signature &amp; date:</td>
<td></td>
</tr>
</tbody>
</table>

### Note to Investigators Regarding the Process of Administering Informed and Understood Consent

(The templates for Participant Information Sheet have been provided herewith):

The prospective participant should be given Participant Information Sheet first.

The participant should then be encouraged to read the Information Sheet and think over, preferably for a period of 24 hours. Following which, the participant should be served a questionnaire to ensure that he/she is aware of his/her own rights as a participant in the clinical trial. The informed consent form should be served to the participant only after ensuring that the participant is now prepared for informed decision making.

The PIs are urged by the HEC to download and use the wording in the glossary available on the TMC website and follow the sample format of Informed Consent Form, unless the PI support reasons for alternative wording.

Use of alternative wording or different format may slow down the review process. The form should be written in second person (“You are invited...”). Use of first person (“I”) can be interpreted as suggestive and coercive.

The study participant should be explained all the details in a language she/he understands.
The Informed Consent Form must have the name and Telephone No. of the Principal Investigator or of any other co-investigator, as the subject must know who to contact in case of an emergency, or even to seek answers to their queries.

The consent form must be dated.

If the prospective participant so desires, a Xerox copy of the Informed Consent Form must be given to him/her.

Copies of the consent form must be available in English, Marathi and Hindi.

Please tailor your ICF to suit the needs of our Indian population, and if this is a multinational Pharma based project, an additional ICF specifically designed for us may be used.

Separate forms should be prepared when minors are used; one for the mature minors (teenagers) and one for the parents.

If your form is more than one page, there should be a line at the bottom of each page for the subject's initials, except for the last page where the signature is obtained.

Be sure to include any elements of informed consent that are appropriate to your study. If they apply to your study, they must be included.

If informed consent form requires more than one page, print the informed consent form front to back.

Please make provision for the assent of the child to the extent of the child’s capabilities such as in the case of mature minors and adolescents.

Please make provision on the form for signatures/thumb impression of the participant/parent or legal guardian, if minor and of the investigator, or person administrating the consent form, and of a witness.
**AX5-V1/SOP 03/V2**

**Child Information Sheet and Assent Form**

<table>
<thead>
<tr>
<th>Study title: “……………………………………………………………………...”</th>
</tr>
</thead>
</table>

**Introduction**

You have come to meet the doctor as you are suffering from ........ You may be having symptoms..................

Describe briefly the purpose of this study

If this is a randomized trial, details of both arms of the trial must be explained in writing to the subject being enrolled.

Disclose appropriate alternative treatments available, if any.

We invite you to participate in this study.

**What will you have to do?**

To participate in this research study, you will be examined by your doctor and if found to fulfill pre-specified criteria, you will be eligible to be enrolled in this research study.

Since you are in the age group of 8-12 years we ask you to sign this assent form if you agree to participate. The assent form describes the research study and states that you have been explained the purpose and the nature of the study to your satisfaction by the attending doctor and you are ready to abide by the trial procedures. Your accompanying parent / guardian will also sign a similar form called as the Parent Informed Consent Form.

List all procedures, which will be employed in the study. Point out any that are considered experimental/or otherwise, and explain technical and medical terminology in simple, non-technical & direct language.

In addition, to record the same parameters daily your parent / guardian will also be provided with a diary where they will enter the same findings accordingly. You will have to tell them about your symptom and they will mark accordingly in the diary.

**Side effects**

All medicines/procedures produce some side effects – the medicine you will take/the procedure you will undergo can produce *(Describe the side effects).* Your Physician will take due precautions so that you do not experience these side-effects. If you experience any of these listed effects or any other unlisted effects do contact your study doctor immediately. The study doctor will treat you accordingly.

Your parents will not have to bear the cost of the medical treatment / hospitalization as a result of these side effects.
In addition, during the trial period if you suffer from any other diseases, if you consider some of the side effects as serious or you undergo hospitalization during the study period, please immediately contact the study doctor:

**Dr.**

**Phone:**

The occurrence of any of the side effects (known / unknown) and concomitant diseases will be noted by the physician at every visit. The assessment of acceptability of the formulation/procedure will be performed by the treating physician at the end of the study.

**Risks and discomforts**

There is no foreseen significant risk / hazard to your health, if you wish to participate in the study. You will not bear the expenses regarding the therapy. If you follow the directions of the doctors in charge of this study and you are injured due to any substance or procedure given under the study plan, the Sponsor will pay for the medical expenses for the treatment of that injury.

**Benefits**

If you participate in the study you will receive ...............If you appear to have any acute illness ...............you will be offered free treatment for those visits in accordance with local standard medical care. You will not be offered free treatment for chronic diseases or conditions not related to study procedures.

Your participation in the study may help others, because this participation will help us determine if the study drug/procedure is safe.

**Confidentiality**

Your existing medical records may be accessed; personal health information about you may be collected and processed by study investigators for the purpose of performing the study. Information about you will be collected and stored in files with an assigned number, and not directly with your name. All documents related to the study will only be accessed by the study investigator, sponsor, the Ethics Committee and the Regulatory authority.

Your parent / guardian will have the right to access personal information about you at any time with the study doctor and the right to correct this personal information. Your parent / guardian can take away your authorization to collect process and disclose data about you at any time.

**Right to refuse or withdraw**

You do not have to take part in this research if you do not wish to do so. Refusing to participate will not affect your treatment. You will still have all the benefits that you would otherwise have got at this clinic/hospital. You may stop participating in the research at any time you wish without losing any of your rights. Your treatment will not be affected in any way.
The study doctor may decide to withdraw you from the study if he/she considers it is in your best interest.

You will be informed of important new findings developed during the course of the study so you will be able to consider your participation in the study in light of new information.

**Whom to contact**

If you have any questions, please ask them now. You may also ask questions later. If you wish to ask questions later, contact

**Dr.**  
**Phone:**

If you have any queries regarding your rights as a study participant, you may contact, the Chairperson of the Institutional Ethics committee.

**Dr.**  
**Phone:**

**Your responsibilities**

It is the responsibility of your parent / guardian to come along with you to the hospital during the study period for all the visits unless you withdraw or are prematurely discontinued from the study. It is also your responsibility and your parent / guardian to report any expected or unexpected reactions (side effects) that you notice during the study period.

It is also the responsibility of your parent / guardian to inform the doctor if you consume any other medication apart from the study treatment.

We expect your co-operation throughout the study.
Child Assent Form

I______________________________, exercising my free power of choice, hereby give my consent for participation in the study entitled:

“........................................................................................................................................”

I have been informed, to my satisfaction, by the attending physician, about the purpose of the study and the nature of the procedure to be done. I am aware that my parents/guardians do not have to bear the expenses of the treatment if I suffer from any trial related injury, which has causal relationship with the said trial drug.

I am also aware of right to opt out of the trial, at any time during the course of the trial, without having to give reasons for doing so.

_______________________________
Name and Signature of the study participant      Date:

_______________________________
Name and Signature of the attending Physician      Date:
Research protocol & related documents

- Initial Review Application
- Resubmission of Protocols with Corrections
- Protocol Amendment and any other amendments
- Continuing Review of Approved Protocols

Receive & verify as per document checklist

Stamp the receipt of documents

Complete document receipt form

Store hard copies and soft copy of project

Numbering the project
Human Ethics Committee, Tata Memorial Centre (HEC, TMC)

Title: Initial Review of Submitted Protocol

SOP Code: SOP 04a/V2 Date: 01/09/2009 Pages: 16
4a.1 Purpose

The HEC should review every research proposal on human participants and must approve the proposal before the research is initiated. HEC should ensure that scientific evaluation has been completed and approved by SRC before ethical review is taken up. The committee should evaluate the possible risks to the participants with proper justification, the expected benefits to participants/community and adequacy of documentation for ensuring privacy & confidentiality.

The purpose of this Standard Operating Procedure (SOP) is to describe how the HEC members will review an initially submitted protocol for approval using the Assessment Form for initial review. The Assessment Form AX1-V1/SOP04a/V2 is designed to standardize the review process and to facilitate reporting, recommendations, and comments offered to each individual protocol.

4a.2 Scope

This SOP applies to the review and assessment of all protocols submitted for initial review and approval from the HEC. The specific points in the guidelines attached to the Assessment Form for initial review must be adequately addressed in the protocol itself and/or protocol-related documents under review. Relevant comments made during discussion and deliberation about a specific protocol should be recorded in the minutes of the meeting. The decision reached by the HEC will be communicated to the PI.

4a.3 Categorization of protocols

The Member Secretary, HEC or secretariat shall screen the proposals for their completeness and depending on the risk involved in the research proposals categorize them into three types, viz. Exemption from review, Expedited review, and Initial review. An investigator cannot categorize his/her protocol in to the above three types. This SOP describes the process of initial review.

4a.4 Initial Review

All research presenting with more than minimal risk, research protocols which do not qualify for exemption or expedited review and projects that involve vulnerable population and special groups should be subjected to full review by all the members.

While reviewing the research protocols, the following situations should be carefully assessed against the existing facilities at the research site for risk/benefit analysis:

a. Collection of blood samples by finger prick, heel prick, ear prick, or venipuncture from (Refer APP6/V1) :-
   i. Healthy adults and non-pregnant women who weigh normal for their age and not more than 500 ml blood is drawn in an 8 week period and frequency of collection is not more than 2 times per week
   ii. From other adults and children, where the age, weight, and health of the participants, the collection procedure, the amount of blood to be collected, and the frequency with which it will be collected has been considered and not
more than 50 ml or 3 ml per kg whichever is lesser, is drawn in an 8 week period and not more than 2 times per week

iii. From neonates depending on the haemodynamics, body weight of the baby and other purposes not more than 10% of blood is drawn within 48 – 72 hours. If more than this amount is to be drawn it becomes a risky condition requiring infusion/blood transfusion

iv. Prospective collection of biological specimens for research purposes by noninvasive means.

For instance:
- skin appendages like hair and nail clippings in a non-disfiguring manner
- dental procedures - deciduous teeth at time of exfoliation or if routine patient care indicates a need for extraction of permanent teeth; supra and subgingival dental plaque and calculus, provided the collection procedure is not more invasive than routine prophylactic scaling of the teeth
- excreta and external secretions (including sweat)
- uncannulated saliva collected either in an unstimulated fashion or stimulated by chewing gum or by applying a dilute citric solution to the tongue
- mucosal and skin cells collected by buccal scraping or swab, skin swab, or mouth washings
- sputum collected after saline mist nebulization and bronchial lavages

b. Collection of data through noninvasive procedures routinely employed in clinical practice. Where medical devices are employed, they must be cleared/ approved for marketing, for instance –

- Physical sensors that are applied either to the surface of the body or at a distance and do not involve input of significant amounts of energy into the participant or an invasion of the participant’s privacy
- Weighing or Testing Sensory Acuity
- Magnetic Resonance Imaging
- Electrocardiography, Echocardiography Electroencephalography, Thermography, detection of naturally occurring radioactivity, Electroretinography, Ultrasound, Diagnostic Infrared Imaging, Doppler Blood Flow and such alike
- Moderate exercise, muscular strength testing, body composition assessment, and flexibility testing where appropriate given the age, weight, and health of the individual

c. Research involving clinical materials (data, documents, records, or specimens) that will be collected solely for non-research (clinical) purposes
d. Collection of data from voice, video, digital, or image recordings made for research purposes
e. Research on individual or group characteristics or behaviour not limited to research on perception, cognition, motivation, identity, language, communication, cultural
beliefs or practices, and social behaviour or research employing survey, interview, oral history, focus group, program evaluation, human factors evaluation, or quality assurance methodologies

g. Research involving collection and storage of genetic materials (Refer APP10/V1)

4a.5 Elements of Review

The primary task of the HEC is to review of research proposals and their supporting documents with special attention given to the informed consent process, documentation, and the suitability and feasibility of the protocol. HEC will take into account prior scientific review by the SRC, and the requirements of applicable laws and regulations.

The following will be considered, as applicable:

4a.5.1 Scientific Design and Conduct of the Study

- The appropriateness of the study design in relation to the objectives of the study
- The statistical methodology (including sample size calculation), and the potential for reaching sound conclusions with the smallest number of research participants
- The justification of predictable risks and inconveniences weighed against the anticipated benefits for the research participants and the concerned communities
- The justification for the use of control arms; criteria for prematurely withdrawing research participants
- Criteria for suspending or terminating the research as a whole
- The adequacy of provisions made for monitoring and auditing the conduct of the research, including the constitution of a DSMB, the adequacy of the site, including the supporting staff, available facilities, and emergency procedures
- The manner in which the results of the research will be reported and published

4a.5.2 Care and Protection of Research Participants

- Suitability of the investigators’ qualifications and experience for the proposed study
- Any plans to withdraw or withhold standard therapies for the purpose of the research, and the justification for such action
- Medical care to be provided to research participants during and after the course of the research
- Adequacy of medical supervision and psycho-social support for the research participants
- Steps to be taken if research participants voluntarily withdraw during the course of the research
- Criteria for extended access to, the emergency use of, and/or the compassionate use of study products
- Arrangements, if appropriate, for informing the research participant’s general practitioner or family doctor, including procedures for seeking the participant’s consent to do so
4a.5.3 Protection of Research Participant Confidentiality

- A description of the persons who will have access to personal data of the research participants, including medical records and biological samples
- The measures taken to ensure the confidentiality and security of personal information concerning research participants

4a.5.4 Informed Consent Process

- A full description of the process for obtaining informed consent, including the identification of those responsible for obtaining consent (Refer APP7/V1 & APP8/V1)
- Adequacy, completeness, and comprehension of written and oral information to be given to the research participants, and, when appropriate, their Legally Acceptable Representative(s) (LAR) (Refer APP5/V1)
- Clear justification for the intention to include research participants who cannot consent, and a full account of arrangements made to obtain their consent/authorisation
- Assurances that research participants will receive information that becomes available during the course of the research relevant to their participation including their rights, safety, and well-being
- Provisions made for receiving and responding to queries and complaints from research participants or their representatives during the course of a research project

4a.5.5 Community Considerations

- Impact and relevance of the research on the local community and on the concerned communities from which the research participants are drawn
- Steps taken to consult with the concerned communities during the course of designing the research
- Influence of the community on the consent of individuals
- Proposed community consultation during the course of the research
- Extent to which the research contributes to capacity building, such as the enhancement of local healthcare, research, and the ability to respond to public health needs
- A description of the availability and affordability of any successful study product to the concerned communities following the research
• The manner in which the results of the research will be made available to the research participants and the concerned communities

4a.5.6 Recruitment of Research Participants

• The characteristics of the population from which the research participants will be drawn (including gender, age, literacy, culture, economic status, and ethnicity) (Refer APP2/V1)
• The means by which initial contact and recruitment is to be conducted
• The means by which full information is to be conveyed to potential research participants or their representatives
• Inclusion criteria for research participants
• Exclusion criteria for research participants
• Students or staff recruitment in research (Ref. APP1/V1)

4a.6 Responsibility

The IRB Secretariat is responsible for receiving, verifying, and managing the hard copies of the received packages. In addition, the Secretariat should create a protocol specific file, distribute the packages to the HEC members for review by HEC and communicate the review results to the investigators.

HEC members are responsible for receiving, verifying, and reviewing the research protocols.

4a.7 Detailed instructions

Distribution of the project documents

• The distribution of the project documents for HEC review will be as follows: Chairperson, Member Secretary, and the lead discussant/s will get complete project proposal while all other members should be given only the duly filled TMC Project Submission form and informed consent forms.

Assigning Lead discussants

• Member Secretary, HEC assigns 1 or 2 lead discussants to each research protocol. A lead discussant is the member of HEC responsible for a detailed review of the assigned protocol
  o The lead discussant is informed preferably 10 days prior to the meeting through the agenda. In case, the lead discussant is not in a position to review due to some reason; he/she should inform the Member Secretary, HEC at the earliest, so that the research protocols can be assigned to other member.
  o In the event of his/her absence, a lead discussant can send written comments on the research protocols to the Member Secretary, which will be tabled and discussed during meeting. However, a final decision on the research protocol will be arrived at, by a broad consensus at the end of discussion among attending members and not solely based on written comments.
It is the responsibility of the assigned lead discussant/s to review the research protocols assigned to them thoroughly, offer their observations, comments, and decisions to the HEC during the meeting and return all research protocols to the secretariat on the day of the meeting.

**Responsibilities of HEC members**

- Check the contents of the package
- Sign and date an acknowledgement form / receipt upon receiving the package
- Return the acknowledgement form/ receipt back to the delivery person /IRB Secretariat
- Check the meeting date to see if he/she is available to attend the meeting.
- Identify the project assigned for review
- Notify the IRB Secretariat 3 days prior to the convened HEC meeting regarding the missing documents, if any
- The members must return the packages to the IRB Secretariat on the day of the scheduled meeting. In case, HEC member is not in a position to attend the scheduled meeting, the responsibility of returning of packages would be of the respective HEC member.

4a.8 **Review the Protocol:**

Review all elements as per section 4.3. The protocol will be reviewed by each member as per guidelines to review a study protocol described in AX1-V1/SOP04/V2

4a.9 **Use of study assessment forms**

It is the responsibility of the HEC members to use assessment form as a checklist while reviewing each research protocol. The duly filled, signed and dated assessment forms should be returned along with the research protocols to the Secretariat at the end of the meeting. The assessment form is designed to standardize the review process. The study assessment form helps to ensure that all elements of research protocol are reviewed and are accordingly documented during the discussion / meeting Study Assessment Form Template (AX1-V1/SOP04a/V2)

*Note: The completed assessment form is the official record of the decision reached by the HEC for the specific protocol*

4a.9.1 **Gather the assessment reports**

The HEC Secretariat will collect the Assessment Forms AX1-V1/SOP04a/V2, the comments from each reviewer and file in the original set of the study file.

4a.10 **HEC meeting**

The details of review procedures and communication of decision is described in detail in SOP05/V2
References


Glossary

**Document**: Document may be of any forms, e.g., paper, electronic mail (e-mail), faxes, audio or video tape, etc.

**Expedited review/meeting**: A review process by only member secretaries of both the HECs or HEC subcommittee, who then report the decision to the full board in a formal meeting. An expedited review is an accelerated review for minor changes to the approved protocol, for research proposal with minimal risk and documents of minor nature.

**Full Board/ Regular Review**: Review of initial, resubmitted, continuing review, amendments of protocols and or ICFs and any other documents which are tabled in a formally convened meeting of the full HEC committee for detailed discussion and decisions.

**Initial Review**: The first time review of the protocol done by one or two individual reviewers/lead discussants (HEC members) during the formally convened full board HEC meeting.

**Pre-clinical study**: Animal and *in vitro* studies provide information on possible toxicities and mechanisms of action, and starting doses for human studies.

**Phase I studies**: Initial introduction of an investigational new drug (IND) into humans, studies designed to determine the metabolism and pharmacological actions of drugs in humans, and studies designed to assess the side effects associated with increasing doses.

**Phase II study**: A study of drug metabolism, structure-activity relationships, and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes.

**Phase III study**: A study expands controlled and uncontrolled trials performed after preliminary evidence suggesting effectiveness of the drug has been obtained. They are intended to gather
the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.

**Phase IV study**: A study that seeks to expand an approved medication’s use into a new population, new indication, or new dose.

**Study Assessment Form**: An official record that documents the protocol review process.

**Vulnerable subjects**: A vulnerable category of subjects includes children, prisoners, pregnant women, handicapped or mentally disabled persons, refugees, displaced persons and economically or educationally disadvantaged persons, who are likely to be vulnerable to coercion or undue influence.
### Study Assessment Form to be used at the HEC meeting.

**Page 1 of 5**

**Study Assessment Form**

<table>
<thead>
<tr>
<th>Protocol Number :</th>
<th>Date (DD/MM/YY):</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol Title :</td>
<td></td>
</tr>
<tr>
<td>Principal Investigators:</td>
<td>MMC Registration No.</td>
</tr>
<tr>
<td>Institute:</td>
<td>Contact No.</td>
</tr>
<tr>
<td>Co – investigator(s):</td>
<td>Contact No.</td>
</tr>
</tbody>
</table>

**Delineation of responsibilities of investigators:**

<table>
<thead>
<tr>
<th>Total No. of Participants:</th>
<th>No. of Study site/s:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funding Agency:</td>
<td>Contact No.</td>
</tr>
<tr>
<td>Duration of the Study:</td>
<td>Status: [ ] New [ ] Revised [ ] Amended</td>
</tr>
<tr>
<td>Reviewer’s name :</td>
<td>Contact No.</td>
</tr>
</tbody>
</table>

**Type of the Study :**

- [ ] Intervention
- [ ] Epidemiology
- [ ] Document based
- [ ] Individual based
- [ ] Genetic
- [ ] Social Survey
- [ ] Others, specify……

**Review Status:**

- [ ] Regular
- [ ] Expedited
- [ ] Emergency

**Description of the Study in brief:** Mark whatever applied to the study.

- [ ] Randomized
- [ ] Stratified Randomized
- [ ] Double blinded
- [ ] Placebo controlled
- [ ] Cross-over
- [ ] Parallel
- [ ] Multicenter study
- [ ] Screening
- [ ] Use of Tissue samples
- [ ] Use of Blood samples
- [ ] Use of genetic materials

**Brief the study design and the statistic used:**

**Study Objectives:**

*Please see my attached comments in a separate sheet*

| ………………………………………………………………………………………………………………… |
| ………………………………………………………………………………………………………………… |
| ………………………………………………………………………………………………………………… |
| ………………………………………………………………………………………………………………… |
# Mark and comment on whatever items applicable to the study

<table>
<thead>
<tr>
<th></th>
<th>Objectives of the Study</th>
<th>What should be improved?</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>clear</td>
<td>unclear</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Need for Human Participants</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Methodology:</th>
<th>What should be improved?</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>clear</td>
<td>unclear</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Background Information and Data</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>sufficient</td>
<td>insufficient</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Risks and Benefits Assessment</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>acceptable</td>
<td>unacceptable</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Inclusion Criteria</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>appropriate</td>
<td>inappropriate</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Exclusion Criteria</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>appropriate</td>
<td>inappropriate</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Discontinuation and Withdrawal Criteria</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>appropriate</td>
<td>inappropriate</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Involvement of Vulnerable Participants</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Voluntary, Non-Coercive Recruitment of Participants</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Sufficient number of participants?</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Control Arms (placebo, if any)</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>Question</td>
<td>Yes</td>
</tr>
<tr>
<td>---</td>
<td>--------------------------------------------------------------------------</td>
<td>-----</td>
</tr>
<tr>
<td>13</td>
<td>Are qualification and experience of the Participating Investigators</td>
<td></td>
</tr>
<tr>
<td></td>
<td>appropriate?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>☐ Yes</td>
<td>☐ No</td>
</tr>
<tr>
<td>14</td>
<td>Disclosure or Declaration of Potential Conflicts of Interest</td>
<td></td>
</tr>
<tr>
<td></td>
<td>☐ Yes</td>
<td>☐ No</td>
</tr>
<tr>
<td>15</td>
<td>Facilities and infrastructure of Participating Sites</td>
<td></td>
</tr>
<tr>
<td></td>
<td>☐ Appropriate</td>
<td>☐ Inappropriate</td>
</tr>
<tr>
<td>16</td>
<td>Community Consultation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>☐ Yes</td>
<td>☐ No</td>
</tr>
<tr>
<td>17</td>
<td>Involvement of Local Researchers and Institution in the Protocol Design,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Analysis and Publication of Results</td>
<td></td>
</tr>
<tr>
<td></td>
<td>☐ Yes</td>
<td>☐ No</td>
</tr>
<tr>
<td>18</td>
<td>Contribution to Development of Local Capacity for Research and Treatment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>☐ Yes</td>
<td>☐ No</td>
</tr>
<tr>
<td>19</td>
<td>Benefit to Local Communities</td>
<td></td>
</tr>
<tr>
<td></td>
<td>☐ Yes</td>
<td>☐ No</td>
</tr>
<tr>
<td>20</td>
<td>Availability of similar Study / Results</td>
<td></td>
</tr>
<tr>
<td></td>
<td>☐ Yes</td>
<td>☐ No</td>
</tr>
<tr>
<td>21</td>
<td>Are blood/tissue samples sent abroad?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>☐ Yes</td>
<td>☐ No</td>
</tr>
<tr>
<td>22</td>
<td>Are procedures for obtaining Informed Consent appropriate?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>☐ Yes</td>
<td>☐ No</td>
</tr>
<tr>
<td></td>
<td>Content of the Informed Consent Document</td>
<td>Comment:</td>
</tr>
<tr>
<td>---</td>
<td>------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>23</td>
<td></td>
<td>clear</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Language of the Informed Consent Document</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td></td>
<td>clear</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Contact Persons for Participants</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td></td>
<td>Yes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Privacy &amp; Confidentiality</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td></td>
<td>Yes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Inducement for Participation</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>27</td>
<td></td>
<td>Unlikely</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Provision for Medical / Psychosocial Support</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>28</td>
<td></td>
<td>appropriate</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Provision for Treatment of Study-Related Injuries</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>29</td>
<td></td>
<td>appropriate</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Provision for Compensation</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td></td>
<td>appropriate</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Provision for post-trial access</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>31</td>
<td></td>
<td>appropriate</td>
</tr>
</tbody>
</table>
**Assessment Report**

<table>
<thead>
<tr>
<th>Protocol Title:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Elements Reviewed</th>
<th>Attached</th>
<th>Not attached</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Review of Revised Application</th>
<th>Date of Previous review:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DECISION:</th>
<th>Approved</th>
<th>Approved with Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resubmission</td>
<td>Disapproved</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Comment:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Signature:</th>
<th>Date:</th>
</tr>
</thead>
</table>

Review Date (DD/MM/YYYY): Protocol number:
Flow Chart

Protocols

Exemption from Review  Initial Review  Expedited Review

Receive, verify & Distribute

Responsibilities of HEC Secretariat

Responsibilities of HEC members

- Verify the Contents of the package
- Review of protocol
- Fill assessment forms and submit during meeting

HEC Meeting—record the HEC discussion and decision

HEC decision is communicated to the PI

Storage of original documents with relevant correspondence
Human Ethics Committee, Tata Memorial Centre (HEC, TMC)

Title: Expedited Review of Submitted Protocol

SOP Code: SOP 04b/V2 Date: 01/09/2009 Pages: 6
4b.1 Purpose

The purpose of this SOP is to provide criteria for categorisation of research protocols which can be reviewed through expedited process as well as instructions on management, review, and decision of the expedited review.

4b.2 Categorization of protocols

The Member Secretary, HEC or secretariat shall screen the proposals for their completeness and depending on the risk involved in the research proposals categorise them into three types, viz., Exemption from review, Expedited review, and Initial review. An investigator cannot categorize his/her protocol in to the above three types. This SOP describes expedited review in detail.

4b.3 Expedited Review

The proposals involving no more than minimal risk to research participants may be subjected to expedited review

An expedited review may be conducted, only if the protocols involve -

1. Revised proposal previously approved through full review by the HEC or continuing review of approved proposals where there is no additional risk or activity is limited to data analysis or health record research (Refer APP9/V1)
2. Anonymous surveys and retrospective chart reviews
3. Analysis of discarded pathological specimens / stored paraffin blocks without personal identifiers
4. Proposals involving previously banked materials and/or tissues as per policies of respective authorities like – tumour tissue repository, following scientific approval by SRC
5. Research activities that involve only procedures listed in one or more of the following categories:
   a. Clinical studies of drugs and medical devices only when -
      i. Research is on already approved drugs except when,
         a. Study of drug interaction
         b. Conducting trial on vulnerable population
         OR
      ii. Adverse Event (AE) or unexpected Adverse Drug Reaction (ADR) of minor nature is reported
   b. Research involving clinical materials (data, documents, records, or specimens) that have been collected for non-research (clinical) purposes
6. Other documents which would be considered for expedited review are as follows but may not restrict to:
   i. Minor deviations from originally approved research during the period of approval (usually of one year duration
   ii. Change in the name, address of sponsor
iii. Change in contact details of PI and HEC
iv. Change in PI or hand over of trials or projects
v. Inclusion or deletion of name/s of co-investigator/s
vi. Request for change in PI, Co-I, change in any member involved in the research
vii. Minor amendments in the protocol, CRF
viii. Minor corrections in budget
ix. Other administrative changes in the IB, ICF, etc.

4b.4 **Scope**

This SOP applies to the review and approval of research protocols and documents with not more than minimal risk to participants

4b.5 **Responsibility**

It is the responsibility of the Member Secretary to identify (as per section 4b.3) which research protocols or documents should be reviewed through expedited process.

4b.6 **Detailed instructions to the IRB secretariat:**

4b.6.1 **Receive the submitted documents**

- Receive the application documents submitted by investigators as per the check list
- Acknowledge the submitted documents
- Hand over the received documents to the Member Secretary, HEC

4b.6.2 ** Expedited Process**

- The subcommittee comprising of Member Secretaries of both the HECs will review the documents which qualify for expedited review (refer section no. 4b.3-point 6).
- After determining that the Protocol/Project or documents qualify for an expedited review, Member Secretary informs the Chairperson and Chairperson nominates one or two HEC members to review the protocol. In this case, the subcommittee comprising of Members Secretaries of both the HECs, an external HEC member from any one of the committee and a HEC member from the institution will be formed. The external member will chair the meeting.
- Review may be made either by circulation of comments, telephone discussion, or meeting
- The expedited review should not take longer than 2 weeks, from the date of receipt of the research protocol approved by SRC.
- The minutes of the expedited review subcommittee meeting should be ratified in the next regular full board meeting.
- If consensus cannot be reached, the Chairperson will revert the proposal or the documents back to the HEC for a full board review.
4b.6.3 Communication between the HEC and the investigator

- The decision of subcommittee, HEC, will be communicated to the PI immediately after minutes of subcommittee are finalized.
- If project is disapproved or requires resubmission after certain modifications, this will be informed to the PI in writing. The reasons for disapproval of a project will be specified in the letter sent to PI.

References


Glossary

Document: Document may be of any forms, e.g., paper, electronic mail (e-mail), faxes, audio or video tape, etc.

Expedited review/meeting: A review process by only member secretaries of both the HECs and HEC subcommittee, who then report the decision to the full board in a formal meeting. An expedited review is an accelerated review for minor changes to the approved protocol, for research proposal with minimal risk and documents of minor nature.
Flow Chart

Protocols

Exemption from Review

Initial Review

Expedited Review

Receive and verify

Determine protocols for expedited review

Expedited review process - Subcommittee meeting

Subcommittee minutes ratified in full board meeting

Decision is communicated to the PI
Human Ethics Committee, Tata Memorial Centre (HEC, TMC)

Title: Exemption from the Ethical Review for Research Projects

SOP Code: SOP 04c/V2 Date : 01/09/2009 Pages: 10
4c.1 **Purpose**

The purpose of this Standard Operating Procedure (SOP) is to describe which research projects can be exempted from ethics review and do not require the approval of the HEC. The Exemption Form AX1-V1/SOP04c/V2 is designed to standardize the process of exemption.

4c.2 **Categorization of protocols**

The Member Secretary, HEC or secretariat shall screen the proposals for their completeness and depending on the risk involved in the research proposals categorise them into three types, viz., Exemption from review, Expedited review, and Full review. An investigator cannot categorize his/her protocol in to the above three types. This SOP describes exemption from ethics review in detail.

4c.3 **Exemption from review**

Proposals which involve less than minimal risk fall under this category. *Minimal risk* would be defined as one which may be anticipated as harm or discomfort not greater than that encountered in routine daily life activities of general population or during the performance of routine physical or psychological examinations or tests. However, in some cases like surgery, chemotherapy or radiation therapy, great risk would be inherent in the treatment itself, but this may be within the range of minimal risk for the research participant undergoing these interventions since it would be undertaken as part of current every day life (ICMR 2006).

The exemption from review may be seen in following situations:

i. Research on educational practices such as instructional strategies or effectiveness of or the comparison among instructional techniques, curricula, or classroom management methods

   Exceptions:
   1. When research on use of educational tests, survey or interview procedures, or observation of public behaviour can identify the human participant directly or through identifiers, and the disclosure of information outside research could subject the participant to the risk of civil or criminal or financial liability or psychosocial harm
   2. When interviews involve direct approach or access to private papers

ii. The research proposals which do not involve live human participants or data derived from them are exempt from ethics review. For example,

   ✓ Audits of educational practices
   ✓ Research on microbes cultured in the laboratory
   ✓ Research on immortalized cell lines
   ✓ Research on cadavers or death certificates provided such research reveals no identifying personal data
   ✓ Analysis of data freely available in public domain
In some circumstances research which appears to meet low risk criteria may need to be reviewed by the HEC. This might be because of requirements of:

- The publisher of the research
- An organization which is providing funding resources, existing data, access to participants etc.

4c.4 Scope

This SOP applies to the all protocols submitted for exemption from review by the HEC. The specific points in the Exemption Form should guide the Member Secretary to determine whether the protocol qualifies for exemption from review. The decision should be taken by the Member Secretary in consultation with the Chairperson and should be informed to the members in the forthcoming HEC meeting.

4c.5 Responsibility

It is the responsibility of the Member Secretary to record the decision in the Exemption Form with reasons. The HEC Secretariat is responsible for recording and filing the decision including the reasons for that decision. The Chairperson must sign and date letter conveying the decision AXI-V1/SOP04c/V2.

4c.6 Detailed instructions to the IRB Secretariat:

4c.6.1 Receive the submitted documents

- The Secretariat will receive the Exemption from review Application Form AXI-V1/SOP04c/V2, Protocol and other documents submitted by the investigators.
- Acknowledge the submitted documents
- Hand over the received documents to the Member Secretary, HEC

4c.6.2 Determine protocols eligible for exemption from review

The Member Secretary, HEC will determine whether a protocol qualifies for exemption from review based on criteria explained in (section 4c.3).

4c.6.3 Exemption Process

- If the protocol and related documents satisfy the criteria as listed in 4c.3, the Member Secretary in consultation with the Chairperson will review the brief summary of the project and the Exemption Form.
- The Member Secretary records the decision on the Exemption Form.
- The Secretariat communicates the decision to the investigator.
- The Member Secretary informs the HEC members about the decision at the next full board meeting.
- In case the protocol does not fit in any of the above stated criteria, the Member Secretary / Chairperson may keep the application for review and discussion at the full board meeting.
4c.6.4 Communication between the HEC and the investigator

- The decision regarding request for Exemption from review, signed by the HEC Chairperson, will be forwarded by the Secretariat to the PI within 14 days after the decision regarding the exemption is taken.
- The Member Secretary will inform the HEC members of the decision at the forthcoming regular meeting and minute it in the meeting notes.

References


Glossary

Exemption from review: A research study is said to be exempt from review when it does not require the Ethics Committee approval for its conduct
Review Exemption Application Form

TMC Project No. : _____________________ (To be filled by HEC Secretariat)

1 Principal Investigator’s Name: _____________________________________________

2 Department: ________________________________________________________________

Title of Project: ______________________________________________________________

4 Names of other participating staff and students:

5 Brief description of the project:

Please give a brief summary (approx. 300 words) of the nature of the proposal, including the aims/objectives/hypotheses of the project, rationale, participants’ description, and procedures/methods to be used in the project:-

6 State reasons why exemption from ethics review is requested?

✓ Audits of educational practices
✓ Research on microbes cultured in the laboratory
✓ Research on immortalized cell lines
✓ Research on cadavers or death certificates provided such research reveals no identifying personal data
✓ Analysis of data freely available in public domain
✓ Any other

(This should include justification for exemption e.g. study does not involve human participants. If exemption is being requested on the basis of low risk involved in the study please refer to Note on Page Nos. 97-98 of this annexure.)

7 IND APPLICATION EXEMPTION CHECKLIST

This checklist is intended to be used by the investigator as a preliminary test of whether an IND application needs to be submitted to the DCGI for studies involving DCGI/RA-approved drugs.

If any question is answered “yes”, an IND application must be submitted to the DCGI. If the answers to all questions are “no”, then the study may meet the criteria for an exemption from an IND.
1. Name of drug
   Dosage
   Route

2. Does the study involve a different route of administration of the marketed drug than already approved?
   □ YES  □ NO

3. Does the study involve the administration of different drug dosage levels that significantly increase risk or decrease the acceptability of risk to study subjects?
   □ YES  □ NO

4. Does the study involve the administration of the drug to a different patient population for whom there may be increased risk or decreased acceptability of risk?
   □ YES  □ NO

5. Does the study entail any other factor that significantly increases the risk or decreases the acceptability of risk to study subjects?
   □ YES  □ NO

6. Are the results of the study intended to be reported to the DCGI/RA in support of any significant change in labeling or advertising for the drug (only for corporate sponsored studies)?
   □ YES  □ NO

Signature of Investigator: ________________ Date: ________________

Principal Investigator's signature: ________________ Date ________________

Forwarded by the Head of the department:

Name: ___________________________
Signature: ________________________
Date ___________________________

Recommendations by the HEC Member Secretary:

□ Exemption

□ Can not be exempted, Reasons __________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________

□ Discussion at full board

Signature of the Member Secretary: ___________ Date ___________
Final Decision:

☐ Exemption

☐ Cannot be exempted,

Reasons ____________________________________________________________
__________________________________________________________________

☐ Discussion at full board

Signature of the Chairperson: ________________ Date _________________

Final Decision at Full Board meeting held on __________________________

Signature of the Chairperson: ________________ Date _________________

NOTE:

No research can be counted as low risk if it involves:

(i) Invasive physical procedures or potential for physical harm
(ii) Procedures which might cause mental/emotional stress or distress, moral or cultural offence
(iii) Personal or sensitive issues
(iv) Vulnerable groups
(v) Cross cultural research
(vi) Investigation of illegal behaviour(s)
(vii) Invasion of privacy
(viii) Collection of information that might be disadvantageous to the participant
(ix) Use of information already collected that is not in the public arena which might be disadvantageous to the participant
(x) Use of information already collected which was collected under agreement of confidentiality
(xi) Participants who are unable to give informed consent
(xii) Conflict of interest e.g. the researcher is also the lecturer, teacher, treatment-provider, colleague or employer of the research participants, or there is any other power relationship between the researcher and the research participants.
(xiii) Deception
(xiv) Audio or visual recording without consent
(xv) Withholding benefits from “control” groups
(xvi) Inducements
(xvii) Risks to the researcher
This list is not definitive but is intended to sensitize the researcher to the types of issues to be considered. Low risk research would involve the same risk as might be encountered in normal daily life.

Please check that your application / summary has discussed:

- Procedures for voluntary, informed consent
- Privacy & confidentiality
- Risk to participants
- Needs of dependent persons
- Conflict of interest
- Permission for access to participants from other institutions or bodies
- Inducements

In some circumstances research which appears to meet low risk criteria may need to be reviewed by the HEC. This might be because of requirements of:

- The publisher of the research
- An organisation which is providing funding resources, existing data, access to participants etc.
Flow Chart

Protocols

Exemption from Review

Received the submitted documents with exemption form

Initial Review

Review of protocol and Exemption form by Member Secretary & Chairperson

Expedited Review

Record the decision on Exemption form in consultation with the Chairperson

Decision is communicated to the PI

Informing the decision to the members in the forthcoming meeting

Recording and filling the decision
Human Ethics Committee, Tata Memorial Centre (HEC, TMC)

Title: Agenda Preparation, Meeting Procedures and Recording of Minutes

SOP Code: SOP 05/V2 Date: 01/09/2009 Pages: 14
5.1 Purpose

The purpose of this procedure is to elaborate administrative process and provide instructions for preparation, review, approval, and distribution of meeting agenda, minutes, and notification letters of HEC, TMC meetings.

The day, time, and venue of HEC meetings for both committees are specified as follows:
HEC-I meets at 8.30 am on the last Friday of every month unless otherwise specified
HEC-II meets at 8.00 am on the third Friday of every month unless otherwise specified

Maximum interval between 2 regular meetings will be not more than 3 months.

Venue: Meeting room, 3rd Floor, IRB office, Main Hospital Building, TMH, Parel, Mumbai 400012.

5.2 Scope

This SOP applies to administrative processes concerning the conduct of the meeting.

5.3 Responsibility

It is the responsibility of the Secretary, HEC of each committee and IRB staff to prepare for the respective HEC meeting.

5.4 Detailed instructions

5.4.1 Before full board HEC meeting

- Prepare the agenda of the HEC meeting (AX1-V1/SOP05/V2)
- Schedule protocols on the agenda on a first come first serve basis. TMC has constituted two HECs, so the protocols are assigned randomly to the committees. However, in case PI is a member of one of the HECs, the protocol is referred to the other HEC to avoid conflict of interest.

5.4.2 Distribution of Protocol/Documents Packages to the HEC Members

- Distribute copies of the protocols to the HEC members by either electronic mail (in case of electronic submission of protocols) or by courier preferably 10 days in advance of the scheduled meeting
- Verify (verbally, by e-mail, by fax or by mail) with the members whether the protocol packages are received
- It is the responsibility of the HEC member to verify items of the parcel on receipt and in the event of any missing items, intimate the IRB office immediately so that the relevant documents could be made available to the members before the meeting.
5.4.3 Preparation for the meeting

- Reserve the IRB meeting room on the scheduled meeting date and time. The meeting will be held in the meeting room of IRB, unless otherwise specified.
- Ensure that the room, equipment (projectors, recorder, etc) and facilities are available in good housekeeping conditions on the day of the meeting.
- On the previous day of the meeting keep all original files of protocols on the agenda in the meeting room for ready reference during the meeting.

5.4.4 Conduct of Meeting

- The members should gather in IRB meeting room on scheduled time.
  - The Chairperson should determine that the quorum (SOP 02/V2 section no. 2.9) requirements are met.
  - The Chairperson should ask for declaration of conflict of interest either verbally or written on any protocol for discussion.
  - If a HEC member has conflict of interest involving a project then he / she should declare the same, before the meeting commences and leave the meeting room before the discussion on the same. This should be recorded in the minutes
- The Member Secretary should table the minutes of the previous meeting and present the agenda for discussion
- The HEC may invite investigators to attend the full board meeting related to their studies, and clarify doubts, if any
- The meeting proceeds in the sequential order of the agenda; however the Chairperson may change the order, if the situation so demands
- The Member Secretary will request the lead discussant to discuss the research protocol. The lead discussant will submit the duly filled study assessment form at the end of the discussion or at the conclusion of HEC meeting.
- Amendment will be reviewed by previously assigned lead scientific discussant.
- In case the lead discussant cannot attend the meeting, secretary, HEC or any other HEC member may brief the HEC about the research protocol and also discuss the written comments/duly filled study assessment form, if provided by the lead discussant.
- The Member Secretary, HEC / IRB administrative officer minutes/records the proceedings of the HEC meeting.

5.4.5 Decision Making Process

HECs provide complete and adequate review of the research proposals submitted to them. The committees will review new project proposals, amendments, annual progress of ongoing projects, SAE reports, and assess final reports of all research activities through a scheduled agenda.

- A HEC member will withdraw from the meeting for the decision procedure concerning an application where a conflict of interest exists.
- If HEC member has her/his own proposal for HEC review he/she will not participate in the HEC discussion on that particular project.
Decision may only be taken when sufficient time has been allowed for review and discussion of an application in the absence of non-members (e.g., the investigator, representatives of the sponsor, independent consultants) from the meeting, with the exception of IRB staff.

Decisions will only be made at meetings where a quorum (SOP 02/V2 section no. 2.9) is present.

The documents required for a full review of the application should be complete and the relevant elements considered before a decision is made.

Only HEC members who attend the meeting will participate in the decision.

Decisions will be arrived at through consensus. When a consensus is not possible, the HEC will vote.

If the full board approves a research proposal in principle subject to minor modifications, the revised project proposal submitted by the PI will be reviewed and approved by the Member Secretary, HEC or in some cases by the primary reviewer on behalf of the full board. Such revised proposals will not be taken up for the full board review. However, in case of major changes, the revised documents will be discussed in full board meeting.

An HEC may decide to reverse its positive decision on a study if it receives information that may adversely affect the risk/benefit ratio.

Any advice that is non-binding will be appended to the decision.

In cases of conditional decisions, clear suggestions for revision and the procedure for having the application re-reviewed will be specified.

A negative decision on an application will be supported by clearly stated reasons. If the investigator wishes to appeal to the decision, he/she may do so by contacting the IRB Secretariat.

The discontinuation of a trial will be recommended if the HEC finds that the goals of the trial have already been achieved midway or unequivocal results are obtained.

If necessary, the investigator may be invited to present the protocol or offer clarifications in the meeting. Representative of the patient groups or community can be invited during deliberations to offer their viewpoint.

Subject expert/s may be invited to offer their views, but expert/s should not participate in the decision making process. However, his/her opinion must be recorded.

The proceedings of the HEC meetings will be documented and signed by the Member Secretary.

5.4.6 After the HEC meeting

5.4.6.a Preparing the minutes and the decision letters

- The Member Secretary will compile the proceedings of HEC meeting in a concise and easy-to-read style and will check spelling, grammar and context of the written minutes.
- The minutes of the meeting will be compiled within a week.

5.4.6.b Approval of the minutes and the decision

- The minutes of the HEC meeting will be signed by Member Secretary, HEC.
- The minutes of the HEC meeting will be ratified in the subsequent HEC meeting.
- The HEC decisions will be communicated to the PIs.

**5.4.6.c Filing of the minutes of the meeting**

- Place the original version of the minutes in the minutes file and copy of the minutes are filed in the corresponding research protocol file.

**5.4.7 Communicating Decision**

The decision will be communicated in writing to the PI, preferably within a period of 10 days of the HEC meeting at which the decision was made.

The communication of the decision will include, but is not limited to, the following,

- TMC Project No. and title of the research proposal reviewed
- The clear identification of the protocol of the proposed research or amendment, date and version number (if applicable).
- The names and specific identification number version numbers/dates of the documents reviewed, including the potential research participant information sheet/material and informed consent form
- The name and title of the Principal Investigator
- The name of the site(s)
- The date and place of the decision
- A clear statement of the decision reached
- Validity of approval usually will be yearly for multiyear projects, however may change on case to case basis.
- Any suggestions by the HEC
- A conditional decision (i.e. approval with recommendations or modifications, suggestions for revision and the procedure, any other requirements by the HEC), will be valid only for six months from the date of issue of letter. If the PI does not comply with the HEC suggestions during these three months, a reminder will be issued. The modifications will be re-reviewed by Member Secretary, HEC or primary reviewer/s and/or may be referred for full board review (AX3-V1/SOP05/V2).
- In the case of a positive decision, the PI is notified of the following requirements through an approval letter (AX2-V1/SOP05/V2)
  - a statement of the responsibilities of the PI; for example, confirmation of the acceptance of any requirements recommended by the HEC
  - submission of progress report(s) decided on case to case basis, usually yearly.
  - the need to notify the HEC in cases of protocol amendments (other than amendments involving only logistical or administrative aspects of the study)
  - the need to notify the HEC in the case of amendments to the recruitment material like the potential research participant information, or the informed consent form
  - the need to report serious and unexpected adverse events related to the conduct of the study
the need to report unforeseen circumstances, the termination of the study, or significant decisions by other HEC
- the information the HEC expects to receive in order to perform ongoing review
- the final summary or final report
- the schedule/plan of ongoing review by the DSMB of sponsored trials

- In the case of a negative decision, the reasons should be clearly stated in the communication to the PI
- The PI will also be notified of the duration of the approval, which will not exceed one year
- All decision and approval letters will be signed by the Member Secretary, HEC
- Every page of consent forms (English, Hindi, Marathi) of investigator initiated trials and first page of ICFs of sponsored trials (English, Hindi, Marathi) will be signed and dated by Member Secretary, HEC. These approved ICFs will be sent to the PI along with the approval letter.
- The Chairperson / Member Secretary, HEC, will sign and date the approval letter and approval certificate in the original research protocol.

References


Glossary

Agenda: A list of things to be done; a program of business for the meeting

Minutes: An official record of proceedings at a meeting

Quorum: Number of HEC members required to act on any proposal presented to the committee for action.
AGENDA FORMAT

I) Minutes
II) Projects for Initial Review
III) Amendments
IV) Letters
V) Minutes of DSMSC & SAEs
FORMAT FOR APPROVAL LETTER OF ETHICS COMMITTEE

To,

Dr. ____________________
Principal Investigator,
Tata Memorial Hospital.

Ref: Project No.

Dear Dr.

Human Ethics Committee reviewed and discussed your application (dated) to conduct the research study entitled “_________” during the HEC meeting held on (date).

The following documents were reviewed and approved:

1. Project Submission form.
2. Study protocol (including protocol amendments), dated________, version no(s).
3. TMC-Scientific Review Committee approval letter dated ________
4. Patient information sheet and informed consent form (including updates if any) in English and/Vernacular language.
5. Investigator’s brochure, dated_______, version no.______
6. Proposed methods for patient accrual including advertisement(s) etc. proposed to be used for the purpose.
7. Current CVs of Principal investigator, Co-investigators
8. Package inserts
9. Insurance policy/compensation for participation and for serious adverse events occurring during the study participation.
10. Investigator’s Agreement with the sponsor
11. Investigator’s undertaking
12. DCGI/DGFT approval
13. Clinical Trial Agreement (CTA)/Memorandum of Understanding (MOU)/Material Transfer Agreement (MTA), if applicable
The following members of the Human Ethics committee (HEC) were present at the meeting held on Date __________ Place __________

Name of member/Position on HEC/Affiliation/Gender

_____________ Chairman of the Ethics committee
_____________ Member secretary of the ethics committee
_____________ Name of each member with designation

The trial is approved in its presented form. The approval is valid until one year from the date of sanction. You may make a written request for renewal / extension of the validity, along with the submission of annual status report.

Following points must be noted:

1. HEC should be informed of the yearly progress of the study.
2. **HEC has approved recruitment of ____ patients on this study.**
3. PI and other investigators should co-operate fully with DSMSC, who will monitor the trial from time to time.
4. The decision was arrived at through consensus. Neither PI nor any of proposed study team members was present during the decision making of the HEC.
5. At the time of PI's retirement/intention to leave the institute, study responsibility should be transferred to colleague after obtaining clearance from HOD, Status report, including accounts details should be submitted to HOD, DSMSC and extramural sponsors.
6. The HEC functions in accordance with the ICH-GCP/ICMR/Schedule Y guidelines.
7. In case of any new information or any SAE, which could affect any study, must be informed to HEC, DSMSC and sponsors. The PI should report SAEs occurred for HEC approved studies within 7 days of the occurrence of the SAE. If the SAE is ‘Death’, the IRB Secretariat will receive the SAE reporting form within 24 hours of the occurrence.
8. In the events of any protocol amendments, HEC must be informed and the amendments should be highlighted in clear terms as follows:
   a. The exact alteration/amendment should be specified and indicated where the amendment occurred in the original project. (Page no. Clause no. etc.)
   b. Alteration in the budgetary status should be clearly indicated and the revised budget form should be submitted
   c. If the amendments require a change in the consent form, the copy of revised Consent Form should be submitted to Ethics Committee for approval.
   d. If the amendment demands a re-look at the toxicity or side effects to patients, the same should be documented.
e. If there are any amendments in the trial design, these must be incorporated in the protocol, and other study documents. These revised documents should be submitted for approval of the SRC and HEC, only then can they be implemented.

f. Approval for amendment changes must be obtained prior to implementation of changes. Without including all the above points, the amendment is unlikely to be approved by the Ethics committee.

g. Any deviation/violation/waiver in the protocol must be informed to the HEC.

Thanking You,

Yours Sincerely,

Member Secretary,
Human Ethics Committee
AX3 –V1/SOP05/V2

FORMAT FOR CONDITIONAL APPROVAL FOR PROJECT/AMENDMENTS

Conditional approval.

Dr…
Principal Investigator,
TMH/TMC.

Ref: Project No.

Dear Dr…

The above referenced project was tabled, reviewed and discussed during the Human Ethics Committee meeting held on date/time/place

List of documents reviewed.

The following members attended the meeting.

The committee suggested the following:
  a.
  b.
  c.

The approval will be granted subject to the compliance with all the above suggestions of the HEC.

Kindly resubmit the two copies of revised proposal or documents within three months for re-review.

This conditional approval is valid only for six months from the date of issue of letter.

Thanking you,

Yours sincerely,

Secretary, HEC
Flow Chart

Agenda Preparation by Secretary/IRB Administrator

Distribution of Protocol/Documents Packages to the HEC Members by Secretariat

Preparation for the meeting by Secretariat

Conduct of meeting

Recording of Minutes & Decision

Filing of Minutes

Communication of decision to PI
Human Ethics Committee, Tata Memorial Centre (HEC, TMC)

Title: Review of Amended protocol/ Protocol related documents

SOP Code: SOP 06/V2 Date: 01/09/2009 Pages: 6
6.1 Purpose

The purpose of this procedure is to describe how protocol amendments or any other amendments/letters are reviewed by the HEC.

6.2 Scope

This SOP applies to amended study protocols/documents and letters that are submitted for HEC approval. Amendments made to protocols or any other amendments related to the study may not be implemented until reviewed and approved by the HEC.

6.3 Responsibility

It is the responsibility of the HEC secretariat to manage protocol amendments, documents and letters.

Receipt of the Amendment Package

- The amendment package forwarded by the PI is received by the secretariat. The amendment package along with the covering letter should be accompanied by Amendment Reporting Form (AX2-V1/SOP06/V2).
- The secretariat of the HEC should follow the procedures as in SOP03/V2 (Procedures for Management of protocol submission).

Upon receipt of the amendment package the IRB, Secretariat should follow the following procedure:

The Member Secretary, HEC, classifies the amendments into minor or major and tables the major amendments on the agenda of the subsequent scheduled meeting (for Minor amendments refer to 6.4.3). The amendments and other documents which need full board review are processed as per the SOP 04a/V2

6.4. Review amended protocols/documents/letters: Review as per Section 4.3 SOP 04a/V2

6.4.1 Decision

- If the HEC approves the amendments, the secretariat staff communicates this decision to the PI (AX1-V1/SOP06/V2).
- If the HEC does not approve the amendments, the secretary should immediately notify the investigator in writing of the decision and the reason for not approving the amendment.
- If the HEC recommends or suggests modifications to any of the documents, or the amendments, the secretariat sends a written communication to the investigator about the specific changes asking him or her to make the necessary changes and resubmit the documents to HEC.
6.4.2 Storage of Documents:

File the amendments in the corresponding research protocol file, as per the SOP 10/01 on documentation and archival.

6.4.3 Minor amendments and notifications

**Minor amendments** (those that do not increase the risk or decrease the potential benefit to subjects) may be approved by the Member Secretaries, HEC in the expedited review subcommittee meeting (Refer SOP no. 04b/V2.)

**Minor notifications** may be noted by the Member Secretary, HEC and not tabled in HEC meeting.

This may include but may not restrict to:
- Renewed insurance policy
- DCGI and DGFT approvals
- Administrative notes

References


Glossary

**Amendment protocol package:** A package of the amended parts and related documents of the protocol, previously approved by the HEC/IRB, TMC. In the course of the study, the PI may decide to make changes in the protocol.
Format for Project Amendment/Document Amendment Approval letter

To
XXXXX(PI)
Department

Ref: - Project title

Dear Dr. ——

We have received the following document/s on (date)

1.

At the HEC meeting held on ——date/time/place, the above mentioned documents were reviewed. After deliberation, the committee has decided to approve the aforementioned study-related documents.

The members who attended this meeting held on —— date and place of meeting—— at which the above mentioned document was discussed, are listed below.

1.
2.
3.

It is to be noted that neither you nor any of your proposed study team members were present during the decision-making procedures of the HEC.

Yours truly,

Signature with Date
Member
Secretary,
HEC
IRB Secretariat
Amendment Reporting Form

<table>
<thead>
<tr>
<th>Project No. :</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Title :</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator :</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Have you highlighted the amended portion in the document or tabulated details of changes?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Does this amendment entail any changes in ICFs</th>
<th>Yes / No</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>If yes, whether amended ICFs are submitted pl. specify Version No. &amp; Date.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Please mention version no. and date of amended Protocol / Investigators brochure / Addendum.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No. of active trial participants</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

Signature of the Principal Investigator & Date:
Flow Chart

Receive the amendment package

Determine whether Expedited or Full review.

Review amended protocols / documents / letters

Communicate decision to PI

Storage of documents
Human Ethics Committee, Tata Memorial Centre (HEC, TMC)

Title: Continuing review of study Protocols

SOP Code: SOP 07/V2 Date: 01/09/2009 Pages: 14
7.1 Purpose

The purpose of continuing review is to monitor the progress of the entire study which was previously approved; not just the changes in it but to ensure continued protection of the rights and welfare of research subjects.

Continuing review of the study may not be conducted through an expedited review procedure, unless 1) the study was eligible for, and initially reviewed by, an expedited review procedure; or 2) the study has changed such that the activities remaining are eligible for expedited review.

7.2 Scope

This SOP applies to conducting continuing review of study protocols involving human subjects at intervals appropriate to the degree of risk but not less than once a year. Depending upon the degree of risk to the participants, the nature of the studies and the vulnerability of the study participants and duration of the study, the HEC may choose to review the studies more frequently.

7.3 Responsibility

It is the responsibility of the secretary, HEC to determine the date of continuing review and to remind the HEC and the PIs.

All the approved protocols will be reviewed annually. The Chairperson is responsible for determining the date of continuing review if the project will be reviewed more frequently in the year. This decision is taken during the HEC meeting wherein the project is finally approved.

The HEC is responsible for reviewing the progress made in the protocol, the occurrence of unexpected events or problems, and the rate of accrual of participants. The protocol, informed consent documents and assent documents are examined to ensure that the information remains accurate.

The HEC has the same options for decision making on a continuing review package as for an initial review package. The decision is made as, approval to continue the study; approval with recommendations; or disapproval. All Principal Investigators along with the submission of the annual project progress report will also apply for extension of approval of the project.

7.4 Detailed Instructions

7.4.1 Determine the date of continuing review

- The Secretariat will look through the master file of projects approved by the HEC for the due date of continuing reviews.
- The Secretariat will plan for continuing review of annual progress reports to be reviewed at least one month ahead and as close as possible to the due date (i.e. one year after the date of original approval) of the protocol.
The Member Secretary will consult the Chairperson whether to include the annual project report/s in the forthcoming HEC meeting for discussion or to review by Member Secretary/Chairperson and inform the members at the full board meeting or to send to two HEC members nominated by Chairperson for review.

7.4.2 Notify the PI or the study team

- The Secretariat will inform the PI at least two months of the due date for the continuing review in writing, (AX2-V1/SOP 07/V2) requesting for 2 copies of the annual / periodic progress report to allow the Study Team sufficient time to collate the information and to prepare a report package required for the continuing review.
- The Secretariat will provide a Continuing Review Application Form (AX1-V1/SOP 07/V2) (available at the IRB Secretariat) to the Study Team and file the acknowledgement in the master file of the research protocol.
- Any PI who fails to submit the report for review within the stipulated time, will have to clarify the delay in writing, this will be forwarded to the Chairperson, HEC.

7.4.3 Manage continuing review package upon receipt

- The Secretariat will receive a package submitted by the Study Team of continuing review for each approved protocol.
- Upon receipt of the package, the Secretariat of the HEC will perform the following (as per instructions in SOP03/V2 for procedures on receipt of submitted packages).

7.4.4 Verify the contents of the package

- The Secretariat will verify that the contents of the package include the following documents:
  1. Continuing Review Application Form (AX1-V1/SOP 07/V2)
  2. The Progress Report with:
     Information about the number of participants enrolled to date and since the time of the last review, an explanation for any “yes” (ticked on the Continuing Review Application Form AX1-V1/SOP 07/V2) answers on the application form and a discussion of scientific development, either through the conduct of this study or similar research that may alter risks to research participants.
- The progress report summary of the protocol since the time of the last review (1 copy).
  1. Request letter for extension of approval of the project, if the project is ongoing.
- The Secretariat will check for complete information and for the presence of the required signatures of the Principal Investigator in the Continuing Review Application Form.

7.4.5 Filing the continuing review package

The Administrative Officer will file the continuing review package in master file of the research protocol.
7.4.6 **Notify the Members of the HEC**

The Secretariat will distribute the protocol progress report to HEC members prior to the meeting.

7.4.7 **Prepare meeting agenda**

The Secretariat will follow for procedures on the preparation of meeting agenda and place the forwarded Annual Progress Report on the agenda for the meeting of the HEC, if deemed necessary by the Chairperson/Member Secretary, on the date which is as close as possible to the due date (i.e. one year after the date of original approval) of the protocol.

7.4.8 **Protocol Review Process**

- The HEC Chairperson/ Member Secretary/ members will use the Continuing Review Application Form (AX1-V1/SOP07/V2) to guide the review and deliberation process. The HEC members could arrive at any one of the following decisions at the HEC meeting:

  1. Noted and the project can be continued without any modifications
  2. Modifications recommended - Protocols for which modifications have been suggested by the HEC may not proceed until the conditions set by the HEC in the decision have been met. Protocols should be amended and submitted to the HEC within **one** month for re-review. Protocols that have been *approved with recommendations* by the HEC may not proceed until the conditions set by the HEC in the decision have been met. Protocols should be amended and submitted to the HEC within **one** month for re-review
  3. Disapproved.

- This decision is recorded by the Member Secretary on AX3-V1/SOP07/V2
- The HEC Chairperson will sign and date the HEC decision on Continuing Review Report after a decision has been reached.
- The completed HEC decision on Continuing Review Report is the official record of the decision reached by the HEC for the protocol.
- The HEC Secretariat will maintain and keep the HEC decision forms and minutes of the meeting relevant to the continuing review as part of the official record of the review process.

7.4.9 **Store original documents**

Place the original completed documents with the other documents in the Continuing Review Package in the protocol file.

7.4.10 **Communicate the HEC Decision to the PI**

The Secretariat will notify the PI of the decision (AX4-V1/SOP 07/V2). If the decision is to recommend modifications, the recommendations will be notified to the PI and he/she will be requested to resubmit the protocol/protocol related documents as amendment within 1 month for approval. Till then the project is suspended. These letters must be sent to the PI within 14 days.
References


## Continuing Review Application Form

<table>
<thead>
<tr>
<th>TMH STUDY No.:</th>
<th>PROTOCOL TITLE:</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI:</td>
<td>Institute:</td>
</tr>
<tr>
<td>Date of HEC approval:</td>
<td>Start Date of study:</td>
</tr>
<tr>
<td>Duration of study:</td>
<td></td>
</tr>
</tbody>
</table>

### HAVE THERE BEEN ANY AMENDMENTS SINCE THE LAST REVIEW?
- [ ] NO
- [ ] YES
  
  (Describe briefly in attached narrative)

### WERE THE ICD AMENDMENTS APPROVED BY HEC?
- [ ] NO
- [ ] YES

If no mention the amendments not approved

Which ICF amendment is the site following at this date

### SUMMARY OF PROTOCOL PARTICIPANTS:
- Accrual ceiling set by HEC
- New participants accrued since last review
- Total participants accrued since protocol began

Number of active patients

Has any information appeared in the literature, or Evolved from this or similar research that might affect the HEC evaluation of the Risk/Benefit analysis of human subjects involved in this protocol?
<table>
<thead>
<tr>
<th>Question</th>
<th>Answer</th>
</tr>
</thead>
<tbody>
<tr>
<td>_____ Number of patients who have completed the study</td>
<td>NO</td>
</tr>
<tr>
<td>IMPAIRED PARTICIPANTS</td>
<td></td>
</tr>
<tr>
<td>□ None</td>
<td></td>
</tr>
<tr>
<td>□ Physically</td>
<td></td>
</tr>
<tr>
<td>□ Cognitively</td>
<td></td>
</tr>
<tr>
<td>□ Both</td>
<td></td>
</tr>
<tr>
<td>HAVE THERE BEEN ANY CHANGES IN THE PARTICIPANT POPULATION, RECRUITMENT OR SELECTION CRITERIA SINCE THE LAST REVIEW?</td>
<td>NO</td>
</tr>
<tr>
<td>□ YES (Discuss in the attached narrative)</td>
<td></td>
</tr>
<tr>
<td>HAVE ANY PARTICIPANTS WITHDRAWN FROM THIS STUDY DURING THE LAST ONE YEAR?</td>
<td>NO</td>
</tr>
<tr>
<td>□ YES (Discuss in the attached narrative, state reasons for drop-outs)</td>
<td></td>
</tr>
<tr>
<td>HAVE ANY PARTICIPATING INVESTIGATORS BEEN ADDED OR DELETED SINCE LAST REVIEW?</td>
<td>NO</td>
</tr>
<tr>
<td>□ YES (Identify all changes in the attached narrative)</td>
<td></td>
</tr>
<tr>
<td>HAVE ANY NEW COLLABORATING SITES (INSTITUTIONS) BEEN ADDED OR DELETED SINCE THE LAST REVIEW?</td>
<td>NO</td>
</tr>
<tr>
<td>IS REPORT OF INTERIM DATA ANALYSIS AVAILABLE?</td>
<td>NO</td>
</tr>
<tr>
<td>□ YES (Discuss in the attached narrative—no. of patients at our site who had SAEs, whether reports of SAEs at our site have been submitted to the HEC, whether reports of SAEs at other sites have been submitted to the HEC, types of adverse events. This should be tabulated with complete details)</td>
<td></td>
</tr>
<tr>
<td>IS REPORT OF THE DATA SAFETY AND MONITORING BOARD AVAILABLE?</td>
<td>NO</td>
</tr>
<tr>
<td>□ YES (submit as an attachment)</td>
<td></td>
</tr>
<tr>
<td>When was study last monitored?</td>
<td></td>
</tr>
<tr>
<td>____________________________________________________________________</td>
<td></td>
</tr>
<tr>
<td>Did the monitoring team have any adverse comments regarding the study?</td>
<td></td>
</tr>
<tr>
<td>(If, Yes, please attach a copy of their comments)</td>
<td></td>
</tr>
<tr>
<td>Attach a copy of current statement from accounts showing utilization of funds.</td>
<td></td>
</tr>
</tbody>
</table>
HAVE ANY INVESTIGATORS DEVELOPED AN EQUITY OR CONSULTATIVE RELATIONSHIP WITH A SOURCE RELATED TO THIS PROTOCOL WHICH MIGHT BE CONSIDERED AS CONFLICT OF INTEREST?

CONFLICT OF INTEREST

- NO
- YES (Append a statement of disclosure)

SIGNATURES:

Date: ..................
Principal Investigator
AX2-V1/SOP 07/V2

Reminder letter by the HEC to PI

Name of Principal Investigator: -
Address of Principal Investigator: -
Ref: - Project Title: XXXXXX

The above referenced project was approved by the HEC on XXXXXXX and is due for continuing annual review by the HEC. You are requested to submit an annual status report in the prescribed format AX1-V1/SOP 07/V2 on or before XXXXX.

Signature with date
Secretary
HEC Decision on Continuing Review Report

Project Title:
PI:
Review a) Annual Progress Report
b) Other
Date of HEC meeting:
Further the review and approval of resubmitted protocol is subjected to:

- Reviewed by Chairperson / Member Secretary only. HEC members were informed at Full Board/ Expedited meeting.
- Reviewed in Full Board
- Reviewed by any 2 HEC members in Full Board /Expedited meeting

1. Name of HEC member: _________________________
   Sign: ____________________________________________

2. Name of HEC member: _________________________
   Sign: ____________________________________________

Decision

- Noted and the project can be continued without any modifications
- Modifications recommended, requiring protocol resubmission
- Protocol discontinued

State the recommendations:
Member - Secretary

Signature with date

Chairperson

signature with date
AX4-V1/SOP 07/V2

Project Report Approval Letter

PI Name :
PI address :
Ref : Project Title

This is with reference to your letter dated ___________ regarding the annual status report of the above mentioned project. The Annual Study Status Report was discussed and noted in the HEC meeting held on ___________. The HEC has noted the progress report. The following recommendations are suggested (wherever applicable)

Signature with date
Member Secretary
HEC
Flow Chart

1. Determine the date of continuing review
2. Notify the PI or study team
3. Manage continuing review package upon receipt
4. Verify the contents of the package
5. Prepare meeting agenda
6. Protocol review process
7. Store original documents
8. Communicate the HEC decision to the PI
Human Ethics Committee, Tata Memorial Centre (HEC, TMC)

Title: Reporting of Protocol Deviation/Non-Compliance/Violation/Waiver

SOP Code: SOP 08/V2 Date: 01/09/2009 Pages: 8
8.1 **Purpose**

To provide instructions for taking action and maintaining records, when investigators/ trial sites, fail to -

- follow the procedures written in the approved protocol
- comply with national / international guidelines for the conduct of human research, including those
- who fail to respond to the HEC requests

8.2 **Scope**

This SOP applies to all HEC approved research protocols involving human subjects.

8.3 **Responsibility**

1. HEC secretariat is responsible for receiving deviations /violations/waiver reports as per (AX1–V1/SOP08/V2) submitted by the PI and placing it on agenda of the meeting. Reporting of deviation/ non-compliance/violation/waiver in any other reporting format will not be accepted.
2. HEC members should review and take action on such reports.

8.4 **Detailed instruction**

8.4.1 **Detection of Protocol deviation/ non-compliance/ violation/waiver**

8.4.1.a The HEC members performing monitoring of the project at trial site can detect protocol deviation/non-compliance / violation, if the project is –

- not conducted as per protocol / national / international regulations
- when scrutinizing annual / periodic reports / SAE reports
- any other communication received from the Investigator / trial site / sponsor / study monitor / CRO

8.4.1.b The Secretariat can detect protocol deviation / non-compliance / violation from failure to

- comply with statutory requirements
- respond to requests from HEC within reasonable time limit
- respond to communication made by HEC

8.4.1.c The PI himself / herself may forward protocol deviation / non- compliance / violation / waiver reports to inform the HEC.

Protocol Waiver is analogous to a Protocol Deviation, except that prior IRB approval must be obtained before implementing the necessary departures from the protocol. Therefore, Protocol Waivers are anticipatory, while Protocol Deviations are not.
e.g. Protocol Waiver means a prospective decision by a sponsor or investigator to permit accrual of a subject who does not satisfy the approved inclusion / exclusion criteria for enrollment.

8.4.1.d Communication / complaint / information received from research participant who has been enrolled or any individual who has been approached for enrollment

8.4.1.e Any report / communication brought to the notice of member secretary / Chairperson of HEC

8.4.1.f Communication received from the Director, TMC informing HEC about an alleged protocol violation / non-compliance / protocol deviation

8.4.2 Noting protocol deviation / non-compliance / violation / waiver by the Secretariat

- The HEC members who have performed monitoring of a particular trial site and detect protocol deviation / non-compliance / violation will inform the Secretariat in writing within 24 hours [one working day].
- Whenever protocol deviation / non-compliance / violation has been observed, the Secretariat will ensure that the issues as well as the details of non-compliance involving research investigators are included in the agenda of the HEC meeting.

The deviations / violations will be scrutinized for gravity and implications in the formal full board HEC meeting. The HEC decision will be communicated to PI.

8.4.3 Board discussion, Decision and Action

- If the protocol deviation / non-compliance / violation is detected by HEC member during monitoring visit he/she will present the protocol deviation / noncompliance / violation information.
- If detected by Secretariat / forwarded by PI, the Secretary will present the protocol deviation / non-compliance / violation / waiver information.
- The Chairperson / HEC members will review the information available and take a decision depending on the seriousness of the violation.
- The decision will be taken to ensure that the safety and rights of the research participants are safeguarded. The decision will be taken by consensus and if no consensus is arrived at, voting will be conducted.

The actions taken by HEC could include one or more of the following:

- Inform the PI that HEC has noted the violation / noncompliance / deviation and inform the PI to ensure that deviations / noncompliance / violations do not occur in future and follow HEC recommendations.
- Enlist measures that the PI would undertake to ensure that deviations / noncompliance / violations do not occur in future.
• Reprimand the PI
• Call for additional information
• Suspend the study till additional information is made available and is scrutinized
• Suspend the study till recommendations made by the HEC are implemented by the PI and found to be satisfactory by the HEC
• Suspend the study for a fixed duration of time
• Inform the Director, TMC
• Revoke approval of the current study
• Inform DCGI / Other relevant regulatory authorities
• Keep other research proposals from the PI/ Co-PI under abeyance
• Review and / or inspect other studies undertaken by PI/Co-PI

8.4.4 Notify the investigator

• The IRB secretariat records the HEC decision Drafts and types a notification letter.
• The Chairperson / Secretary signs and dates the letter.
• The IRB Secretariat makes four copies of the notification letter.
• The IRB Secretariat sends the original copy of the notification to the investigator.
• The IRB Secretariat sends a copy of the notification to the relevant national authorities and other trial sites, in case of multi-centric trial.
• The IRB Secretariat sends the fourth copy to the sponsor or the CRO of the study.

8.4.5 Records and follow up to be kept by IRB Secretariat

• Keeps the last copy of the notification letter in the “non-compliance” file.
• Stores the file on the shelf with an appropriate label.
• Follows up the action after a reasonable time.
• Maintains a file that identifies investigators who are found to be non-compliant with national / international regulations or who fail to follow protocol approval stipulations or fail to respond to the HEC request for information/action

References


Glossary

**Deviation / on-compliance / Violation:** The HEC monitors whether investigators do not perform the study in compliance with the approved protocol, ICH GCP, FDA regulations and/or fail to respond to the HEC request for information/action.

**Waiver:** Protocol Waiver is analogous to a Protocol Deviation, except that prior IRB approval must be obtained before implementing the necessary departures from the protocol.
## Deviation (D)/Waiver (W)/Violation (V) Reporting Form

| Specify if D/W/V- | Nature: | Minor | Major | Other 
|------------------|---------|-------|-------|--------
|                  | (Tick whichever applicable) |

If other, please specify:

**Date of occurrence: dd/mm/yyyy (Not applicable incase of Waiver)**

**No of similar D/W/V occurred for the same trial:**

**Patient No.:**

**IRB Project No:**

**Project Title:**

**Complete Details of D/W/V:**

**Action taken by PI/Co-PI/Co-I : (Not applicable in case of Waiver)**

**Impact on trial subject (if any) : (Not applicable in case of Waiver)**

**Name of PI:**

**Sign of PI:**

**Date:**
Flow Chart

Detection of Protocol deviation / noncompliance / Violation, Request for waiver by PI

Noting protocol deviation / non-compliance / waiver

Board discussion, decision and action

Notify the PI of HEC action

Maintain records
Title: Review of Serious Adverse Events (SAE) Reports
9.1 Purpose

The purpose of this SOP is to provide instructions on the review and follow-up reports of serious adverse events (SAEs) and unexpected events for any active study approved by the HEC.

Unanticipated risks are sometimes discovered during the course of studies. Information that may impact on the risk/benefit ratio should be promptly reported to and reviewed by the HEC to ensure adequate protection of the welfare of the study participants. The unanticipated risks may as well include any event that in the investigator's opinion, may adversely affect the rights, welfare or safety of subjects in the study.

9.2 Scope

This SOP applies to the HEC review of SAE and unexpected events reports, both on site and off site, including follow up reports submitted by investigators. The detailed instructions regarding on site and off site SAE review are described in the following section 9.4

9.3 Responsibility

The primary responsibility of the HEC is to review and address SAE and unexpected events involving risks to research participants. In addition, the committee is authorized to offer mediation under appropriate circumstances.

HEC should also make sure that researchers are made aware of the policies and procedures concerning reporting and continuing review requirements.

The IRB Secretariat is responsible for receiving the complete SAE / unexpected events reports and directing them to DSMSC for detailed review as described in the DSMSC - Policy and Procedures manual (2003). Following the DSMSC meeting, the Secretary, DSMSC will then submit the report to the Member Secretary, HEC. The Member Secretary, HEC will then table the DSMSC minutes in the subsequent HEC meeting.

Notifying the IRB Secretariat, DSMSC, or Secretary, HEC does not relieve the PI from his/her responsibility to notify the sponsor and regulatory authorities.

9.4 Detailed instructions

A. On site SAEs

9.4.1 SAE related activities before HEC meeting

- The IRB Secretariat will verify that the reports are complete, signed and dated by the PI. In case the IRB Secretariat notes that the report is incomplete, it will be forwarded to Member Secretary, HEC for decision and also revert back to PI.
The IRB secretariat should receive the reports of SAEs occurred for HEC approved studies within 7 days of the occurrence of the SAE.

If the SAE is ‘Death’, the IRB Secretariat should receive the SAE reporting form (AX1-V1/SOP 09/V2) within 24 hours of the occurrence.

If the PI has not adhered to the above stipulated time period, the IRB Secretariat will notify the discrepancies in the reporting time and time of occurrence of SAE to the PI.

9.4.2 Actions to be taken by Member Secretary, HEC

- The Member Secretary will review the SAE Report, write comments and forward it to the Secretary, DSMSC, immediately.
- If the SAE reported is ‘death’, the Member Secretary, HEC, will review the SAE report and forward it to member Secretary, DSMSC within 1 working day for immediate action. If deemed necessary, Member Secretaries of HEC I and II and Member Secretary, DSMSC will review the SAE, death, either in person, by e-mail or telephone and inform the Chairperson, HEC.
- The Member Secretary will table the DSMSC minutes which includes SAE review, at the next scheduled HEC full board meeting.

9.4.3 Actions to be taken by Chairperson

The Chairperson, HEC on basis of the information and comments received from the Member Secretary, HEC and DSMSC, and applying his/ her judgment will direct the IRB Secretariat to any one or more actions listed below, but are not limited to.

- suspending enrolment of new research participants till further review by the HEC
- suspending all trial related procedures (except those intended for safety and well-being of the participant) till further review by the HEC
- suspend some trial-related procedures (listed by the secretariat).
- calling for an emergency review by full board.
  - This review should be initiated within 48 working hours (2 working days) of receipt of information.
  - This review could be done through a meeting, teleconference, email or telephonic conversation.
  - The IRB Secretariat will take appropriate steps to ensure that HEC members are informed about this full board meeting.
  - Depending upon the complexity of the issue(s) involved, the chairperson could direct the Member Secretary, HEC, to invite one or more experts whose opinion would be valuable. These experts could participate after they agree to the confidentiality clause and abide by the rules and regulations of HEC.
- soliciting opinion of one or more expert in writing. The information can be provided to expert after he/ she/ they agree(s) to the confidentiality clause and abide by the rules and regulations of HEC. The expert would be requested to provide an opinion in writing within 2-14 working days, depending upon the gravity and seriousness of the matter.
B. Off Site SAEs

- Off Site SAEs where adverse event reports that are serious, unexpected and related (definitely, probably and possibly) to the drug need prompt reporting to the HEC.
- The SAEs that are expected (if listed in the informed consent) or unexpected but unrelated to the drug (classified as per the Off site Safety Report Classification form – AX2-V1/SOP09/V2) have to be logged (AX3-V1/SOP09/V2) by the PI and to be submitted every 3 months and/or submitted along with continuing review report. The log has to be maintained continuously until the end of the study.
- Those off site SAEs which qualify for prompt reporting, (classified as per the Off site Safety Report Classification form – AX2-V1/SOP09/V1) will be reported to IRB Secretariat, and forwarded to Member Secretary, HEC and Secretary DSMSC for further action.
- If the HEC and DSMSC need to review the off site SAE reports, the committee will request copies of SAE reports at any time, as and when necessary.
- If a trend is observed in SAEs by PI, such a trend will be reported to IRB Secretariat, action on such reports will be taken by the Member Secretary, HEC and Secretary DSMSC, as per 9.3-9.4
- The IRB Secretariat will not accept the complete set of “Off site Safety Reports” and/or the log. However, the IRB will accept the log of (AX3-V1/SOP09/V2) the SAEs every 3 months and/or at the time of continuing review/submission of annual status report.

9.5 During the HEC meeting

On site SAEs

- The Secretary, DSMSC will inform all the HEC members about the SAEs and actions taken. The minutes of DSMSC meeting will be discussed.
- If appropriate, specific action or combination of actions will be taken, based on the consensus decision of the HEC discussion. Some of which are listed below:
  - Terminate the study;
  - Suspend the study till review is completed;
  - Suspend the study till additional information is obtained;
  - Suspend the study for a fixed duration of time;
  - Suspend the study till amendments requested for by the HEC are accepted;
  - Suspend enrolment of new research participants;
  - Suspend certain activities under the protocol (while going on with activities intended to protect the safety, well-being of participants who have already been enrolled);
  - Recommend an amendment to the protocol, the ICD, Participant information sheet, investigator brochure and/ or any other document.
  - Request additional details
  - Request further follow up information
  - Direct the PI to inform participants already enrolled in the study about the SAE and obtain their consent regarding continuation in the research trial, if necessary.
o Direct the PI to inform participants already enrolled in the study about the SAE and request them to undertake additional visits, additional procedures, additional investigations, etc. as prescribed in the amendment.

o Note the SAE report in the HEC records if information submitted is found to be adequate

o Any other action

**Off site SAEs**

- The Secretary, DSMSC will inform all the HEC members about those off site SAEs which qualify for prompt reporting, (classified as per the Off site Safety Report Classification form – AX2-V1/SOP09/V) and were reviewed in DSMSC meeting. The minutes of DSMSC meeting will be discussed.
- If appropriate, specific action or combination of actions will be taken, based on the consensus decision of the HEC discussion. Some of which are listed below:
  o Terminate the study;
  o Suspend the study till review is completed;
  o Suspend the study till additional information is obtained;
  o Suspend the study for a fixed duration of time;
  o Suspend the study till amendments requested for by the HEC are accepted;
  o Suspend enrolment of new research participants;
  o Suspend certain activities under the protocol (while going on with activities intended to protect the safety, well-being of participants who have already been enrolled);
  o Recommend an amendment to the protocol, the ICD, Participant information sheet, investigator brochure and/ or any other document.
  o Request additional details;
  o Request further follow up information;
  o Direct the PI to inform participants already enrolled in the study about the SAE and obtain their consent regarding continuation in the research trial, if necessary.
  o Direct the PI to inform participants already enrolled in the study about the SAE and request them to undertake additional visits, additional procedures, additional investigations, etc. as prescribed in the amendment.
  o Any other action

9.6 **After the review of SAE**

- The IRB secretariat will send a formal letter to the investigator/s with instructions for specific actions as per the HEC decision.
- The HEC will instruct the PI to forward follow-up reports of the SAE to the IRB.
- The HEC will instruct the PI regarding compliance to actions recommended by the HEC within 14 days of receipt of the HEC letter.
- In case a PI fails to respond to the HEC letter, the matter will be discussed at the next full board meeting and a decision will be taken for specific action by simple majority.
The Member Secretary / Chairperson will sign and date the letter.

The IRB Secretariat will send the letter and file a copy of the letter in the master file of the research protocol.

References


Glossary

**Adverse Event:** Any untoward medical occurrence in a patient or clinical investigation participant administered an investigational product and which does not necessarily have a causal relationship with this treatment. The adverse event can therefore be any unfavorable or unintended sign or experience associated with the use of the investigational product, whether or not related to the product.

**Adverse Drug Reaction:** In the pre-clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not established all noxious or unintended responses to the product related to any dose should be considered adverse drug reactions. The phrase “responses to a medicinal product” means that a causal relationship between the product and the adverse event is at least a reasonable possibility, i.e., the relationship can not be ruled out. Regarding marketed products, a response to a product which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis or therapy of diseases or for modification of physiological function.

**IND:** Investigational New Drugs means substances with potential therapeutic actions during the process of scientific studies in human in order to verify their potential effects and safety for human use and to get approval for marketing.
Serious Adverse Event Review Report for SAE

As per ICH-GCP:
Serious Adverse Event (SAE) or Serious Adverse Drug Reaction (Serious ADR)
Any untoward medical occurrence (due to the participation in the concerned trial) that at any dose:
• results in death,
• is life-threatening,
• requires inpatient hospitalization or prolongation of existing hospitalization,
• results in persistent or significant disability / incapacity,
or
• is a congenital anomaly/birth defect

Investigator(s) shall report all SAE (as above) to the Sponsor within 24 hours and to the Ethics Committee that accorded approval to the study protocol within 7 working days of their occurrence and within 24 hours in the event of death.

Does the Principal Investigator feel this SAE is related to participation in the trial?
☐ Yes ☐ No ☐ Possibly

Does the protocol have an inbuilt data monitoring plan?  ☐ Yes ☐ No

1. Title of project and Project No:

2. Principal Investigator:

3. Report date

Report type  ☐ initial  ☐ follow up

4. Patient case no:

5 a. Age

5 b. Gender

6. Mention the total number of SAE (prior) occurred at our site________ other site(s)_________

7. Mention number of similar SAEs (prior) occurred for same study at our site________ other site(s)_________
### Suspect drug/device/intervention information

8. Suspect drug (include generic name)/device/intervention

9. Dose:

10. Route(s) of administration:

11. Therapy dates (from/to)

12. Therapy duration:

13. Did the reaction decline after stopping the drug/procedure
   - [ ] YES
   - [ ] NO
   - [ ] NA

### Concomitant drugs and history

14. Concomitant drug(s) and date of administration:

15. Patient relevant history (e.g. diagnosis, allergies)

### Reaction information

16. Description of adverse event (indicate if this is follow-up report and if so, include follow-up information only) **Underline the adverse event**

17. Tick whichever is applicable for specific adverse event

   A) [ ] expected event [ ] unexpected event (this refers to trial being conducted and not disease process)

   B) [ ] hospitalization [ ] increased hospital stay [ ] death [ ] others (If others, please specify)

   C) [ ] No permanent significant functional/cosmetic impairment
      - [ ] Permanent significant functional/cosmetic impairment
      - [ ] Not applicable

18. Describe the medical treatment provided (if any) to the research subject:

19. Outcome was
   - [ ] resolved [ ] ongoing [ ] death

20. Was the research subject continued on the research protocol
   - [ ] yes [ ] no
21. In your opinion, does this report require any alteration in trial protocol?
   — yes — no

if yes then please specify.

Signature of Principal Investigator ________________________________ date: _______________

Upon receipt of this report, the HEC/DSMSC will decide whether additional information is needed or whether further investigation of the incident is required.

For HEC use only

I _______ agree _______ disagree with the assessment of the Principal Investigator.

DSMSC Reviewer ________________________________ date: __________

Explanation:

____________________________________________________________
AX2-V1/SOP09/V2

Off site Safety Reports Classification Form

NOTE to PI:

The following questions will act as a guide for submission of the “Safety Reports”. This form is merely providing guidance for reporting / logging of Off site Safety Reports.

If the answer to all three questions is “Yes”, prompt reporting is required and such off site Safety Reports need to be reported to HEC along with the log.

If any one answer is “No”, it needs to be logged as prescribed format. (AX3-V1/SOP 09/V2). This log should be submitted to the IRB Secretariat every 3 months and/or along with Continuing Review report.

Project No.

Project Title :

<table>
<thead>
<tr>
<th>Questions</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is adverse event serious?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is adverse event related?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is adverse event unexpected?</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Date of reporting
Signature of PI
Name of PI
NOTE to PI:

1. Please log in details of Off Site Safety Report.
2. The following log has to be maintained continuously until the end of the study.
3. This log should be submitted to the IRB Secretariat every 3 months and/or along with Continuing Review report.
4. The log must be submitted to the IRB Secretariat immediately, if prompt reporting is required and/or if a trend related to the occurrence of SAE is observed.
5. Please note the complete set of Off site Safety Reports need not be sent to IRB Secretariat as and when received. If the IRB needs to review the reports, they can request copies at any time.

Project No.:  
Project Title: 

No. of Participants already enrolled in TMC:

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Country</th>
<th>Date of Onset</th>
<th>Adverse event</th>
<th>Out Come</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Name and Signature of PI:  
Date:
Flow Chart

Onsite SAEs

IRB Secretariat will receive, verify and forward reports to Member Secretary, HEC

Review by Member Secretary & forwarded to DSMSC

Review by DSMSC members in DSMSC meeting

DSMSC minutes tabled in next HEC meeting

Inform PI about specific actions of HEC

Inform PI about specific actions of HEC/DSMSC, if any

Storage of SAE reports & decision letters in files

In case of death, if deemed necessary, Review by Member Secretary, HEC and DSMSC. Comments are forwarded to Chairperson

Actions taken by Chairperson

Inform PI about specific actions of HEC
Flow Chart

Off site Safety Report

AE
- Serious
- Unexpected
- Related or unrelated

Prompt reporting to HEC

Review by HEC & DSMSC

HEC decision communicated to Principal Investigator

If a trend observed

AE not serious and / or unrelated and / or expected

Log prepared & maintained by PI & submitted at the time of continuing report

If required IRB can request copies of SAE reports whenever required
Human Ethics Committee, Tata Memorial Centre (HEC, TMC)

Title: Maintenance of Active Project Files, Archival of Closed Files and Retrieval of Documents

SOP Code: SOP 10/V2 Date: 01/09/2009 Pages: 8
10.1 **Purpose**

To provide instructions for preparation and maintenance of active study files and other related documents approved by the HEC, TMC, and storing of closed files and retrieval of documents.

10.2 **Scope**

This SOP applies to all protocol/study files and their related documents that are maintained in the IRB office and closed files.

10.3 **Responsibility**

It is the responsibility of IRB staff to ensure that all study files are prepared, maintained, and kept securely for a period of three years after the closure of the project (under a proper system that ensures confidentiality and facilitates retrieval at any time).

10.4 **Maintain the active study files**

- Master file is the file comprising of all essential documents and correspondence related to the study/protocol. Trial master files should be established at the beginning of the trial, in the IRB secretariat.
- The approved study files are assigned unique identifiers (serial project no.).
- Gather, classify and combine all related documents together of the approved study files appropriately.
- Keep all active files in a secured file cabinet with controlled access. A log book of authorized individuals accessing the files will be maintained.
- Maintain the study files in an easily accessible and secure place for at least 3 years after the study closure.
- All closed study files will be separately archived.
- Final disposal of study/master files on completion of archival period.

10.5 **Disposal of closed files and copies of protocols and documents submitted for HEC review.**

The trial master file will be maintained in the IRB office for a period of three years following closure of the study. After completion of archival period the closed files will be shredded and disposed off. However, all the copies of research projects and documents submitted for HEC review will be shredded off by the authorized IRB personnel after the HEC meeting without any notification to PI. A log book of disposed documents will be maintained.

10.6 **Accessibility / Retrieval**

Master files will be made available for inspection and copying by authorized representatives of regulatory authorities after receiving the request in writing.
In case, any investigator needs a copy of any document from the master file, he/she should make a written request. (AX1 –V1/SOP10/V2). The IRB staff will furnish a copy of the required document within a week with HEC Secretary’s consent. The IRB will issue a copy of the following documents on formal written request:

### 10.7 Final Disposal of Master files

The master files will be disposed off after archival period of 3 years. A formal written off register (AX2- V1/SOP 10/V2) will be maintained, providing details of documents being written off / disposed off.

**Glossary**

**Active Study File:** Any approved protocol, supporting documents, records containing communications and reports that correspond to each currently approved study

**Closed Study File:** The study which is completed or terminated or discontinued or suspended or not initiated is considered to be closed.
**AX1–V1/SOP10/V2**

**Document Request Form**

<table>
<thead>
<tr>
<th>Project No.:</th>
<th>Project Title:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name of PI:</th>
<th>Requested by:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Documents requested:

Purpose of the request:

Principal Investigator’s Signature:

Signature of the requesting person:

Permission of Secretariat: YES/NO

Member Secretary, HEC
## AX2 –V1/SOP10/V2

### Format of written off register

<table>
<thead>
<tr>
<th>Project No.</th>
<th>Title</th>
<th>PI</th>
<th>No of files</th>
<th>EC approval</th>
<th>Study Initiation Date</th>
<th>Study Closure Date</th>
<th>Name &amp; Sign of Authorized Individual</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Flow Chart

Study/Master file

Active Study File
- Preparation
- Maintenance
- Storage
- Retrieval

Closed Study File
- Archival
- Disposal
- Copies of protocols and documents submitted for HEC review
11.1 Purpose

To describe the procedures for documenting the HEC activities.

11.2 Scope

This SOP will apply to all research activity involving human subjects, without regard to the source type of funding.

11.3 Responsibility

It is the responsibility of IRB staff to maintain HEC files at IRB office.

11.4 Detailed Instructions

11.4.1 HEC records will include the following

1. HEC members' records
   a. Acceptance letters of each member
   b. signed and dated recent *Curriculum vitae* and confidentiality agreement letters of each member
   c. Training records for each HEC member
   d. Documentation of resignation/termination

2. HEC membership roster

3. HEC attendance roster

4. HEC meeting agenda and minutes

5. Standard Operating Procedures

6. Annual reports

11.4.2 Access to HEC records

HEC records will be made available for inspection by authorized representatives of regulatory authorities after receiving the request in writing.
Flow Chart

HEC records

- HEC members’ records
- HEC membership roster
- HEC attendance roster
- HEC meeting agenda and minutes
- Standard Operating Procedures
- Annual reports

IRB staff

Access to records
Authorized representatives of regulatory authorities
Human Ethics Committee, Tata Memorial Centre (HEC, TMC)

Title: Review of study completion reports

SOP Code: SOP 12/V2  Date: 01/09/2009  Pages: 6
12.1 Purpose

The purpose of this SOP is to provide instructions on the review of Study Completion Report for every study previously approved by the HEC.

12.2 Scope

This SOP applies to the review of the Study Completion Report which is an obligatory review of each investigator’s activities presented to the HEC as a written report of study completed.

Although HEC provides a Study Completion Report Form (AX1-V1/SOP12/V2) to the investigator, any mechanism (letter format, form provided by the Sponsor, etc.) may be used, provided that the information submitted is sufficient.

12.3 Responsibility

It is the responsibility of the HEC members to review the study completion report and notify it or request for further information, if necessary.

12.4 Detailed instructions

12.4.1 Before each board meeting

- The secretariat will receive 15 copies / as per strength of HEC membership, of Study Completion Reports from the PI.
- The Secretariat will follow instructions as in SOP 03/V2 (Management of Protocol Submission) for receiving and checking the report packages.
- It is the responsibility of the IRB Secretariat to review the report for completeness before submission for the Board meeting.
- The IRB Secretariat should keep the study completion reports on the agenda for HEC meeting. (Procedures for Agenda preparation, Meeting procedures and recording of Minutes- SOP 05/V2)

12.4.2 Before and during board meeting

- HEC member(s) should review a copy of the Final Report.
- The members will discuss the report in the HEC meeting.
- If appropriate to the discussions, the Chairperson may call for consensus to accept it or request further information or take any other action as suggested by HEC.

12.4.3 After the board meeting

- The Secretariat will note the decision in the meeting minutes and the study will be considered as closed if the document is accepted.
- The HEC decision is communicated to the investigator. In case further information / action is requested, the same should be followed by the PI and communicated to the IRB office within 30 days. This update will be tabled in the full board meeting of HEC.
The Secretariat will accept and file the Final Report in the project master file.

The IRB secretariat will archive the entire study protocol and the report for a period of 3 years from the date of completion of the project, if the report is accepted.

References


# Annexure

**AX1-V1/SOP 12/V2**

## Study Completion Report Form

<table>
<thead>
<tr>
<th>(To be Filled by PI)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>TMC Project No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol Title:</td>
</tr>
<tr>
<td>Principal Investigator:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Phone number, email address</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Sponsor</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Address</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Phone, Email</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Total no. of study participants recruited</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Study Initiation Date</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Total no. of study participants approved by the HEC for recruitment</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>No. of study arms</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Duration of the study</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Objectives</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Results (brief) (use extra blank sheets, if more space is required)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>SAEs at our center (Total number and type)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Whether all SAEs intimated to the HEC (Yes/No)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>No. of patients withdrawn</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Reasons for withdrawal</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Protocol deviations/violations (Number and nature)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Signature of PI</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Date:</th>
</tr>
</thead>
</table>

Review of study completion reports
Human Ethics Committee, Tata Memorial Centre (HEC, TMC)

Title: Management of Premature Termination / Suspension / Discontinuation of the Study

SOP Code: SOP 13/V2

Date : 01/09/2009

Pages: 6
13.1 Purpose

The purpose of this SOP is to describe how the HEC proceeds and manages the premature termination / suspension / discontinuation of a research study. Protocols are usually terminated at the recommendation of the HEC, DSMSC, PI, sponsor or other authorized bodies wherein subject enrollment and subject follow-up are discontinued before the scheduled end of the study.

13.2 Scope

This SOP applies to any study approved by HEC that is being recommended for termination/ suspension/discontinuation before its scheduled completion.

13.3 Responsibility

It is the responsibility of the Chairperson, HEC to terminate any study that the HEC has previously approved when the safety or benefit of the study participants is doubtful or at risk. The Secretariat is responsible for management of the premature termination / suspension /discontinuation process.

13.4 Detailed instructions

13.4.1 Receive recommendation for study Termination / Suspension / Discontinuation

- The Secretariat will receive recommendation and comments from DSMSC, PI, Sponsor or other authorized bodies for premature termination of study protocol.
- The HEC members / Chairperson can prematurely terminate the study if protocol non-compliance /violation is detected and HEC decision is to terminate the study.
- SAE occurring at trial site may require the study to be prematurely terminated for the safety of the patients.
- The Secretariat will inform the PI to prepare and submit a protocol termination package along with Premature Termination Report (available at IRB office)
- The Secretariat will receive the study protocol termination package prepared and submitted by the PI and verify the contents of the package for inclusion of:
  - Premature Termination Report (AX1- V1/SOP13/V2) signed and dated by the PI should contain a brief written summary of the protocol, its results, and accrual data.
  - The Secretariat will check the completeness of the information, including accrual data since the time of the last continuing review.
  - The Secretariat will initial and date the package upon receipt.

13.4.2 Review and discuss the Termination / Suspension / Discontinuation Package

- HEC will review the termination package at regular full board meeting to discuss about the recommendation.
- The Secretary in the meeting will inform of the premature termination of the project and the HEC members will review the Premature Termination Report (AX1- V1/SOP13/V2)
- If the Premature Termination Report is unclear/more information is required from the PI, the Secretariat is instructed to send a query to the PI.
13.4.3 Notify the PI

- The Secretariat will make notification letter acknowledging the approval of termination or query letter to request information regarding the premature termination.
- The Secretariat will send the notification letter to the PI for their records within 14 days after the meeting.

13.4.4 Store the protocol documents

- The Secretariat will keep the original version of the Premature Termination Report in the Protocol file and send the file to archive.
- The protocol documents will be stored for a period of 3 years from the date of project Termination.
- If a query is sent to PI, on receipt of the reply letter, it is reviewed in the forthcoming full board meeting and steps in 13.4.2 will be performed by the Secretariat.

References

**Premature Termination / Suspension / Discontinuation Report**

<table>
<thead>
<tr>
<th>TMH Project No.:</th>
<th>Protocol Title:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PI:</th>
<th>Phone:</th>
<th>E-Mail:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Trial Site:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sponsor:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HEC Approval Date:</th>
<th>Date of Last Progress Report Submitted to HEC:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Starting Date:</th>
<th>Termination Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No. of Participants Enrolled:</th>
<th>No. of Participants Completed:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No. of Ongoing Participants:</th>
<th>No. of Drop Outs:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAE (Total No.):</th>
<th>SAE Event:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Summary of Results:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reason for Termination/Suspension/Discontinuation:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PI Signature:</th>
<th>Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**AX1- V1/SOP13/V2**
Flow Chart

Receive recommendation for study termination / suspension / discontinuation

Review and Discuss Termination / Suspension / Discontinuation Package

Notify the PI

Store the Documents

Management of Premature Termination/Suspension/Discontinuation of the Study
Human Ethics Committee, Tata Memorial Centre (HEC, TMC)

Title: Request for Waiver of Written Informed Consent

SOP Code: SOP 14/V2 Date: 01/09/2009 Pages: 8
14.1 Purpose

The purpose of this SOP is to describe the type of research projects for which the HEC may grant waiver for requirement of obtaining written informed consent and the format of the application form to be used by the investigators for requesting waiver of consent. The Application Form AX1-V1/SOP 14/V2 is designed to standardize the process of applying for consent waiver.

14.2 Scope

This SOP applies to all protocols with a request of granting consent waiver submitted for review by the HEC. The decision should be taken by the HEC members at the expedited subcommittee meeting or in some cases during full board meeting.

14.3 Responsibility

It is the responsibility of the Member Secretary to table the request in the expedited subcommittee meeting or in some cases, during full board meeting.

14.4 Detailed instructions

- When a request for waiver of consent is submitted by the PI along with the study documents to the HEC secretariat, in the given format AX1-V1/SOP 14/V2 stating the reasons for the consent waiver; the following steps are taken:
  - The HEC Secretariat will check if the concerned documents are filled completely and the required list of documents is enclosed.
  - The HEC members will review the request taking into consideration the types of studies for which waiver of consent may be granted.
  - The HEC will ensure that there are adequate mechanisms described in the protocol for protection of the identity of the research participants and maintaining confidentiality of the study data. This is necessary as the participant cannot be assured directly about confidentiality of health data through a formal informed consent process, when consent waiver is granted.
  - The decision whether to grant the waiver is taken in expedited subcommittee meeting or in some cases during full board meeting.
  - The decision regarding approval/disapproval of waiver is informed to the PI in writing. If the waiver is not granted, the HEC will provide reasons for the same.

14.5 Type of research projects which may qualify for consent waiver:

A request to waive written informed consent must be accompanied by a detailed explanation. The investigator is also required to provide assurance regarding protection of identity of research participants and maintenance of confidentiality about the data of the research participants. The following criteria (ICMR 2006 guidelines) must be met for a research project so that it can qualify for granting a waiver of both written and verbal consent.
1. The proposed research presents no more than minimal risk to subjects. *(ICMR guidelines, 45CFR 46)* e.g. a retrospective review of patient case records to determine the incidence of disease/recurrence of disease. [Minimal risk would be defined as that which may be anticipated as harm or discomfort not greater than that encountered in routine daily life activities of general population or during the performance of routine physical or psychological examinations or tests. However, in some cases like surgery, chemotherapy or radiation therapy, great risk would be inherent in the treatment itself, but this may be within the range of minimal risk for the research participant undergoing these interventions since it would be undertaken as part of current everyday life].

2. When it is impractical to conduct research since confidentiality of personally identifiable information has to be maintained throughout research as may be required by the sensitivity of the research objective. *(ICMR 2006 guidelines)* e.g. conducting interviews with citizens about their religious beliefs/people with HIV and AIDS/conducting phone interviews with homosexuals.

The only record linking the participant and the research would be the consent document and when there is a possible legal, social or economic risk to the participant entailed in signing the consent form as they might be identified as such by signing the consent form, the requirement for obtaining consent can be waived of by the HEC.

[In case of telephonic interviews, waiver of written informed consent may be requested but this does not mean that verbal consent cannot be utilized].

The following points need to be considered.

a. The following documents need to be submitted for the HEC review
   - A script for verbal consent - a verbal consent script provides all of the elements of consent in a more informal style. In addition, each subject should be provided with an information sheet that describes the study and gives contact names and numbers.
   - The interview schedule (questions to be asked) will confirm that the interview is a simple 5 minute call and that no questions are asked that compromise a person’s confidentiality or position.

b. Normally, investigators will be asked to keep a log of those who were approached about the study, and offered verbal consent. A simple chart can indicate the subjects as participant 1, participant 2, and participant 3. A column can indicate that verbal consent was given and a date. Since a specific number of study participants are to be recruited. It is important that investigators keep some record to indicate that they are not enrolling more subjects than they originally requested.

3. Research on publicly available information, documents, records, work performances, reviews, quality assurance studies, archival materials or third party interviews, service programs for benefit of public having a bearing on public health programs, and consumer acceptance studies. *(ICMR 2006 guidelines)*
4. Research on anonymised biological samples from deceased individuals, left over samples after clinical investigation, cell lines or cell free derivatives like viral isolates, DNA or RNA from recognized institutions or qualified investigators, samples or data from repositories or registries etc. (ICMR 2006 guidelines)

5. In emergency situations when no surrogate consents can be taken. *(ICMR 2006 guidelines)* when consent of person/ patient/ responsible relative or custodian/ team of designated doctors for such an event is not possible, the HEC can allow waiver of consent for recruiting participant in a research study. However, information about the intervention should be given to the patients whenever he/she gains consciousness or to relative/ legal guardian when available later.

References:

1. Ethical Guidelines for Biomedical research on Human Participants, ICMR (2006)
Application form for requesting waiver of consent

1. Principal Investigator's name: ________________________________________

2. Department: ________________________________________________________

3. Title of project: ______________________________________________________

4. Names of other participating staff and students:

5. Request for waiver of informed consent:
   - Please check the reason(s) for requesting waiver (Please refer the back of this annexure for criteria that will be used by HEC to consider waiver of consent).
     1. Research involves 'not more than minimal risk'
     2. There is no direct contact between the researcher and participant
     4. Any other (please specify)
   - Statement assuring that the rights of the participants are not violated
   - State the measures described in the Protocol for protecting confidentiality of data and privacy of research participant

Principal Investigator's signature with date: _______________________________
Flow Chart

1. Receive the submitted documents
2. Review of protocol & application for waiver of consent
3. Decision regarding waiver of consent
4. Communicate the decision to the investigator
5. Recording & filing the decision
Human Ethics Committee, Tata Memorial Centre (HEC, TMC)

Title: Site Monitoring

SOP Code: SOP 15/V1  Date: 01/09/2009  Pages: 8
15.1 Purpose

The purpose of this SOP is to provide the procedures to select a site for monitoring and how the site will be monitored.

15.2 Scope

This SOP applies to any visit and/or monitoring of any study sites of HEC approved study protocols.

15.3 Responsibility

It is the responsibility of the HEC members to perform or designate some qualified agents to perform on its behalf on-site inspection of selected study sites of relevant projects it has approved.

The HEC members or Secretariat in consultation with the Chairperson may initiate an on-site evaluation of a study site for cause or for a routine audit.

15.4 Detailed instructions

15.4.1 Selection of study sites

- Sites will be identified for routine monitoring at the time of approval of the project by the Full Board which will be recorded in the minutes.
- “For cause” monitoring will be performed at sites for reasons identified by any member of HEC, approved by Chairperson. For cause monitoring could be initiated, in any of the following conditions: for high number of protocol violations, large number of studies carried out at the study sites, remarkable SAE reports, high recruitment rate, Non-compliance or suspicious conduct and any other cause as decided by HEC.

15.4.2 Before the visit

- If the site was identified for routine monitoring, the Secretariat will inform the HEC members in the Full Board meeting, 1 month prior to the stipulated date of monitoring.
- For cause / routine monitoring of the project, the HEC Chairperson will designate an HEC member or appoint an independent monitor to perform the task of monitoring.
- The Secretariat will inform the PI in writing about the date / time of monitoring visit and request for confirmation letter from the PI to be available for the monitoring visit.
- The HEC member / Independent monitor will also:
  - Contact the site to notify them that they will be visiting them. At that time, the monitor and the site will coordinate the time for the site evaluation visit.
  - The Secretariat will make the appropriate travel arrangements for the HEC member / Independent monitor.
  - The HEC member / Independent monitor will review the HEC project files for the study and site profile and make appropriate notes.
The HEC member / Independent monitor may copy some parts of the HEC project files for comparison with the site files and collect the Site Monitoring Visit Report Form (AX1-V1/SOP15/V1) from the Secretariat.

15.4.3 During the visit
The HEC member/Independent monitor will

- Review the informed consent document to make sure that the site is using the most recent version,
- Review randomly the subject files to ensure that subjects are signing the correct informed consent,
- Observe the informed consent process, if possible,
- Observe laboratory and other facilities necessary for the study at the site, if possible.
- Review the project files for the study to ensure that documentation is filed appropriately.
- Verifying that the investigator follows the approved protocol and all approved amendment(s), if any.
- Ensuring that the investigator and the investigator's trial staff are adequately informed about the trial
- Verifying that the investigator and the investigator's trial staff are performing the specified trial functions, in accordance with the protocol and any other written agreement between the sponsor and the investigator/institution, and have not delegated these functions to unauthorized individuals.
- Verifying that the investigator is enrolling only eligible subjects.
- Verifying that source documents and other trial records are accurate, complete, kept up-to-date and maintained.
- Checking the accuracy and completeness of the CRF entries, source documents and other trial-related records against each other.
- Determining whether all adverse events (AEs) are appropriately reported within the time periods required by GCP, the protocol, the IRB/IEC, the sponsor, and the applicable regulatory requirement(s).
- Collect views of the study participants, if possible.
- Fill the Site Monitoring Visit Report Form AX1-V1/SOP15/V1 and write the comments.

15.4.4 After the visit

- The HEC member / Independent monitor will complete the report (use the form AX1-V1/SOP15/V1) within 14 days describing the findings of the monitoring visit and during the Full Board meeting present them. If the Independent monitor is unable to attend the HEC meeting he / she can courier the Monitoring Visit Report with comments and the HEC Secretary can present the same.
- The Secretariat will place the report in the correct files.
- Full board recommendations to change the study / premature termination / continuation of the project will go to the PI in writing within 14 days of the meeting.
Glossary

Independent Consultants

Many Ethics Committees rarely find time to perform monitoring visit themselves. They may ask outside experts or the staff of Ethics Committees to perform the tasks on their behalf and later report their findings to HEC.

Monitoring visit

An action that HEC or its representatives visit study sites to assess how well the selected investigators and the institutes are conducting researches, taking care of subjects, recording data and reporting their observations, especially SAEs found during the studies. Normally monitoring visit will be arranged in advance with the PI.

Monitoring Report

Reports should include a summary of what the monitor reviewed and the monitor's statements concerning the significant findings / facts, deviations and deficiencies, conclusions, actions taken or to be taken and / or actions recommended to secure compliance.
## Site Monitoring Visit Report

<table>
<thead>
<tr>
<th>Site Monitoring Visit Report</th>
<th>Date of the Visit:</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEC project-</td>
<td></td>
</tr>
</tbody>
</table>

### Study Title:

### Principal Investigators: [Name]

### Institute: [Institute Name]  

### Site: [Site Name]

### Sponsor: [Sponsor Name]

### Total number of subjects enrolled: [Number]

### Total subjects ongoing: [Number]

### No. of subjects completed: [Number]

### No. of drop outs: [Number]

### Are site facilities appropriate?  
- [ ] Yes  
- [ ] No  

### Are Informed Consents of recent version used?  
- [ ] Yes  
- [ ] No  

### Is it approved by the HEC?  
- [ ] Yes  
- [ ] No  

### Whether consent has been taken from all patients?  
- [ ] Yes  
- [ ] No  

### Whether appropriate vernacular consent have been taken?  
- [ ] Yes  
- [ ] No  

### Are Protocols of recent version used?  
- [ ] Yes  
- [ ] No  

### Is it approved by the HEC?  
- [ ] Yes  
- [ ] No  

### Any adverse events found?  
- [ ] Yes  
- [ ] No  

### Any SAEs found?  
- [ ] Yes  
- [ ] No
<table>
<thead>
<tr>
<th>Question</th>
<th>Options</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Were the SAEs informed to HEC within 7 working days &amp; SAE death within 24 hrs.?</td>
<td>Yes/No</td>
<td></td>
</tr>
<tr>
<td>Any protocol non-compliance / violation?</td>
<td>Yes/No</td>
<td></td>
</tr>
<tr>
<td>Are all Case Record Forms up to date?</td>
<td>Yes/No</td>
<td></td>
</tr>
<tr>
<td>Are storage of data and investigating products locked?</td>
<td>Yes/No</td>
<td></td>
</tr>
<tr>
<td>How well are participants protected?</td>
<td>Good/Fair/Not good</td>
<td></td>
</tr>
<tr>
<td>Any outstanding tasks or results of visit?</td>
<td>Yes/No</td>
<td></td>
</tr>
<tr>
<td>Duration of visit: .......hours</td>
<td>Starting from: Finish:</td>
<td></td>
</tr>
</tbody>
</table>

Name of HEC/ representatives:

Completed by: Signature: Date:

Name of study team member (PI/Co-I):
Sign & Date:
Flow Chart

1. Site Selection

2. Identification of HEC members for monitoring during meeting

3. Inform PI in writing

4. Confirmation by PI

5. HEC members prior monitoring — review the HEC protocol file and make notes

6. Collect Site Monitoring visit report

7. Review or monitoring of site

8. HEC member completes the monitoring report and presents in HEC meeting

9. HEC decision along with summary of report communicated to PI
Human Ethics Committee, Tata Memorial Centre (HEC, TMC)

Title: Dealing with participants / patients requests and complaints

SOP Code: SOP 16/V1 Date: 01/09/2009 Pages: 6
16.1 Purpose

The HEC considers protection of the rights and welfare of the human subjects participating in a clinical research approved by the HEC as its primary responsibility. Informed Consent documents reviewed by the HEC contains the statement, “Questions regarding the queries regarding rights of a participant/patient may be addressed to the HEC, Member secretary, with the HEC address and phone number.

This procedure provides guidelines for dealing with and accommodating requests by participants/patients regarding their rights as a participant or to resolve their complaints in any approved research study.

16.2 Scope

This SOP applies to all requests concerning the rights and well-being of the research participants participating in studies approved by the HEC.

16.3 Responsibility

It is the responsibility of the HEC Secretariat for providing required information to the research participants in case of queries received from research participants.

It is the responsibility of the Chairperson to initiate a process to give information to the participants or to identify and address any injustice that has occurred, if complaints are received from research participants.

16.4 Detailed instructions

- The HEC member/ administrative staff receive an inquiry or request from research participant/patient.
- The request and information is recorded in the request record form (Form AX1- V1/SOP 16/V1).
- The Secretariat will inform the Chairperson about the query/complaint received from the research participant.
- The Chairperson/ Members designated by the Chairperson will provide information required by the research participant.
- In case of complaint received from a research participant, the Chairperson initiates a process to identify and address any injustice that may have occurred.
- The Chairperson will direct the Member Secretary to consider the matter for discussion at a full board meeting or to call an emergency meeting of 2 or more HEC members for discussion or to appoint a subcommittee of 2 or more HEC members for enquiry in order to resolve the matter.
- The Chairperson / Member Secretary / designated HEC members will assess the situation and mediate a dialogue between the research participant and the investigator in an attempt to resolve the matter.
The HEC will insist on factual details to determine reality between truth and individual perception.

The final decision will be informed to the research participant by the Secretariat.

The information including any action taken or follow-up will be recorded in the form AX1-V1/SOP 16/V1 and the form is signed and dated.

The HEC members are informed about the action taken and the outcomes in the forthcoming HEC meeting.

16.5 Filing the request document

- The record form is filed in the “response” file by the Member Secretary / administrative staff.
- A copy of the same is kept in the study file.
- The file is stored in a secured place.

Reference

## Request Record Form

<table>
<thead>
<tr>
<th>Date Received:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Received by:</td>
</tr>
<tr>
<td>Request from:</td>
</tr>
<tr>
<td>- Telephone call No</td>
</tr>
<tr>
<td>- Fax No</td>
</tr>
<tr>
<td>- letter / Date</td>
</tr>
<tr>
<td>- E-mail / Date</td>
</tr>
<tr>
<td>- Walk-in: Date / Time</td>
</tr>
<tr>
<td>- Other, specify</td>
</tr>
<tr>
<td>Participant’s Name:</td>
</tr>
<tr>
<td>Contact Address:</td>
</tr>
<tr>
<td>Phone:</td>
</tr>
<tr>
<td>Title of the Participating Study</td>
</tr>
<tr>
<td>Starting date of participation:</td>
</tr>
<tr>
<td>What is requested?</td>
</tr>
<tr>
<td>Action taken:</td>
</tr>
<tr>
<td>Outcome:</td>
</tr>
</tbody>
</table>

Name of the Chairperson / Member Secretary ________________________________

Signature of the Chairperson / Member Secretary __________ Date- __________
Flow Chart

1. Receiving the query / complaint / request from research participant

2. Providing information to research participant by HEC member/Secretariat

3. Initiating process to identify the problem

4. Deliberations to arrive at a solution

5. Communication with the research participant

6. File the request document
APPENDICES

APP1/V1    Policy on Recruitment of TMC Students and Staff
APP2/V1    Policy on the Recruitment of Research Subjects
APP3/V1    Policy on Research Costs to Subjects
APP4/V1    Guidelines on Compensation for Research Subjects
APP5/V1    Policy on the Use of Third Party/Surrogate Consent in Research at TMC
APP6/V1    Policy on Blood Withdrawal for Research Purposes
APP7/V1    Guidelines and Policy on Informed Consent
APP8/V1    Policy for Documentation of Informed Consent
APP9/V1    Health Record Research
APP10/V1   Guidelines for Research Protocols That Require Collection and/or Storage of Genetic Materials
APP12/V1   Recommended Terms for Use in Consent Forms
Policy on Recruitment of TMC Students and Staff for Research

DEFINITIONS

“Student” means any individual who is enrolled at TMC and those individuals who are in training as, Residents, Fellows, or Postdoctoral trainees, including individuals enrolled at a training facility other than TMC training or work program.

“Staff” mean all other TMC employees, including faculty.

POLICY GUIDELINES

TMC students and staff have the same rights as any other potential subject to participate in research project, irrespective of the degree of risk, provided all of the following conditions exist:

- The research must not bestow upon participating TMC subjects any competitive academic or occupational advantage over other TMC students or staff who do not volunteer, and the researchers must not impose any academic or occupational penalty on those TMC students or staff who do not volunteer.
- TMC students and staff must not be systematically treated differently from non-TMC subjects as part of the project.
- Due to the potential for perceived or real coercion to participate, TMC students and staff who desire to participate in the research (especially those under the direct supervision of the PI or listed research collaborators) must be reviewed by Director TMC.
SPECIFIC RECRUITMENT GUIDELINES

(1) In addition to its review for scientific merit and protection of subjects from unnecessary research risks, the HEC will evaluate all protocols for subject recruitment especially with respect to women with childbearing potential, minority groups and children. Exclusion of minorities, women or children will be recommended or approved when inclusion is inappropriate with respect to the health of the subjects or the purpose of the research.

(2) TMC PATIENTS - Patients may be identified as potential research subjects through direct contact of the PI with his or her patients, collaboration with physicians of other medical specialties, contact with individual attending physicians, posted written notices, radio announcements, or other HEC approved methods.

a. Inpatients - May be recruited by the investigator or other member of the research team only after consultation with the patient’s attending physician.

b. Outpatients -

(i) For minimal risk research which does not bear directly upon a specific continuing therapeutic relationship between the individual and a TMC physician, outpatients may be recruited* without prior notification of their personal physicians. However, when possible, each subject’s personal physician should be notified of the study and informed that the patient has been entered into a minimal risk study.

(ii) For more than minimal risk research or any research bearing directly upon a specific diagnosis or treatment, the subject’s personal physician should be notified before enrolling* the subject.

* If the potential research subject is a minor, then contact must be via a parent or legal guardian.
If a research participant may have to bear any costs, which would be unnecessary if the subject had declined to participate in the research, all potential subjects must be fully informed of the nature and estimated extent of these costs when obtaining consent. Examples of additional research costs include:

1) Prolongation of treatment or hospitalization.
2) Extra diagnostic tests necessary for the research.
3) Extra clinical or laboratory assessments to evaluate research treatment outcome.
4) A research treatment (whether randomly assigned or not) which may be more costly than a standard treatment.
5) Other substantial costs associated with extra visits to TMC.
Guidelines on Compensation for Research Subjects

COMPENSATION FOR PARTICIPATION (ICMR Code 2000)

Subjects may be paid for the inconvenience and time spent, and should be reimbursed for expenses incurred, in connection with their participation in research. They may also receive free medical services. However, payments should not be so large or the medical services so extensive as to induce prospective subjects to consent to participate in research against their better judgement (inducement). All payments, reimbursement and medical services to be provided to research subjects should be approved by the HEC.

Care should be taken:

1) when a guardian is asked to give consent on behalf of an incompetent person, no remuneration should be offered except a refund of out of pocket expenses;

2) when a subject is withdrawn from research for medical reasons related to the study the subject should get the benefit for full participation;

3) when a subject withdraws for any other reasons he/she should be compensated in proportion to the amount of participation.

Prospective participants in research should also be informed of the sponsorship of research, so that they can be aware of the potential for conflicts of interest and commercial aspects of the research.

During the initial review of a research protocol, the HEC is required to review both the amount of compensation proposed and the method and timing of disbursement to assure that neither are coercive or present undue influence. The following are some additional guidelines:

1) Any compensation should not be contingent upon the subject completing the study, but should accrue as the study progresses.

2) Unless it creates undue inconvenience or a coercive practice, compensation to subjects who withdraw from the study should be made at the time they would have completed the study, had they not withdrawn.

3) Compensation given as a “bonus” or incentive for completing the study is acceptable, providing that the amount is not coercive. The HEC is responsible for determining if the incentive amount is not so large as to be coercive or represent undue influence.

4) The amount of compensation should be clearly set forth in the informed consent document.
**APP5/V1**

**Policy on the Use of Third Party / Surrogate Consent in Research at TMC**

**APPLICABILITY**

When a TMC investigator proposes to conduct a research project utilizing adult subjects who by virtue of age, physical impairment, mental impairment, language barrier or any other reason may not be able to personally execute legally effective informed consent, the HEC shall review the project on the basis of “risk” and “benefit” and shall determine that each project be assigned to one of the categories below. **This policy does not mean to imply that the requirement for written documentation of consent is waived. Rather, it applies to those studies in which third party/surrogate consent is obtained from a legally authorized representative.** Investigators must complete and submit an HEC Form for review and approval of inclusion of subjects who are decisionally impaired.

Category I - Risks to subjects are minimal, direct benefits may or will accrue to subjects.

Category II - Risks to subjects are minimal, direct benefits will not, or are unlikely, to accrue to subjects but potential societal benefits are inherent in research.

Category III - Risks to subject are greater than minimal, direct benefits may or will accrue to subjects.

Category IV - Risks to subjects are greater than minimal, direct benefits will not, or are unlikely, to accrue to subjects but potential societal benefits are inherent in the research.

**HEC RECOMMENDATIONS TO THE ADMINISTRATION**

When categorization has been accomplished, the HEC will recommend to the TMC Administration to consider implementation or non-implementation of the project based upon the level of benefit to be gained by the individual or society from this project as compared to the level of risk involved.

It is the intent of the HEC to cause to recommend Category I projects to be initiated.

It is the intent of the HEC **not** to recommend initiation of any Category IV projects.
APP6/V1

Policy on Blood Withdrawal for Research Purposes

APPLICABILITY
For many studies where the only research intervention is the collection of blood for analysis, the HEC categorizes the following procedures for obtaining blood from children and adults as minimal risk:

A. General Requirements
1. There are no special health reasons (e.g., anemia) to contraindicate blood withdrawal.
2. In patients from whom blood is already being drawn for clinical purposes, there are no other health reasons to preclude additional blood collection.
3. In subjects from whom blood is not already being drawn for clinical purposes, the withdrawal method is by cutaneous sticks (e.g., heel or finger) or by standard venipuncture in a reasonably accessible peripheral vein, and the frequency of punctures does not exceed two per week.
4. The volume of blood drawn from lactating or known pregnant subjects does not exceed 20 ml per week.
5. All blood withdrawals and collections are carried out by experienced professional or technical personnel.

B. Additional Requirements for Adults (Subjects over 18 years of age)
1. If less than 50 ml is being collected, there are no additional restrictions with regard to hemoglobin or hematocrit.
2. If a volume greater than 50 but less than 200 ml is being collected for “no-benefit” studies, hemoglobin levels should be >11.0 g/dl for males and >9.5 g/dl for females with MCVs >85 fl (These restrictions would not apply if iron deficiency anemia or other forms of anemia were critical for inclusion in the study.).
3. The cumulative volume withdrawn or collected may not exceed 450 ml per twelve-week period (this maximum includes blood being drawn for clinical purposes) from patients 18 years of age or older in good health and not pregnant.

C. Additional Requirements for Children (Subjects under 18 years of age)
1. No more than three (3) skin punctures are to be made in any single attempt to draw blood, and the frequency of punctures does not exceed twice per week.
2. The volume of blood withdrawn, including blood for clinical purposes, does not exceed the lesser of 50 ml or 3 ml/kg in an eight week period and collection may not occur more frequently than 2 times per week.
3. The cumulative volume of clinical and research blood withdrawn per eight-week period does not exceed six per cent (6.0%) of the child’s total blood volume.
4. In patients from whom blood is already being drawn for clinical purposes and when the research is directly related to the child's condition, there is no maximum number of extra volume specimens which can be collected as long as the preceding requirements are met.

5. In subjects from whom blood is not already being drawn for clinical purposes, the maximum number of allowable separate specimens (again, within the limits of the preceding restrictions) depends upon the child's age and whether the research is directly related to the child's condition.

D. Cord Blood

Cord blood from newborns can be used without restrictions when blood is extracted from the placental side of the cord, after it has been clamped and severed.

E. Consent

Oral consent is generally sufficient to collect additional volume (within the limits specified above for minimal risk) from patients in whom blood is being drawn for clinical purposes.
Guidelines and Policy on Informed Consent

A  General Requirements

Except as described below, investigators may not enroll human subjects in research unless they have obtained the legally effective, written, informed consent of the subject or the subject’s legally authorized representative, prior to enrollment of the subject in the research. Investigators are responsible for ensuring that subjects, or their representatives, are given sufficient opportunity to consider whether or not to participate and must seek to avoid coercion or undue influence. Information given to potential subjects or their representatives must be in language that is understandable to the subject or representative. No process of obtaining consent may include language through which the subject waives any of their legal rights or releases or appears to release the investigator, sponsor, or institution or its agents from liability for negligence.

B  Elements of Informed Consent

A current sample informed consent document with required phraseology may be found in Appendix B-2. The sample consent form contains all the required elements of consent. The HEC requires that all consent forms be written in the first person, e.g., “I understand that…”. The following are the basic required elements:

1. A statement that the study involves research, an explanation of the purpose of the proposed research, the duration of the subject’s participation, a description of the procedures, and which procedures are experimental;

2. The number of subjects that will be involved with the study, totally and at TMC;

3. A description of reasonably foreseeable risks or discomforts that the subjects may encounter, and, if appropriate, a statement that some risks are currently unforeseeable;

4. A description of possible benefits, if any, to the subject and others which may be reasonably expected. It should be stated that since it is an experimental treatment or procedure, no benefits can be guaranteed;

5. A discussion of possible alternative procedures or treatments, if any, which are available to the subject. One alternative might be to choose not to participate in the research and this will not affect the usual standard of care;

6. A discussion of how confidentiality of records associated with the subject will be maintained;

7. A description of any compensation or reimbursement for time, inconvenience, travel, parking, and other similar costs to the subject;

8. A description of any provisions for treatment of or compensation for research related injury;

9. A statement of whom to contact for answers about the research and in the event there is a research related injury. (This is generally the PI or another staff member closely...
associated with the study.) A separate contact must be named for questions concerning the subject’s rights;

10. A statement that the subjects’ participation is voluntary, that refusal to participate will not involve penalty or loss of benefits to which the subject is entitled, and that the subject may discontinue participation at any time without penalty or loss of benefits;

11. If appropriate, any circumstances under which the subjects participation may be terminated, with or without the subjects consent; and

12. A description of additional costs for which the subject will be responsible, that are likely to result from participation in the research study.

C WAIVER OF INFORMED CONSENT

The HEC may waive the requirements for obtaining informed consent or approve a consent procedure which does not include, or which alters, some or all of the elements of informed consent listed above, provided that:

1. The research involves no more than minimal risk to the subjects
2. The waiver or alteration will not adversely effect the rights and welfare of the subjects
3. The research could not practicably be carried out without the waiver or alteration; and
4. Whenever appropriate, the subjects will be provided with additional pertinent information after participation.

D DOCUMENTATION OF INFORMED CONSENT

Informed consent must be documented by the use of a written consent form reviewed and approved by the HEC and signed by the subject or subject’s legally authorized representative. A copy must be given to the subject or person signing the form. For TMC patients, a copy of the signed consent form should also be placed in the subject’s medical record. It is assumed that the consent form is only part of the total consent process in which the investigator, perhaps using the written consent form as an outline, describes all facets of the study and answers the subject’s questions. The investigator is responsible for ensuring that research subjects understand the research procedures and risks. Failure of the subjects to ask questions should not be construed as understanding on the part of the subject.

E RECORD RETENTION REQUIREMENTS FOR SUBJECT CONSENT FORMS

1. The PI or project director shall maintain, in a designated location, all executed subject consents. These consent forms are to be available for inspection by authorized officials of the HEC, DSMSC, regulatory agencies and sponsors. For DCGI/RA regulated test article studies, all signed subject consent forms shall be retained by the principal investigator for the appropriate period(s) specified below.

- Drugs: Two (2) years following the date a marketing application is approved or the study is discontinued.

- Devices: Two (2) years after a study is terminated or completed and the records are needed to support DCGI/RA approval.
I. INFORMED CONSENT PROCESS

1. Informed Consent of Subject: For all biomedical research involving human subjects, the investigator must obtain the informed consent of the prospective subject or in the case of an individual who is not capable of giving informed consent, the consent of a legal guardian. Informed consent is based on the principle that competent individuals are entitled to choose freely whether to participate in research or not. Informed consent protects the individual’s freedom of choice and respect for individual’s autonomy.

When research design involves not more than minimal risk (for example, where the research involves only collecting data from subject’s records) the HEC may waive off some of the elements of informed consent.

Waiver of informed consent could also be considered during conditions of emergency. However, this would be permissible only if HEC has already approved the study or use of drug. However, the patient or the legal guardian should be informed after she/he regains consciousness or is able to understand the study.

2. Obligations of investigators regarding informed consent: The investigator has the duty to –

   i. Communicate to prospective subjects all the information necessary for informed consent. There should not be any restriction on subject’s right to ask any questions related to the study as any restriction on this undermines the validity of informed consent.

   ii. Exclude the possibility of unjustified deception, undue influence and intimidation. Deception of the subject is not permissible. However, sometimes information can be withheld till the completion of study, if such information would jeopardize the validity of research.

   iii. Seek consent only after the prospective subject is adequately informed. Investigator should not give any unjustifiable assurances to prospective subject, which may influence the subject’s decision to participate in the study.

   iv. As a general rule obtain from each prospective subject a signed form as an evidence of informed consent (written informed consent) preferably witnessed by a person not related to the trial, and in case of incompetence to do so, a legal guardian or other duly authorised representative.

   v. Renew the informed consent of each subject, if there are material changes in the conditions or procedures of the research or new information becomes available during the ongoing trial.
vi. Not use intimidation in any form which invalidates informed consent. The investigator must assure prospective subjects that their decision to participate or not will not affect the patient - clinician relationship or any other benefits to which they are entitled.

3. **Essential information for prospective research subjects:** Before requesting an individual’s consent to participate in research, the investigator must provide the individual with the following information in the language he or she is able to understand which should not only be scientifically accurate but should also be sensitive to their social and cultural context:

   i. the aims and methods of the research;
   
   ii. the expected duration of the subject participation;
   
   iii. the benefits that might reasonably be expected as an outcome of research to the subject or to others;
   
   iv. any alternative procedures or courses of treatment that might be as advantageous to the subject as the procedure or treatment to which she / he is being subjected;
   
   v. any foreseeable risk or discomfort to the subject resulting from participation in the study;
   
   vi. right to prevent use of his / her biological sample (DNA, cell-line, etc.) at any time during the conduct of the research;
   
   vii. the extent to which confidentiality of records could be maintained ie., the limits to which the investigator would be able to safeguard confidentiality and the anticipated consequences of breach of confidentiality;
   
   viii. responsibility of investigators;
   
   ix. free treatment for research related injury by the investigator / institution;
   
   x. compensation of subjects for disability or death resulting from such injury;
   
   xi. freedom of individual / family to participate and to withdraw from research anytime without penalty or loss of benefits which the subject would otherwise be entitled to;
   
   xii. the identity of the research teams and contact persons with address and phone numbers;
   
   xiii. foreseeable extent of information on possible current and future uses of the biological material and of the data to be generated from the research and if the material is likely to be used for secondary purposes or would be shared with others, clear mention of the same;
   
   xiv. risk of discovery of biologically sensitive information;
   
   xv. publication, if any, including photographs and pedigree charts.

The quality of the consent of certain social groups requires careful consideration as their agreement to volunteer may be unduly influenced by the Investigator.

This is accomplished as part of the total consent process by using a consent form that has been reviewed and approved by the HEC. Confusion sometimes arises as to who can obtain consent and who can be designated to sign the consent form. The following are the acceptable methods for documentation of informed consent of human research subjects at TMC:
1. The HEC must be made aware of the person(s) who will be conducting the consent interviews. These faculty/staff members should be the only personnel allowed to obtain consent unless indicated otherwise. The HEC requires that the person obtaining consent is medically trained.

2. Each subject (or their legally authorized representative) must be provided adequate time to read and review the consent form, in addition to being advised of the procedures, risks, potential benefit, alternatives to participation, etc. This is frequently accomplished using the consent form as an outline for the interview process.

3. After completing the consent interview and assuring that the subject (or their representative) has no further questions and agrees to participate in the research activity, the interviewer should instruct the subject to sign and date the consent form in the appropriate spaces.

4. A witness must sign and date in the appropriate spaces. The witness cannot be the person conducting the consent interview, but is not further restricted.

5. The person conducting the consent interview must then sign and date the consent form in the appropriate spaces (PI or designee). It is assumed that in most cases, all persons signing the consent form will do so at the conclusion of the consent interview.

6. Each subject (or their representative) must be given a copy of the signed consent form. The original consent form should be filed in such a manner as to insure immediate retrieval when required by auditing entities, HEC, or sponsor monitors.

7. The regulations are clear that written documentation informed consent is required. Therefore, obtaining consent from an authorized third party via the telephone is not acceptable.

8. The regulations also include provisions for approval of a waiver or alteration of part or all of the consent process. The HEC will consider written requests for waiver or alteration of the process when accompanied by sufficient justification.

9. Obtaining informed consent from subjects must be accomplished prior to performing the research activity and using only an HEC approved consent form. Written requests for amendments to an existing consent form must be approved by the HEC prior to implementation.

10. Upon receipt of an HEC approved consent form, all old versions should be discarded to prevent inadvertent use of an outdated consent form. Copies of the most recently approved consent form may be made and should be used until superceded by an amended consent form. The consent form must be reviewed at least annually as part of the continuing review process.
Health Record Research

The following is the HEC policy concerning research involving the study of medical records or other forms of health information.

Research projects may involve the study of Patient case files with the stipulations described below. Such studies raise issues of confidentiality that must be carefully addressed by the investigator and the official custodian of the records. If it is anticipated that an individual’s records or specimens will likely be used for research purposes, the potential subject should be informed of the potential use of such materials upon entry into the institution or program in which the materials will be developed or collected and be given an opportunity to either provide or refuse consent to such research. Patient case files may always be used or disclosed for research purposes if it has been de-identified and linkage back to a specific patient would not be possible.

To use or disclose identifiable Patient case files without authorization of the research participant, the investigator must accomplish one of the following:

1) complete and submit an HEC Form to request waiver of the requirements for obtaining informed consent;
2) provide written documentation that the use of disclosure of patient case files is solely used to design a research protocol or to assess feasibility of conducting a study, or;
3) Document that the use or disclosure is solely for research on the patient case files of decedents.

Investigators must maintain in their files a letter from the HEC identifying the date on which the waiver or alteration of the requirements to obtain informed consent was approved by the HEC, and a statement that the HEC has determined that the waiver or alteration satisfies the following criteria:

1) The use or disclosure of patient case files involves no more than minimal risk to the research participants;
2) The alteration or waiver will not adversely affect the privacy rights and welfare of the subjects;
3) The research cannot practically be conducted without the alteration or waiver;
4) The research could not practically be conducted without access to or the use of the patient case files;
5) The privacy risks to individuals whose Patient case files is to be used or disclosed are reasonable in relation to the anticipated benefits, if any, to the individuals, and the importance of the knowledge that may reasonable be expected to result from the research;
6) There is an adequate plan to protect the identifiers from improper use and disclosure;
7) There is an adequate plan to destroy the identifiers at the earliest possible opportunity consistent with the conduct of the research, unless there is a health or research justification for retaining the identifiers, and;

8) There are adequate written assurances that the Patient case files will not be reused or disclosed to any other person or entity, except as required by law, for authorized oversight of the research project, or for other research for which the use or disclosure of Patient case files would be permitted by this policy.

The HEC letter should also contain a brief description of the Patient case files for which use or access has been determined by the HEC to be necessary, a statement that the waiver or alteration was approved by Expedited Review or at a convened meeting, and the letter should be signed by the HEC Chair or the Chair's designee.

Research use or disclosure of identifiable Patient case files with authorization of the research participant is permitted providing that use or disclosure is for only the Patient case files that was originally authorized. In order to use or disclose additional information, the investigator would either have to obtain consent or request a waiver of the requirements to obtain consent.
Guidelines for Research Protocols which require Collection and Storage of Genetics Materials

For the purpose of these guidelines, “Genetic Materials” are defined as human tissue samples (blood, serum, tumor, etc.) on which genetic related research, such as biochemical studies of inherited human traits or identification of DNA mutations, may be performed.

A. Previously acquired samples
   i. Previously acquired genetic material may be used if identifiers are stripped irrevocably from samples.
   ii. If identifiers are present, experiments not described in present protocols must be submitted for HEC review.

B. Prospectively acquired samples
   1. Anonymous samples (further identification made impossible)
      i. Ownership of genetic material will generally remain with the institution. This must be stated in the consent form.
      ii. The general scope of the investigations must be explained in the consent form, but new avenues of investigation in the future are permissible if this possibility is explained in the consent form.
      iii. Whether the genetic material will be shared by other investigators should be explicit in the consent form.
      iv. The consent form should make clear that no specific information relative to the individual donor will be forthcoming; however, information that accrues from the study that is valuable to society may be shared with the individual.
   2. Identified samples
      i. If genetic material is linked to the donor by specific identifiers, ownership of the material will generally remain with the institution. If a commercial use is anticipated for the genetic material, the individual must be notified. The general policy of ownership should be stated in the consent form using the following wording:
         “I understand that additional or “leftover” (blood, serum, tumor, etc.) tissue may be used for future research which may result in financial gain for TMC and the researchers. I also understand that my donated tissue will be one of many that are used in the research and it will be virtually impossible to attribute findings to any one sample. I understand, however, that I am not otherwise waiving any of my legal rights by participating in this study.”
ii. If identifiers are present, new experiments must be reviewed by the EC and new consent obtained from the research participant regardless of the details of ownership.

iii. The investigator may include a provision in the consent form for new experiments not requiring new consent if identifiers are irrevocably removed from the samples. If the investigator anticipates future experiments without identifiers, this possibility should be present in the original consent form. The methods for removal of identifiers must be approved by the EC. Removal of identifiers must not be employed as a method of avoiding ownership issues.

iv. A satisfactory method for sharing or withholding information gained by the research must be in the research protocol and clearly indicated in the consent form.

v. Details for sharing or not sharing the genetic material with other investigators must be present in the protocol and clearly indicated in the consent form.

vi. The length of time the genetic material will be maintained must be indicated in the consent form.

C. Donation of genetic material as a requirement for participation in a research protocol.

i. Donation of genetic material may be required for participation in a protocol only if the presence of the genetic material is necessary to satisfy the central question of the research.

ii. The investigator will be required to make a clear case in the research protocol for the necessity of the genetic material, if donation of genetic material is mandatory.

iii. This policy applies to genetic material with or without identifiers.

As of October 10, 2000 the ICMR formulated Ethical Guidelines for Biomedical Research on Human Subjects. ICMRs goal is to insure that no research participant is enrolled in a human gene therapy/gene transfer research protocol before the local HEC have the benefit of the broad perspective and experience in protocol review and risk assessment.

In November 2001, the Department of Biotechnology also finalised the Ethical Policies on the Human Genome, Genetic Research and Services.

Guidelines are available at the Office of Biotechnology Activities Internet site http://dbtindia.nic.in/ethical.html

The following items are required to be addressed in the protocol to provide the necessary information for HEC review:

A. Background and justification
   i Why is this disease a good candidate for gene transfer or gene therapy?
   ii What previous work has been done, including studies of animals and cultured cell models? Does the work demonstrate effective gene delivery? How does the proposed study relate to previous work?
   iii Is the disease course sufficiently predictable to allow for meaningful assessment of the results of the treatment proposed?
   iv What level of gene expression is presumed to be required to achieve the desired effect?
   v Given responses to the above questions, is there a sufficient justification for the investigator to proceed at this point to a clinical trial?

B. Research design
   i What are the objectives of the proposed study (e.g., establishing feasibility or relative safety of the gene transfer, determining therapeutic effectiveness, establishing a safe dose range, demonstrating proof of principle, etc.)?
   ii Is the goal of the study to ameliorate or cure disease or to enhance healthy individuals?
   iii What is the target tissue for gene transfer (e.g., bone marrow cells, skeletal muscle cells, respiratory epithelial cells, central nervous system tissue, etc.)?
   iv What method(s) (e.g., direct injection, inhalation, ex vivo genetic modification with injection of modified cells) and reagent(s) (e.g., vectors based on retroviruses, adenoviruses, adeno-associated viruses, herpes viruses) will be employed for gene delivery? What is the rationale
for their use? Are other methods or reagents known that are more appropriate with regard to efficacy, safety, and stability?

vi How will the investigator determine the proportion of cells that acquires and expresses the added DNA?

vii How will the investigator determine if the product is biologically active?

viii Is the planned statistical treatment appropriate: i.e., is it likely to provide valid answers to the study question?

C. Procedures

i What research-specific procedures and research-specific investigations are required by the study over and above those that would be required for patients receiving standard clinical care (e.g., physical examinations, venous or arterial blood tests, collection of target cells, imaging procedures, irradiation, chemotherapy, direct injection of vector, re-injection of genetically modified cells, organ or tissue transplantation, surgery, tissue/tumor donation, questionnaires, interviews)?

ii Is long term follow-up appropriate or essential for this protocol? If long term follow-up is proposed, is there justification for the number of visits and the length of time required? Is such follow-up feasible in the case of this protocol (e.g., have provisions been made for subjects who move? Is adequate funding available for such follow-up)?

iii What are the procedures for obtaining or maintaining information in a data/DNA bank (e.g., use of identifiers, limitation on access, need for consent, sharing with other investigators, duration of storage, future subject contact)?

iv Are all of the research-specific procedures necessary? In combination with data collected in the course of clinical care, is it reasonable to expect that the information produced by this study will be sufficient to answer the research question?

D. Confidentiality

i Are the practical steps for maintaining confidentiality of data/records/database information clearly specified and adequate (e.g., encryption, use of unique identifiers, sequestering of records, security measures)?

E. Subject selection

i How has the study population been defined?

ii Has an adequate rationale been provided for each eligibility criterion (e.g., safety considerations, definition of disease, avoidance of additional concurrent therapies, administrative considerations)? Do they strike a defensible balance between scientific validity and generalizability (i.e., is the study population sufficiently, but not unduly, restricted so as to yield interpretable results)?

iii How will subjects be recruited? If a cohort of eligible patients exists, how will selection be made amongst them? If several trials exist for which the same patients are eligible, how will this be presented to prospective subjects?
iv Does the definition of the research population reflect appropriate scientific, clinical, and ethical norms? In recruiting and negotiating with potential subjects, have the norms of nondiscrimination been respected?

F. Risks, discomforts, and benefits

i What risks and discomforts are associated with the research-specific procedures and investigations (e.g., surgery, chemotherapy, radiation, bone marrow transplantation)? Have they been minimized?

ii If a virus-mediated gene transfer is proposed, what is the potential for the presence of a replication-competent or pathological virus or other form of contaminants? How sensitive are the tests to detect such viruses or contaminants? What level of viral presence or other form of contamination would be tolerable in this protocol?

iii Has the possibility of vertical transmission (i.e., gene insertion into germ cells or a fetus) or horizontal transmission (e.g., to family members or health care staff) been considered? What measures have been taken to minimize the risks of transmission? Are other measures possible? If transmission were to occur, what would be the consequences?

iv What are the risks for the vector to activate an oncogene or inactivate a tumor suppressor gene leading to vector-related malignancy?

v Are the risks and discomforts of the study justified given the potential benefit to subjects and the scientific importance of the research?

G. Information to subjects

- Have prospective participants been adequately informed of the following:
  1. What is being studied and why, giving details about study procedures, known or potential risks, discomforts and benefits, and alternatives to participation;
  2. Their rights: (a) to information on an ongoing basis, confidentiality with regard to their participation and handling of their data, and the right to consult with others before making a decision whether to participate; and (b) to withdraw from the study without penalty or loss of benefits, as well as of any health consequences of withdrawal for themselves or their immediate contacts, or limitations on withdrawal, if any;
  3. Any special issues related to this gene therapy trial, such as uncertainty associated with short and long term risks and benefits or the possibility of media attention; and
  4. Any commercial or financial interests in the research.

- Have prospective participants been provided this information in simple language, using translation where necessary, with answers to their questions, referral to other sources of information, and adequate time to make up their minds whether to participate?

- If there is no individual benefit from participation in the research, has this been appropriately disclosed?

- Will the general study results be made available to subjects?

- Do all of the elements of the consent process combine to allow subjects a full opportunity to make an informed choice?

Reference: Ethical Guidelines for Biomedical Research on Human Subjects ICMR 2000
Recommended Terms for use in Consent Forms

To facilitate understanding of consent forms by the subject, it is recommended that the language used is at a reading level of an 12 year old. The following lay terms, definitions and suggestions are recommended to help investigators in this process.

- **abdominal**: the body cavity containing the stomach, intestines, liver, and other organs
- **acute**: new; recent; sudden
- **adjuvant**: helpful; assisting; aiding
- **adverse effect**: bad side effect
- **agitation**: Upset
- **allergic reaction**: itching and swelling; rash; trouble breathing
- **ambulate (-ation –ory)**: walk; able to walk; ability to walk
- **Ameliorate**: make smaller or less, reduce
- **analgesia**: pain relief
- **anaphylactic reaction**: a severe and sometimes dangerous reaction which may cause problems breathing, fainting, itching and skin rash
- **anemia**: low red blood cell count
- **anesthetic (local)**: a drug used to decrease the feeling of pain by numbing an area of the body, without putting you to sleep
- **anesthetic (general)**: a drug used to decrease the feeling of pain or eliminate the feeling of pain by putting you to sleep.
- **anorexia**: lack of appetite
- **arrhythmia**: abnormal heartbeat
- **aspiration**: removal by using a sucking machine; fluid entering the lungs
- **asymptomatic**: without symptoms; having no symptoms
- **barrier method**: diaphragm and condom (with spermicide), cervical cap, or sponge
- **benign**: not malignant; usually without serious consequences
- **bolus**: an amount given all at once
- **bradycardia**: slow heartbeat
- **carcinogenic**: capable of causing cancer
- **carcinoma**: a type of cancer
- **cardiac**: heart
- **catheter**: a tube in a vein for withdrawing or putting fluids into my blood
- **central nervous system**: the brain and spinal cord
- **cerebral**: the brain; of the brain
- **cessation**: stopping
<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHD</td>
<td>coronary heart disease; heart disease</td>
</tr>
<tr>
<td>chemotherapy</td>
<td>treatment of a disease, usually cancer, with chemical agents</td>
</tr>
<tr>
<td>chronic</td>
<td>continuing for a long time</td>
</tr>
<tr>
<td>clinical status</td>
<td>state of health, how you are doing and feeling</td>
</tr>
<tr>
<td>Clinical trial</td>
<td>an experiment in patients</td>
</tr>
<tr>
<td>completed</td>
<td>Done</td>
</tr>
<tr>
<td>congenital</td>
<td>Occurring prior to birth, due to parent’s genetic input</td>
</tr>
<tr>
<td>conjunctivitis</td>
<td>irritation and redness of the thin covering of the eye</td>
</tr>
<tr>
<td>Consequences</td>
<td>result or effects</td>
</tr>
<tr>
<td>controlled trial</td>
<td>study in which the experimental treatment is compared to a standard treatment</td>
</tr>
<tr>
<td>conventional therapy</td>
<td>standard treatment</td>
</tr>
<tr>
<td>coronary</td>
<td>pertaining to the blood vessels that supply the heart</td>
</tr>
<tr>
<td>CT (CAT) scan</td>
<td>computerized series of x-rays</td>
</tr>
<tr>
<td>cutaneous</td>
<td>relating to the skin</td>
</tr>
<tr>
<td>Culture</td>
<td>take a sample of blood, fluid, or tissue to see if bacteria or viruses can be found in it</td>
</tr>
<tr>
<td>dehydration</td>
<td>loss of fluids</td>
</tr>
<tr>
<td>dermatologic</td>
<td>pertaining to the skin</td>
</tr>
<tr>
<td>diastolic</td>
<td>the lower number in a blood pressure reading</td>
</tr>
<tr>
<td>dilation</td>
<td>expansion or stretching</td>
</tr>
<tr>
<td>discomfort</td>
<td>pain; uncomfortable feeling</td>
</tr>
<tr>
<td>disseminated</td>
<td>widely-spread, all through the body</td>
</tr>
<tr>
<td>distal</td>
<td>toward the end; away from the center of the body</td>
</tr>
<tr>
<td>diuretic</td>
<td>water pill; drug that causes an increase in urination</td>
</tr>
<tr>
<td>double-blind</td>
<td>neither the subject nor physician can know what is being given</td>
</tr>
<tr>
<td>dysfunction</td>
<td>improper function</td>
</tr>
<tr>
<td>dysplasia</td>
<td>abnormal cells</td>
</tr>
<tr>
<td>echocardiogram</td>
<td>sound wave test of the heart</td>
</tr>
<tr>
<td>edema</td>
<td>fluid in the tissues; puffiness; swelling</td>
</tr>
<tr>
<td>efficacy</td>
<td>producing a positive result</td>
</tr>
<tr>
<td>electrocardiogram</td>
<td>heart test; tracing of heartbeat or heart rhythm</td>
</tr>
<tr>
<td>emesis</td>
<td>vomiting</td>
</tr>
<tr>
<td>endoscopic</td>
<td>examination of the inside of the body with a lighted tube</td>
</tr>
<tr>
<td>epidural</td>
<td>outside the spinal cord</td>
</tr>
<tr>
<td>eradicate</td>
<td>get rid of</td>
</tr>
<tr>
<td>Erythrocyte</td>
<td>red blood cell</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration; the branch of the government that approves new drugs</td>
</tr>
<tr>
<td>fibrillation</td>
<td>irregular heartbeat</td>
</tr>
<tr>
<td>fibrous</td>
<td>like scar tissue</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>gastrointestinal</td>
<td>stomach and intestines</td>
</tr>
<tr>
<td>granulocyte</td>
<td>white blood cell</td>
</tr>
<tr>
<td>hematocrit</td>
<td>number of red blood cells</td>
</tr>
<tr>
<td>hematoma</td>
<td>bruise; black and blue mark</td>
</tr>
<tr>
<td>holter monitor</td>
<td>portable machine for recording heartbeats</td>
</tr>
<tr>
<td>hormonal therapy</td>
<td>treatment with hormones</td>
</tr>
<tr>
<td>hypertension</td>
<td>high blood pressure</td>
</tr>
<tr>
<td>hypotension</td>
<td>low blood pressure</td>
</tr>
<tr>
<td>hypoxia</td>
<td>low oxygen level in the blood</td>
</tr>
<tr>
<td>immunosuppressive</td>
<td>a drug or therapy that reduces the body's ability to fight infection; helps prevent rejection of a transplanted organ</td>
</tr>
<tr>
<td>incidence</td>
<td>number of times it happens</td>
</tr>
<tr>
<td>infarct</td>
<td>death of tissue due to loss of blood flow</td>
</tr>
<tr>
<td>infectious occurrences</td>
<td>infections</td>
</tr>
<tr>
<td>inflammation</td>
<td>swelling which is usually painful, red and warm</td>
</tr>
<tr>
<td>infusion</td>
<td>putting a substance into the body, usually into the blood</td>
</tr>
<tr>
<td>intravenous</td>
<td>putting it into the vein</td>
</tr>
<tr>
<td>intubate</td>
<td>the placement of a tube into the airway</td>
</tr>
<tr>
<td>ischemia</td>
<td>decrease in oxygen in a tissue, usually because of decreased blood flow</td>
</tr>
<tr>
<td>lactating</td>
<td>producing milk</td>
</tr>
<tr>
<td>laparotomy</td>
<td>a procedure where an incision is made in the abdominal wall to enable a physician to look at the organs</td>
</tr>
<tr>
<td>lethargy</td>
<td>sleepiness; lack of energy</td>
</tr>
<tr>
<td>lumen</td>
<td>cavity of an organ; inside a blood vessel</td>
</tr>
<tr>
<td>lymphocyte</td>
<td>a type of white blood cell important for defense against infections</td>
</tr>
<tr>
<td>Malaise</td>
<td>feeling bad; a feeling of bodily discomfort</td>
</tr>
<tr>
<td>malignancy</td>
<td>cancer which usually spreads and may be fatal if not successfully treated</td>
</tr>
<tr>
<td>marrow suppression</td>
<td>decreased growth of the bone marrow</td>
</tr>
<tr>
<td>metastasis</td>
<td>spread of cancer cells from one part of the body to another</td>
</tr>
<tr>
<td>monoclonal antibody</td>
<td>very specific, purified antibody</td>
</tr>
<tr>
<td>morbidity</td>
<td>sickness/illness</td>
</tr>
<tr>
<td>mortality</td>
<td>death</td>
</tr>
<tr>
<td>motility</td>
<td>the ability to move</td>
</tr>
<tr>
<td>MRI</td>
<td>pictures of the body created using magnetic rather than x-ray energy</td>
</tr>
<tr>
<td>murine</td>
<td>obtained from mice</td>
</tr>
<tr>
<td>myalgia</td>
<td>muscle aches</td>
</tr>
<tr>
<td>myocardial infarction</td>
<td>heart attack</td>
</tr>
<tr>
<td>nasogastric tube</td>
<td>a tube from the nose to the stomach</td>
</tr>
<tr>
<td>necrosis</td>
<td>death of tissue</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>neoplasia</td>
<td>a tumor that may be cancerous or non-cancerous</td>
</tr>
<tr>
<td>neural</td>
<td>brain or nerves</td>
</tr>
<tr>
<td>neutropenia</td>
<td>decrease in white blood cells</td>
</tr>
<tr>
<td>non-invasive</td>
<td>not breaking, cutting or entering the skin</td>
</tr>
<tr>
<td>obviate</td>
<td>to prevent</td>
</tr>
<tr>
<td>occlusion</td>
<td>closing; obstruction</td>
</tr>
<tr>
<td>occult blood test</td>
<td>testing a stool sample for trace amounts of blood</td>
</tr>
<tr>
<td>Oncology</td>
<td>the study of tumors or cancer</td>
</tr>
<tr>
<td>Ophthalmic</td>
<td>pertaining to the eye</td>
</tr>
<tr>
<td>orthopedic</td>
<td>pertaining to bones</td>
</tr>
<tr>
<td>osteoporosis</td>
<td>bone disorder resulting from loss of bone leading to increased risk of fracture</td>
</tr>
<tr>
<td>ovaries</td>
<td>female sex glands that release the egg cells</td>
</tr>
<tr>
<td>pancytopenia</td>
<td>low number of blood cells</td>
</tr>
<tr>
<td>percutaneous</td>
<td>through the skin</td>
</tr>
<tr>
<td>perforation</td>
<td>puncture, tear or hole</td>
</tr>
<tr>
<td>phlebitis</td>
<td>irritation or inflammation of a vein</td>
</tr>
<tr>
<td>placebo</td>
<td>inactive medication; dummy pill; sugar tablet; containing no medication</td>
</tr>
<tr>
<td>platelets</td>
<td>blood cells that help the blood clot normally</td>
</tr>
<tr>
<td>post-</td>
<td>after</td>
</tr>
<tr>
<td>prenatal</td>
<td>before birth</td>
</tr>
<tr>
<td>probability</td>
<td>chance</td>
</tr>
<tr>
<td>prognosis</td>
<td>outlook, probably outcomes</td>
</tr>
<tr>
<td>prophylaxis</td>
<td>A drug given to prevent disease or infection</td>
</tr>
<tr>
<td>prosthesis</td>
<td>artificial body parts, such as arms, legs, hips</td>
</tr>
<tr>
<td>proximal</td>
<td>closer to the center of the body, away from the end</td>
</tr>
<tr>
<td>psychosis</td>
<td>major psychiatric problem</td>
</tr>
<tr>
<td>pulmonary</td>
<td>pertaining to the lungs</td>
</tr>
<tr>
<td>QID</td>
<td>four times a day</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>treatment with radiation</td>
</tr>
<tr>
<td>randomly assigned</td>
<td>similar to the toss of a coin; assignment to a treatment group by chance</td>
</tr>
<tr>
<td>recur</td>
<td>happen again</td>
</tr>
<tr>
<td>refractory</td>
<td>not responding to treatment</td>
</tr>
<tr>
<td>regimen</td>
<td>pattern of giving treatment</td>
</tr>
<tr>
<td>relapse</td>
<td>return or reappearance of a disease</td>
</tr>
<tr>
<td>remission</td>
<td>disappearance of evidence of cancer or other disease</td>
</tr>
<tr>
<td>renal</td>
<td>kidney</td>
</tr>
<tr>
<td>resect</td>
<td>remove or cut out surgically</td>
</tr>
<tr>
<td>respiratory failure</td>
<td>lung failure; stop breathing</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>somnolence</td>
<td>sleepiness</td>
</tr>
<tr>
<td>staging</td>
<td>a determination of the extent of the disease</td>
</tr>
<tr>
<td>stenosis</td>
<td>narrowing of a duct, tube, or blood vessel</td>
</tr>
<tr>
<td>stratify</td>
<td>arrange in groups by age, sex, etc., for analysis</td>
</tr>
<tr>
<td>subcutaneous</td>
<td>under the skin</td>
</tr>
<tr>
<td>subsequent</td>
<td>another, next</td>
</tr>
<tr>
<td>supine</td>
<td>lying on the back</td>
</tr>
<tr>
<td>symptomatic</td>
<td>having symptoms</td>
</tr>
<tr>
<td>syndrome</td>
<td>a condition with a certain set of symptoms</td>
</tr>
<tr>
<td>systolic</td>
<td>the top number in blood pressure</td>
</tr>
<tr>
<td>tachycardia</td>
<td>fast heart beat</td>
</tr>
<tr>
<td>taper</td>
<td>decrease; reduce</td>
</tr>
<tr>
<td>therapy</td>
<td>treatment</td>
</tr>
<tr>
<td>thrombosis</td>
<td>to get or have a blood clot in a blood vessel</td>
</tr>
<tr>
<td>titration</td>
<td>gradual alteration of a drug dose to get the desired effect</td>
</tr>
<tr>
<td>topical</td>
<td>applied to the skin</td>
</tr>
<tr>
<td>toxicity</td>
<td>harm; problem; poisoning; unwanted side effect</td>
</tr>
<tr>
<td>transdermal</td>
<td>through the skin</td>
</tr>
<tr>
<td>transient</td>
<td>short-term; brief</td>
</tr>
<tr>
<td>trauma</td>
<td>injury; wound</td>
</tr>
<tr>
<td>trial</td>
<td>study</td>
</tr>
<tr>
<td>uptake</td>
<td>taking a substance into the body and the cells</td>
</tr>
<tr>
<td>uremia</td>
<td>kidney failure</td>
</tr>
<tr>
<td>varices</td>
<td>enlarged veins, usually in the legs or lining of the tube connecting the</td>
</tr>
<tr>
<td></td>
<td>mouth to the stomach</td>
</tr>
<tr>
<td>vasodilation</td>
<td>widening of the blood vessels</td>
</tr>
<tr>
<td>vasospasm</td>
<td>narrowing of blood vessels due to a spasm of the vessel walls</td>
</tr>
<tr>
<td>vehicle</td>
<td>placebo cream; inactive preparation</td>
</tr>
<tr>
<td>preparation</td>
<td></td>
</tr>
<tr>
<td>venipuncture</td>
<td>taking blood from the vein</td>
</tr>
<tr>
<td>via</td>
<td>by</td>
</tr>
<tr>
<td>waive</td>
<td>give up</td>
</tr>
</tbody>
</table>